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ABSTRACT 
The widespread use of Cry proteins in insecticide formulations and transgenic 
crops for insect control has led to an increased interest in the environmental fate of these 
proteins. Several detection methods are available to monitor the fate of Cry proteins in 
the environment, but enzyme-linked immunosorbent assays (ELISAs) have emerged as 
the preferred detection method, because they are cost-effective, easy to use, and provide 
rapid results. Validation methodology, which is essential to ensure accurate measurement 
of Cry proteins in environmental matrices, has been researched extensively, but most of 
this research has overlooked biological validation of ELISA results. This oversight has 
led to concerns that environmental studies utilizing ELISAs may be overestimating the 
concentrations of Cry proteins in the environment, which may affect the risk assessments 
for these proteins. A literature review discusses the history and usage of Cry proteins for 
insect pest control and discusses the use and validation of ELISAs for detection of Cry 
proteins in environmental samples. The concept of biologically validating ELISA results 
is introduced, and a critical review of published literature examines the state of ELISA 
usage and validation, including identifying areas for improvement. Eight different types 
of model systems were screened for their ability to produce fragments of Cry1Ab protein, 
and five of these model systems prove capable of generating Cry1Ab fragments. The 
fragments from these five model systems are then analyzed with ELISAs and bioassays 
to determine if the fragments are detectable or retain bioactivity. Fragments from four of 
the model systems are not detectable by ELISA and do not retain bioactivity. Fragments 
from the fifth model system are detectable by ELISA and do retain bioactivity. These 
results indicate that the use of ELISAs in environmental fate studies are providing an 
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accurate determination of the concentrations of Cry proteins in the environment and are 
not overestimating the concentrations. However, further work is needed utilizing 
additional model systems, including microbe-based model systems, in order to fully 
understand the fate of Cry proteins in the environment. 
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CHAPTER 1. A REVIEW OF CRY PROTEIN DETECTION 
WITH ELISAS 
A paper to be submitted to the Journal of Agricultural and Food Chemistry 
Vurtice C. Albright III, Richard L. Hellmich, Joel R. Coats 
Abstract 
The widespread use of Cry proteins in insecticide formulations and transgenic 
crops for insect control has led to an increased interest in the environmental fate of these 
proteins. Although several detection methods are available to monitor the fate of Cry 
proteins in the environment, enzyme-linked immunosorbent assays (ELISAs) have 
emerged as the preferred detection method, due to their cost-effectiveness, ease of use, 
and rapid results. Validation of ELISAs is necessary to ensure accurate measurements of 
Cry protein concentrations in the environment. Validation methodology has been 
extensively researched and published for the areas of sensitivity, specificity, accuracy, 
and precision; however, biological validation of ELISA results has been studied to a 
lesser extent. This review discusses the history of Cry proteins, their usage for insect 
control, the use and validation of ELISAs, and it introduces biological validation. The 
state of Cry protein environmental fate research is considered through a critical review of 
published literature to identify areas where the use of validation protocols can be 
improved.  
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Introduction to Cry proteins 
Origin 
Insecticidal crystalline proteins were first discovered, unknowingly, in 1901 when 
S. Ishiwata isolated a microorganism from a diseased Bombxy mori silkworm larva, 
which he named Bacillus sotto (1). [Although initially discovered and named by Ishiwata, 
because he did not formally describe it, Ernst Berliner received credit for naming it 
Bacillus thuringiensis when he discovered a similar microorganism in diseased 
Mediterranean flour moth larvae (Anagasta kuchniella) living in stored grain near the city 
of Thuringia, Germany in 1911 (2)]. In a follow-up report in 1905 Ishiwata noted “death 
occurs before the multiplication of the bacillus…” where the first indication that a toxin 
is at least partially responsible for the pathogenicity of B. thuringiensis arises (2-3). 
Another report in Japan provided more evidence that a toxin and not the bacterium itself 
was likely the responsible agent (2). However, identification of the toxic agent had to 
wait until 1954 when T.A. Angus showed that bipyramidal crystals present in sporulating 
B. thuringiensis cells were actually responsible for B. thuringiensis toxicity (2). He 
observed that the spores alone had no effect on Bombxy mori larvae, while dissolved 
crystals alone had the same effect as the spore-crystal complex and that as crystal count 
increased, toxicity increased as well (2,4). 
From the 1960’s to the 1980’s, new B. thuringiensis subspecies such as kurstaki, 
kurstaki HD-1, and tenebrionis, were identified, bringing with them new crystalline 
proteins or Cry proteins (2). As more Cry proteins were discovered, a naming and 
classification system was needed to help identify the new proteins. The first attempt at 
classifying these toxins was proposed by Hofte and Whiteley (5). They originally 
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separated the Cry proteins into four major classes based on the host range and structure of 
the protein. Cry I proteins were lepidopteran-specific and were 130-140 kilodaltons (kDa) 
in size with a bipyramidal structure. Cry II proteins were significantly smaller, 65-70 
kDa, and were cuboidal in structures. These proteins were also lepidopteran-specific and 
exhibited activity against dipteran species as well. Cry III proteins were coleopteran-
specific proteins that also were smaller and had a rhomboidal structure. The last major 
class were the Cry IV proteins which were much larger (128-135 kDa), and had an ovoid 
structure. This class of Cry proteins was dipteran-specific only (5). 
While this system was useful, it did have some inconsistencies that resulted in 
exceptions to the naming system. For example, in the Hofte and Whiteley nomenclature, 
Cry I proteins were lepidopteran-specific only; however, CryIC was reported also to be 
toxic to Dipterans (6-7). This is just one example, though several other exist. As a result 
of these inconsistencies, Crickmore et al. (7) developed a revised nomenclature system 
for the Cry proteins. Instead of focusing on target species and protein structure, the 
revised nomenclature groups brought together Cry protein toxins based on their sequence 
homology (7). Another major change is that the revised nomenclature switched from 
using Roman numeral to Arabic numerals in the primary rank (i.e., Cry1Ab instead of 
CryIAb) to allow for newly discovered proteins to be integrated more easily. The revised 
nomenclature also established a committee to assist in naming newly discovered Cry 
proteins, whereas the prior system lacked the ability to maintain standardization (7). The 
committee also periodically reviews literature and publishes a comprehensive list of 
known Cry proteins, which is available at 
www.lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/intro.html. Since its introduction, the 
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revised nomenclature has been widely adopted. Currently, there are more than 70 primary 
classes of Cry proteins included on the comprehensive list.  
Mechanism of Action 
The exact mechanism of action of Cry protein toxins is not currently known, but it 
is generally recognized as a multi-step process. Controversy over the final step or steps 
has led to the rise of three different models. The initial steps, however, are similar for all 
three models. First, the Cry proteins must be ingested by a susceptible species as they 
have no contact toxicity (8). Once inside the insect midgut, the Cry proteins are 
solubilized in an alkaline (for lepidopteran and dipteran insects) or a neutral/acidic (for 
coleopteran insects) environment (8). Proteases from the host insect, such as trypsin and 
chymotrypsin, then process the Cry proteins, cleaving off portions of the N- and C-
terminals, leaving only the activated toxin (9). The activated toxin binds to specific 
receptors on the midgut epithelium (8). Here is where the three models diverge.  
In the pore-formation model, the proteins bind to primary receptors in the insect 
midgut, such as cadherin-like receptors (10-11). The protein is cleaved to release the 
helix α-1 of Domain I (11). Cleavage results in the oligomerization of the protein into a 
tetrameric prepore, which binds to secondary receptors such as aminopeptidase A (APN) 
and alkaline phosphatase (ALP) (10-11). The secondary receptors assist insertion of the 
prepore into the membrane, creating a pore in the membrane (10). Multiple pores in the 
midgut epithelial membrane results in a loss of membrane potential and the osmotic 
gradient as ions equilibrate across the membrane and water rushes into the cell (10). This 
influx of water results in cell lysis. Lysis of multiple cells compromises the integrity of 
the midgut and results in the insect’s death (11). 
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In the signal-transduction model, the Cry proteins bind to the same primary 
receptor, cadherin, but instead of further cleavage and oligomerization, the binding 
initiates a Mg+2- dependent signaling pathway through the activation of a guanine 
nucleotide-binding protein (G-protein) (10-11). The G-protein activation then triggers 
adenylyl cyclase which increases cyclic AMP (cAMP) levels and results in the activation 
of protein kinase A, leading to cytoskeleton and ion channel destabilization and the 
eventual death of the insect (10-11). 
A third model has been proposed that combines elements of the previous two 
models. This model, known as the Jurat-Fuentes model after one of the authors who 
proposed it, suggests that toxicity of Cry1Ac to Heliothis virescens is the result of 
osmotic lysis and cellular signaling combined. In this model the Cry proteins bind to the 
cadherin-like protein HevCaLP, resulting in the activation of an intracellular signaling 
pathway. At the same time, the bound protein oligomerizes and binds to the secondary 
receptors APN and ALP, leading to pore formation. Both pathways then contribute to the 
death of the insect (10,12). 
Usage as Insecticides and Development of Transgenic Traits 
Insecticidal formulations containing a mixture of Bacillus thuringiensis spores 
and Cry proteins have been used to control pest insects for decades. Although the first 
commercial insecticide product was introduced in France in 1938 to target lepidopteran 
pests, it was not until the introduction of ThuricideTM in the late 1950’s that these 
formulations were used on a wide scale (13-14). The use of Cry protein formulations 
increased through the 1960’s and 1970’s with the introduction of insecticides targeting 
coleopteran and dipteran species, eventually reaching $100 million in annual sales in the 
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early 1990 (13). Sprays, powders, and other formulations of Cry proteins or the bacterium 
B. thuringiensis continue to be used in agricultural production on crops such as cotton, 
potatoes, tomatoes, and maize to control for several important coleopteran and 
lepidopteran pest species (15-16). Additional agricultural uses include sprays on fruit 
trees to control for light brown apple moth (Epiphyas postvittana) and on other crops like 
avocados, kiwi fruit, and strawberries (16-17). Cry protein-based insecticides also have 
found uses outside of agriculture. Aerial sprays are commonly used in forestry settings to 
control many pest insects including: gypsy moths (Lymantria dispar L) and the spruce 
budworm (Choristoneura fumiferana) in the United States; the pine processionary moth 
in Europe (Thaumetopeea wilkinsoni) and the Middle East (T. pityocampa); the nun moth 
(L. monacha) in Europe; the pine looper (Bupalus piniaria) in Sweden; the white spotted 
tussock moth (Orgyia thyellina) in New Zealand (18-20). Cry protein products are also 
under development to control plant-parasitic nematodes and termites (21-23). Control of 
both of these pests with B. thuringiensis-based formulations faces significant hurdles as 
survival of the bacterium (that germinates from spores in the formulations) in soil is poor 
(22). 
In addition to plant protection, Cry protein-based insecticides also can be used in 
protection of humans. Many disease-causing organisms such as Onchocerca volvulus 
(river blindness) and Wuchereria bancrofti (lymphatic filariasis) can be vectored by black 
flies and mosquitoes (24-25). Control of the dipteran vectors is one key element in 
preventing the spread of these diseases. Since their introduction into the Onchocerciasis 
Control Program in West Africa in 1983 to help control the black fly, Simulium 
damnosum, Cry protein-based insecticides, along with conventional chemical 
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insecticides, have helped to significantly decrease the number of new infections (24-25). 
Formulations containing Cry proteins also are used to control black flies in Brazil 
(Simulium pertinax) and Argentina (S. bonaerense, S. wolffhuegoli, and S. nigristrigatum) 
on a purely nuisance basis, since no cases of disease transmission have been reported for 
these species (26-27).  
Several formulation types of Cry protein-based insecticides have been developed 
to control mosquitos as they are vectors for some of the most significant human disease, 
such as malaria, dengue, and lymphatic filariasis. Sprays, dissolvable tablets, granules, 
and other Cry protein-containing formulations have been used throughout Asia and South 
America and have significantly reduced the occurrence of many of these human diseases 
(24-25). Additional formulations have been used in more temperate climates like 
Germany and the United States to control for other diseases, such as West Nile virus, and 
as nuisance control (24-25).  
Currently, Bt formulations are primarily used by gardeners, organic farmers, and 
in forestry (14). Their widespread use in agriculture has been hindered by several factors. 
Cry protein formulations are not stable in the environment, resulting in low residual 
activity (14). This lack of persistence triggers the need for multiple applications at 5-7 
day intervals to ensure protection is achieved; such near constant spraying is not 
economically viable as the costs of fuel, labor, and insecticides can accumulate rapidly 
(28). The narrow specificity of Cry protein formulations, while beneficial for protecting 
non-target organisms, can lead to the application of multiple formulations to manage 
multiple pest species. Formulations containing Cry proteins typically lack systemic 
activity and cannot penetrate plant tissues to reach pest insects within a plant, such as 
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European corn borers (14). Finally, another factor that has helped curtail the used of Cry 
protein formulations in agriculture has been the development and rapid increase in the 
use of transgenic plants producing Cry proteins for protection against pest insects.  
Development of transgenic plants expressing genes for the production of Cry 
proteins occurred near simultaneously in multiple laboratories. Fischhoff et al. (29) 
developed transgenic tomato plants for the control of several lepidopteran pests using 
both the full length coding sequence from Bacillus thuringiensis var. kurstaki HD-1 
(B.t.k. HD-1) and a coding sequence for truncated versions. Three plants transformed 
with the full length gene were produced, while only two plants with the truncated gene 
were created. However, both plants with the truncated version of the gene achieved 100% 
mortality of Manduca sexta larvae, while only one of the three plants with the full length 
gene had insecticidal activity, and at much lower levels (50-80% mortality). The authors 
then focused solely on the truncated genes and were able to develop plants capable of 
achieving 100% mortality of larvae in 48-72 hours (29). Meanwhile, other labs were 
developing transgenic tobacco plants also to control for M. sexta. Vaeck et al. (30) also 
attempted to transform both a full length Bt gene isolated from B. thuringiensis strain 
Berliner 1715 and several truncated versions of the gene into tobacco plants. They were 
successful in these transformations; however, when compared, they observed no 
insecticidal activity in any of the plants transformed with the full length gene. The 
truncated versions performed significantly better with 100% mortality observed after six 
days in plants transformed with the truncated NPT860 gene. F1 progeny of two of the 
transformed plants also were tested for insecticidal activity and achieved 100% larval 
mortality after five days, thus showing that the Bt genes in transformed plants are 
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inheritable (30). Barton et al. (31) also were developing transgenic tobacco plants for 
protection against M. sexta, but with a different trait. Initial efforts focused on inserting a 
full length gene from B.t.k. HD-1 into tobacco plants. However, these plants did not 
prove viable, and their efforts were quickly shifted to focusing on only the truncated 
version of the gene. Not long after, they had developed transformed plants with truncated 
genes that were capable of achieving mortality at levels similar to those observed in the 
previous two studies (31). 
While many transgenic plants performed well in the efficacy tests, not many 
produced protein at high levels in the plant tissues. This led to concerns that these plants 
might not be commercially viable (32). Thus, several modifications to the gene structure 
were performed in attempts to increase the amount of insecticidal Cry protein produced 
in the plant tissues. Changing promoters, leader sequences, and fusion proteins did not 
lead to significant changes in protein production (30-31). This led Perlak et al. (32) to 
focus on modifying the DNA sequence of the Bt genes in tomato and tobacco plants. 
Partial modifications (removal of sequences predicted to inhibit gene expression) and full 
modifications (removal of ATTTA sequences and potential polyadenylation sequences, 
using plant preferred codons, etc.) were performed. These modifications produced 
substantial results; some plants containing the partially modified gene had 10-fold higher 
protein levels and some plants with the fully modified gene had 100-fold higher protein 
levels (32). Other modifications were able to increase the amount of protein in cotton 
from less than 0.002% of the total protein to 0.05-0.1% of the total protein (33). McBride 
et al. (34) also recognized the need for increasing protein levels but decided that 
producing synthetic genes was too expensive and labor intensive. They chose to focus on 
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expressing the gene in chloroplasts, instead of the nuclear DNA because the plastid’s 
genome is AT-rich, much like Bt genes and unlike plant genes which are typically GC-
rich. This transformation resulted in significant improvement in Cry protein production in 
the plant. As much as 5% of the total soluble protein was Cry protein using this method 
(34). 
Following up on these successes, other transgenic crops were quickly developed, 
including cotton to control for cotton bollworm (Heliothis zea), rice to control for striped 
stemborer (Chilo suppressalis) and leaffolder (Cnaphalocrosis medinalis), and potato to 
control for Colorado potato beetle (Leptinotarsa decemlineata) (33,35-36). Field trials 
were performed to determine the efficacy of transgenic plants to control pest insects 
under more natural conditions. Tomato plants artificially infested with M. sexta exhibited 
only limited feeding immediately after hatching near the site of introduction, while the 
non-transgenic controls were entirely defoliated after two weeks (37). The transgenic 
tomato plants also reduced damage caused by H. zea (natural and artificial infestations) 
and Keiferia lycopersicella (natural infestations); however, significant damage still 
occurred in the tomato fruits, possibly as a result of insufficient levels of the Cry protein 
in the fruit (37). Six different maize plant varieties expressing Cry1Ab protein were field 
tested against two generations of artificial infestations of European corn borer (Ostrinia 
nubilalis Hübner). Despite the heavy infestation pressure, excellent protection was 
reported. Foliar damage to transgenic maize rated an average of 3 on a modified Guthrie 
scale (1 – no visible injury, 9 – severe leaf injury) while control plants had an average 
rating of 6.8 (38). Additionally, mean tunnel length in transgenic maize ranged from 1.7 – 
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7.2 cm while in non-transgenic control plants the mean tunnel length averaged 28 – 144 
cm (38).  
All of this research led to the approval in 1995 of the first transgenic crops 
conferring insect resistance for commercial use (39). Included in the first round of 
approvals was MaximizerTM maize (Ciba-Geigy), BollgardTM cotton and New LeafTM 
potatoes (both Monsanto products) all of which were first planted commercially in 1996 
(39-40). The next year saw additional approvals of insect-resistant maize products from 
Monsanto and Northrup King. Initially, only traits for the control of corn borer (maize), 
Colorado potato beetle (potato) and tobacco budworm, bollworm, and pink bollworm 
(cotton) were available. Traits for control of corn rootworm and corn earworm in maize 
were introduced commercially in 2003 and 2010, respectively (40). Since these initial 
introductions, transgenic cotton and maize expressing Cry proteins for insect resistance 
have been widely adopted. As of 2015, 81% of maize and 84% of cotton planted in the 
United States have expressed one or more insecticidal traits for protection against a 
variety of insect pests (41). As previously mentioned, New LeafTM potatoes were 
introduced at the same time as the first transgenic maize and cotton plants. However, 
while transgenic maize and cotton use increased rapidly, New LeafTM potato usage 
faltered as sales never rose above 5% of the total amount of potato seed sold and it was 
eventually pulled from the market after only six years (42). 
Although maize and cotton are the only transgenic crops expressing insecticidal 
traits currently in use, other crops are in various stages of development. Development of 
transgenic tomato, tobacco, and rice plants expressing genes for production of 
insecticidal Cry proteins has already been mentioned in this review (29-32,34-35,37). 
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However, these research efforts have yet to produce any commercially available products 
(40,43). In addition to the aforementioned crops, other crops have been developed to 
produce Cry proteins for insect resistance, and some have even been approved for 
commercial usage in other countries. Transgenic soybean plants have been engineered to 
produce Cry1Ac for the control of Helicoverpa zea, Helioverpa armigera, Pseudoplusia 
includes, Heliothis virescens, Anticarsia gemmatalis, and Hypena scabra (44-46). This 
trait, however, exhibited little or no effectiveness against Spodoptera litura, S. exigua, 
and Agrotis ypsilon (46). Though not commercially available in the United States, a 
transgenic soybean plant producing the Cry1Ab protein was registered for commercial 
use in Brazil in 2011 (47).  
Several other vegetable species also have been genetically modified to produce 
Cry proteins for insect protection. The most successful, and only one currently in 
commercial usage, is sweet corn engineered to produce Cry1Ab. It was first introduced in 
1998 by Novartis Seeds,  and initially struggled to gain a large market share due to a lack 
of public acceptance; however, it is currently estimated that Bt sweet corn accounts for  
18-25% of the total fresh sweet corn market (data on usage in processed sweet corn not 
available)(48-49). Another transgenic plant close to commercial usage is the brinjal, or 
eggplant. A transgenic brinjal producing Cry1Ac for control of the fruit and shoot borer 
(Leucinodes orbonalis) was approved for commercialization in India in 2009, but never 
reached market due to significant political pressure (50). However, it was released to a 
limited number of farmers in Bangladesh in early 2014 (51). Numerous Brassica species 
producing various Cry proteins also have been developed to control for the diamondback 
moth, Plutella xylostella. Transgenic cabbage producing Cry1Ab and Cry1B, transgenic 
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broccoli producing both Cry1C alone and in a pyramid with Cry1Ac, transgenic 
cauliflower producing Cry1C or Cry 9Aa, and transgenic canola producing Cry1Ac all 
have been shown to have excellent control against diamondback moth larvae (52-57). 
Additionally, activity against the cabbage looper, Trichoplusia ni was observed for the 
Cry1C cauliflower and the Cry1Ac canola (52-53). Cry1A-producing rutabaga has been 
developed for control of the cabbage caterpillar, Pieris rapae (58). Despite the extensive 
research into these transgenic Brassica vegetables, viable commercial products have not 
yet been developed. In an early effort to commercialize some of these products, a private-
public partnership was formed in 2003 with the intent of making pyramided Bt cabbage 
and cauliflower available for commercial use in India; however, the collaboration ended 
in 2010 when a major partner backed out before any commercial products could be 
brought to market (48).  
Two non-traditional crop plants under development that produce insecticidal Cry 
proteins are poplar and eucalyptus trees. Poplar trees are important to the paper and 
timber industries due to their rapid growth rate, but are susceptible to damage from a 
variety of coleopteran and lepidopteran pests, including Chrysomela tremulae and the 
gypsy moth Lymantria dispar (59-60). Transgenic poplar trees have been developed to 
provide protection against either coleopteran or lepidopteran pests using the cry3Aa gene 
and a modified cry1A gene respectively (59-60). Significant protection is incurred by 
these traits with 67-89% mortality of L. dispar larvae and 100% mortality of C. tremulae 
larvae and adults (59-60). The other non-traditional transgenic plant expressing a Bt gene 
currently under development is a eucalyptus tree expressing the cry3A gene (61). Like 
poplar trees, eucalyptus trees are important sources for timber and pulp for paper, 
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primarily in Australia, and are susceptible to defoliation by the Tasmanian eucalyptus 
leaf beetle (Chrysophthara bimaculata) (61). Eucalyptus trees expressing the cry3A gene 
have been shown to have excellent protection against C. bimaculata with 87% larval 
mortality after only four days (61). 
Non-Target Toxicity Concerns 
Although individual Cry proteins have a narrow spectrum of activity against 
specific insect orders, some non-target effects have been reported. Much work has 
focused on monarch butterflies (Danaus plexippus) after a paper by Losey et al. (62) 
reported decreased growth rates and survival of monarchs fed with pollen from transgenic 
Bt corn in a laboratory study and Jesse and Obrycki (63) reported lethal effects from a 
field study. Follow-up studies determined only one type of Bt maize (Event 176), which 
is no longer commercially available, was lethal to monarch larvae (64-66).  Effects from 
other types of commercially available maize were expected to be minimal due to low 
toxicity and low exposure (67).  Continuous exposure of larvae to pollen from Cry1Ab Bt 
maize throughout development, a worse-case exposure scenario, found evidence of 
reduced feeding, decreased weight gain, longer development time, and increased larval 
mortality (66). The estimated additional mortality to monarch population due to this 
exposure was only 0.6% (66).   
Other non-target insects in the order Lepidoptera also have been reported to be 
susceptible to Cry1Ab. Spodoptera littoralis exposed to Cry1Ab were reported to have 
decreased larval survival and weight gain and increased development time in laboratory 
studies (68). The lycaenid butterfly Pseudozizeeria maha fed on Cry1Ab-containing 
pollen in laboratory studies exhibited decreased larval survival (69). Higher mortalities 
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and decreased weight gain also have been reported for Pieris brassicae, Pieris rapae, and 
Plutella xylostella in laboratory studies (70).  
Some closely related Trichopteran species have been reported to be susceptible to 
lepidopteran-active Cry proteins. Decreased growth rates have been reported for the 
caddis fly Lepidostoma liba fed transgenic maize detritus; the detritus was not analyzed, 
so the quantity and quality of the Cry proteins the larvae were exposed to is unknown 
(71-72). (Although subsequent studies refute this claim, see 73). Increased mortality and 
decreased abundance in fields where Cry1Ab was present have been reported for 
Helicopsyche borealis and Pycnopsyche sp. respectively (71,74). Effects on non-target 
Dipterans have been reported with the aquatic midge Chironmus dilutus showing 
decreased survival on Cry3Bb1 and the crane fly Tipula abdominalis exhibiting 
decreased growth rates on transgenic Cry1Ab maize (though the latter may be due to 
tissue differences between transgenic maize and near-isoline non-transgenic maize) 
(73,75). A non-insect species, the isopod Caecidotia communis, also was reported to have 
decreased growth rates on Cry1Ab maize (though again, tissue differences may account 
for the differences)(73). Another study reported that Cry1Ab had no effects on two 
isopod species; however, difference in nutritional content between corn hybrids were 
likely responsible for differences in Trachelipus rathkii growth (76). [For further reading 
on the effects of Cry proteins to non-target organisms, see 77-79].  
Environmental Chemistry 
As a result of these potential non-target toxicity issues, it is important to address 
questions surrounding the environmental fate of Cry proteins. Environmental fate 
questions that must be addressed include, but are not limited to: degradation, persistence, 
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mobility, and bioavailability of the Cry proteins. However, before any of these questions 
can be answered, researchers must have adequate tools for detecting and quantifying the 
amount of Cry proteins in the environment. There are currently a wide variety of 
detection methods available for Cry proteins, including high-performance liquid 
chromatography/mass spectrometry, biological assays (bioassays), and Western blotting. 
A drawback of these methods is that they are time- and labor-intensive and as a result, are 
generally cost-prohibitive for most researchers. Thus, most researchers elect to use 
enzyme-linked immunosorbent assays (ELISAs) to detect Cry proteins in environmental 
matrices. 
Introduction to ELISAs 
Theory 
Immunoassays harness the power of the adaptive immune system in which 
lymphocytes produce antibodies in response to foreign molecules such as bacteria and 
viruses (80). These antibodies have high specificity to epitopes on the foreign molecule 
they target. If the binding of an antibody to a foreign molecule can be visualized, then 
antibodies could be used for the detection of specific foreign molecules (81). Normally, 
one end of the antibody binds to the antigen while the opposite end binds to a phagocyte, 
which will ingest and destroy the invading molecule (80). However, in an immunoassay, 
the phagocyte-binding end of the antibody is conjugated to a reporter molecule. Early 
immunoassays used radioactive labels as the reporter molecule attached to the antibodies. 
However, due to concerns regarding worker safety and handling and disposal of 
radioactive materials, alternative reporter molecules were sought, including using 
enzyme-labeled antibodies (82). The first paper reporting the use of enzyme-labeled 
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antibodies was published in 1971 by Engvall and Perlmann. The assay developed in that 
paper, which the authors called an enzyme-linked immunosorbent assay or ELISA, 
conjugated an enzyme, instead of a radiolabeled molecule, to an antibody to 
quantitatively measure immunoglobulin G in rabbit serum (82-83). Since the publication 
of that paper, ELISA use has increased dramatically across many scientific disciplines. 
ELISAs are the most popular method currently used to detect Cry proteins in 
environmental samples. There are several types of ELISA methods currently available 
including direct, indirect, and competition ELISAs; however, sandwich ELISAs are the 
most commonly used type for detection of Cry proteins (84). In a direct sandwich ELISA, 
a capture antibody is bound to a solid phase, such as the bottom of a well in a 96-well 
plate (Figure 1). The sample containing the antigen (in this case, the antigen is the Cry 
protein of interest) is then added to the well, and the antigen binds to the capture 
antibody. The wells are then washed, removing any unbound antigen. The detecting 
antibody conjugated to an enzyme is added and binds to a different epitope on the 
antigen, forming a protein sandwich. After another wash step, a substrate is added which 
is processed by the enzyme, producing a colorimetric response indicating the presence or 
absence of the antigen. ELISAs for detection of Cry proteins can be made quantitative 
through the use of a standard curve to provide a general idea of the amount of a specific 
Bt protein present (81,84-85). Indirect sandwich ELISAs also may be used instead of 
direct sandwich ELISAs. Indirect sandwich ELISAs are similar to direct sandwich 
ELISAs, except that they use a second capture antibody that is not conjugated to an 
enzyme to bind to a different epitope on the antigen. The detecting antibody then binds to 
the second capture antibody (81,85). 
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Antibodies 
Foreign molecules, or antigens, can be injected into a mammalian host (i.e., mice, 
rabbits, etc.). The presence of the antigen then elicits the immune system of the host 
animal to produce antibodies specific to the antigen of interest (81). By using a Cry 
protein as the antigen being injected, antibodies specific to that protein can be produced. 
The two main types of antibodies currently used in ELISAs are polyclonal and 
monoclonal antibodies. Polyclonal antibodies are produced by injecting a host organism 
with the antigen of interest and collecting and purifying the host’s serum. This results in a 
heterogeneous mixture of numerous antibodies with varying specificities and affinities 
for the antigen of interest. The heterogeneous mixture can lead to very sensitive 
immunoassays, as having multiple antibodies present increases the chances of antigen 
recognition and binding. However, this can also lead to non-specific binding to other 
antigens with similar epitopes. Polyclonal antibodies are the easiest and cheapest to 
produce in large quantities, but their availability is limited to the life span of the host. 
Additionally, it is not possible to reproduce the exact serum from another host due to 
variability between individuals of the same species (81,86-87). 
Monoclonal antibodies consist of a homogenous mixture of a single antibody. 
They are produced by injecting a host organism with the antigen of interest and then 
collecting and fusing individual lymphocytes from the host to myeloma cells, resulting in 
a hybridomal cell line that can produce a single type of antibody. Multiple hybridomas 
are screened to identify those hybridomas that produce the most antibodies with the best 
binding ability. Though they are much more time-consuming and expensive to set up, 
once established, the hybridoma can produce the specific antibody for extended periods 
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of time in tissue culture. Non-specific binding is less of an issue with monoclonal 
antibodies, however, sensitivity can be lowered if the targeted epitope is damaged or 
altered significantly (81,86-87). 
Current usage 
One of the first studies to investigate the use of ELISAs for detecting Cry proteins 
was Wie et al. (88). The authors investigated the prospect of using ELISAs to detect and 
quantify the amount of crystal toxins from B. thuringiensis subspecies. They determined 
that the ELISA method was highly accurate and extremely sensitive. While specificity 
between dipteran-active and lepidopteran-active toxins could be achieved, there was 
significant cross-reactivity between lepidopteran subspecies of B. thuringiensis (88). 
Since that initial study, however, significant amounts of research have been devoted to 
improving the antibodies used and the ELISA procedure as a whole (86,89-92). Early use 
of ELISAs for detection of Cry proteins required developing antibodies in the laboratory 
for the specific protein of interest (93). More recently, commercial manufacturers have 
been developing ready-made kits with antibodies specific to 1-2 Cry proteins.  Table 1 
contains a list of ready-made ELISA kits available from several manufacturers.  
There are a wide range of uses for ELISAs currently in agriculture. ELISAs can 
be used to screen cell cultures or plants for the presence of a novel protein of interest to 
determine which cell culture or plant is expressing the protein after genetic 
transformation in a laboratory. These cell cultures or plants can then be further screened 
to remove cultures or plants that are expressing the protein at insufficient levels. As trials 
expand into greenhouses or field settings, ELISAs can be utilized in event selection to 
identify low trait expressing plants, allowing them to be culled from the gene pool (94). 
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Once a product is ready for commercial usage, ELISAs can be used to determine protein 
expression levels in roots, leaves, pollen, and other various plant tissues. Such 
information is typically required by regulatory agencies as part of the extensive 
registration packages. ELISAs also may be employed as quality assurance/quality control 
tools during seed production to ensure the products (i.e., seeds) being delivered to the 
customers will perform as promised (95). Following harvest, ELISAs can be used to 
identify transgenic crops from non-transgenic crops and ensure that transgenic crops do 
not become mixed with non-transgenic crops throughout the supply and processing chain, 
where required by governmental regulations (96).  
One of the biggest use of ELISAs in agriculture research, and the focus of the 
remainder of this paper, is for monitoring of Cry proteins in environmental matrices pre- 
and post-harvest. As with any pesticide, insecticides containing Cry proteins may enter 
soil and water matrices through direct application, such as foliar sprays and soil drenches, 
or indirect application, such as spray drift and spills. Cry proteins also may move into 
water via surface water runoff and soil erosion. Another pathway that Cry proteins in 
transgenic crops can enter the ecosystem is through the transportation of crop material. 
This typically occurs post-harvest as crop residues are incorporated into the soil or 
transported to water bodies (via wind or surface water runoff),  and begin to degrade, 
releasing Cry proteins (71,97-98). Cry proteins also may enter soil and water bodies 
through exudation from plant roots or via pollen deposition (62,99). Understanding the 
movement and fate of Cry proteins in the environment is crucial in determining the risk 
of Cry proteins to non-target organisms.  
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Presence/absence, dissipation, persistence, and partitioning of Cry proteins in soil 
and water matrices can all be addressed by ELISAs for both insecticide formulations 
containing Cry proteins and transgenic crops producing Cry proteins. In lab studies, 
Douville et al. (100) spiked soil and water samples with pure Cry1Ab protein to 
determine persistence in the environment. Aquatic environments degraded the protein 
more rapidly than soils, with half-lives of 4 and 9 days respectively (100). This result was 
corroborated by other research groups. In a study on the aquatic fate of Cry3Bb1, half-
lives of Cry3Bb1 protein in various maize tissues in aquatic microcosms were less than 
three days, and no Cry3Bb1 was detected in the water or sediment (75). A related study 
looked at dissipation of Cry3Bb1 in maize tissues in soils, and determined there was a 
slightly longer half-life for the various maize tissues in soil (101). Another research group 
showed that two different formulations containing Cry4, a mosquitocidal protein, were 
below the limit of detection of the ELISA after 7 days (LOD = 2 ppb) in aquatic 
microcosm studies (92).  
In field studies, the information on persistence and dissipation is mixed. 
Sundaram et al. (102) investigated persistence of a commercial Bt kurstaki formulation 
Foray® 48B, on oak leaves following foliar application to protect against the gypsy moth 
Lymantria dispar L. Their results indicated that the amount of endotoxin present was 
below the limit of quantification of 8 ppb after only two days (102). Gruber et al. (103) 
studied the presence of Cry1Ab in soil in fields following cultivation of transgenic maize 
in the same four fields for nine consecutive years. The authors found no evidence for 
accumulation or persistence of Cry1Ab during long-term cultivation as only one site had 
protein levels above the limit of detection six weeks after harvest, and no protein was 
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detected at any of the sites the following spring (103). Daudu et al. (104) tracked the 
degradation of Cry1Ab in leaf and stem residues in litter bags buried in soils and found 
that after 14 days, less than 0.02% of the Cry1Ab remained in the leaf and stem residues. 
In addition, no Cry1Ab protein was detected in the soil around the litter bags, indicating 
that the Cry protein was rapidly degraded (104). 
In contrast, Baumgarte and Tebbe (105) studied the amount of Cry1Ab protein in 
soil and plant tissue residues in two agricultural fields where transgenic maize was 
grown. Cry1Ab was detected in soils and plant tissues at both field sites during the 
growing season and post-harvest, with Cry1Ab still detected in one field seven months 
later (105). Tank et al. (106) found free Cry protein in 23% of 215 water samples taken 
from streams near agricultural fields six months after harvest.  
Advantages and Disadvantages 
 The use of ELISAs for detection of Cry proteins in environmental matrices has 
several advantages and disadvantages. ELISAs are highly sensitive, with detection limits 
in the ng/mL range, and are highly selective due to the specificity of the antibodies 
(96,107). ELISAs are easier to perform and produce results more quickly than 
conventional methods like liquid chromatography paired with mass spectrometry 
(LC/MS). While the amount of time dedicated to sample preparation may be similar, 
analysis of the samples is much faster with ELISAs. For example, analysis of a 96-well 
microtiter plate designed to detect Cry1Ab or Cry1Ac protein requires two hour 
incubation with the sample and antibodies, a washing step, and 20 minute incubation with 
the substrate to allow for a colorimetric change to occur (108). If plating of the samples 
and read time on a plate reader are included, the total analytical time is 3.5-4 hours, or 2-
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2.5 minutes per sample, while analysis with LC/MS could take 10-15 minutes per sample 
(including re-equilibration time), for a total of 16-24 hours. The ability to process a large 
amount of samples in a short time span also makes ELISAs cost effective (96). As of 
May 2015, a 480 well Cry1Ab/1Ac kit from Agdia, Inc. (Elkhart, IN, USA) cost 
approximately $600 USD, or $1.25 per sample (not including controls) (109). Depending 
on equipment set-up, the cost to operate a LC/MS can be $30-100 per hour. Assuming 
costs are $30 per hour, and run time per sample is 10 minutes, to analyze 480 samples 
with LC/MS would cost $2,400 ($5 per sample). 
 A drawback with the use of antibodies, however, is that the antibodies may cross-
react with closely related proteins, such as antibodies specific for Cry1Ab cross-reacting 
with Cry1Ac (107,110-111). Also, non-specific binding may occur between other 
proteins in environmental samples and the antibodies, enzymes, or even the plastic 
microtiter plates utilized in the assays (80,112). Further, if the protein structure is altered 
or the antibody binding sites are damaged, there can be reduced antibody-antigen 
binding, which may affect the accuracy of the analysis (96). Conversely, ELISAs can 
only distinguish between bioactive and non-bioactive proteins when the protein structures 
are altered significantly. Thus, if only minor structural alterations exist that render the 
protein inactive against susceptible insect species, but do not affect the binding of the 
antibodies to the protein epitopes, then a protein that is not bioactive may be detected by 
the assay, producing a false-positive result (93,113). Finally, ELISAs are not readily 
conducive to multi-analyte analysis (110). Some attempts have been made to allow for 
detection of multiple analytes, but these are not true multi-analyte analyses, as they 
require dividing a microtiter plate into multiple sections, one for each analyte. This can 
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greatly reduce the number of samples per plate; if samples are screened for three different 
analytes, the number of samples per plate decreases from 96 to 32 (114). 
Validation of ELISAs 
As with any analytical method, validation of ELISAs is necessary to ensure that 
the performance of the assay meets specific criteria. These criteria, as well as the scope of 
the validation procedure, may vary according to the intended use of the assay; however, 
at a minimum, validation procedures typically address the sensitivity, specificity, 
accuracy, and precision of ELISAs to ensure that the target analyte can be detected and/or 
quantified in a reproducible manner. Several excellent articles and book chapters have 
been published on the topic of ELISA validation and cover the topic in greater detail than 
in this review (81,84,112). Additionally, several articles have been published describing 
validated methods for detection of Cry proteins in various matrices (111,115-117). The 
remainder of this section will briefly cover the key areas of validation: sensitivity, 
specificity, accuracy, and precision. 
Sensitivity 
 The sensitivity of an ELISA is determined by the smallest amount of target 
analyte that an assay can reproducibly detect. For a quantitative ELISA, determining the 
quantitative range, upper limit of quantitation (ULOQ) and lower limit of quantitation 
(LLOQ) are important parameters for defining sensitivity. The quantitative range is the 
range over which the ELISA will produce quantitative results within acceptance criteria; 
it is determined by the concentrations over which the standard curve produces a linear 
response. The upper limit of quantitation and lower limit of quantitation are the highest 
and lowest concentrations, respectively, that can be measured with an acceptable level of 
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accuracy and precision. They are commonly defined as the highest and lowest points, 
respectively, on the standard curve. The sensitivity for a qualitative ELISA is often 
defined by the limit of detection, or the lowest concentration at which it is possible to 
differentiate between a positive and negative sample. The limit of detection can be 
defined as an absorbance reading that is two or three standard deviations above a negative 
or background control sample (84,112).  
Specificity 
 The specificity of an ELISA is the capacity of the assay to differentiate between 
the Cry protein of interest and other components that may be present in the samples. 
There are two main constituents to specificity: cross-reactivity or interference of other 
transgenic proteins, and cross-reactivity or interference of matrix components. Checking 
for cross-reactivity with other proteins (including transgenic proteins) is essential to 
determining if the antibodies utilized in the ELISA will bind to other closely related 
proteins, such as Cry1Ab and Cry1Ac. Fortunately, for researchers using commercial 
ELISA kits, this work is typically performed by the manufacturer. Equally important is 
determining if the matrix (i.e., soil, tissue, water) can affect the capacity to detect and/or 
quantify the Cry protein of interest. Matrix components may contain homologous 
endogenous counterparts that could potentially cross-react with the antibodies, producing 
a response. Non-specific binding between the antibodies and matrix components also 
may produce a positive response, while decreased ability of the assay to quantify the 
protein may occur if matrix components interfere with the antibody-Cry protein 
interaction (112).  
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Accuracy 
 The accuracy of an ELISA is its ability to determine the true amount of Cry 
protein in a sample. Accuracy of an ELISA can be determined through the use of 
extraction efficiency and fortification-and-recovery studies. Extraction efficiency is used 
to express the capability of an extraction method to separate the Cry protein of interest 
from the sample matrix, which is determined by utilizing serial extractions of the same 
sample. The amount of protein in the first extraction is divided by the sum of the protein 
in all the extractions. Extraction efficiencies between 70-100% with a coefficient of 
variation (CV) of less than 20% are ideal. Fortification-and-recovery testing (also known 
as spike-and-recovery) is used to determine recovery across multiple points in the 
quantitative range. In this test, negative soil, tissue, or water samples (samples free of Cry 
proteins) are fortified or spiked with a known amount of protein. The samples are then 
extracted once according to the extraction procedure, and the amount of protein 
recovered is divided by the total amount of protein initially added. Ideal mean recovery 
values are between 70-120%, with a CV of less than 20% (84,112). The inherent 
variability in biological systems and the small quantities of Cry proteins that are typically 
found in environmental samples make accurate measurements challenging and can lead 
to recovery values greater or less than 100%. Some major factors in the extraction 
process that can affect the recovery of Cry proteins in the extraction efficiency and 
fortification-and-recovery procedures from various environmental matrices includes the 
type of extractant/solvent used, number of times a samples is extracted and the duration 
of each extraction, and the type of agitation used (grinding, shaking, etc.). 
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Precision 
 The precision, or reproducibility, of an ELISA describes the amount of variation 
that may occur within an assay or across multiple assays. The use of commercial ELISA 
kits can help reduce some of this variability, especially if kits from the same lot number 
(i.e., same source of antibodies, enzyme conjugate, etc.) are used for all samples. 
However, not all sources of variability can be accounted for by the use of commercial 
kits, such as day-to-day and analyst-to-analyst variability, and thus, the precision of the 
assay needs to be verified. Assay precision can be tested by analyzing aliquots of the 
same quality control samples of known concentration multiple times (across days, 
analysts, etc.). The mean and standard deviation of all of these samples can then be used 
to calculate the coefficient of variation for the samples. Ideally, the coefficient of 
variation will be less than 20%, though this can vary depending on the intended use of the 
assay (81,84,112). 
 One way to think about accuracy and precision is to imagine a dart board (Figure 
2). In this analogy, the center ring of the dart board, or bulls-eye, represents the true 
amount of Cry protein in a sample. Method validation ensures that an analytical method 
has all samples tightly grouped in the center ring; this method is then said to be both 
accurate and precise (reproducible) (Figure 2A). Failure to validate an analytical method 
may produce results that are reproducible, but inaccurate (Figure 2B), accurate, but not 
reproducible (Figure 2C), or neither accurate nor reproducible (Figure 2D) (81).  
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Biological Validation 
The procedures and criteria for validating the analytical performance of ELISAs 
are well described, as previously discussed. One area that is not well defined is the 
biological validation of ELISA results. False-positive ELISA results, a positive detection 
when no antigen is present, are a known issue with ELISAs across many areas of science 
(118-120). One potential source of false-positive results when analyzing environmental 
samples for Cry proteins is the detection of partially degraded proteins by the ELISA. 
This may result from the prevalent use of polyclonal antibodies in commercial ELISA 
kits. Polyclonal antibodies bind to multiple epitopes on a protein; therefore, a partially 
degraded protein may have a sufficient number of antibody binding sites still intact to 
allow for a positive detection. 
Several published studies support this possibility. Einspanier et al. (121) collected 
samples from the gastrointestinal tract (GIT) at slaughter of cows fed either transgenic 
Cry1Ab maize or non-transgenic isoline maize; the samples were analyzed with a 
commercial ELISA kit for Cry1Ab/1Ac. The results indicated that Cry1Ab protein 
resisted digestion and appeared to accumulate in some intestinal juice samples. Cross-
reactivity of the ELISA with animal, microbial, or plant compounds was ruled out 
because this phenomenon was not observed in cows fed non-transgenic isoline maize. In 
a follow-up study, the authors hypothesized that the positive ELISA detection may have 
been the result of a fragmented, yet immunoreactive Cry1Ap protein reacting with the 
antibodies (119). This hypothesis was tested in a second feeding study. Cows were fed 
either transgenic Cry1Ab maize or non-transgenic isoline maize and GIT samples were 
collected at slaughter. In addition to ELISAs, Western blotting was performed on all 
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samples. The ELISA results emulated the initial study; Cry1Ab protein was detected in 
all samples and the concentration appeared to increase during passage through the GIT. 
Cross-reactivity with animal, microbial, or plant components was again ruled out. The 
Western blot data told a different story. Fully intact Cry1Ab was not detected in any GIT 
samples; fragment bands at approximately 17 and 34 kDa were observed in cows fed 
transgenic maize, while no comparable protein bands were observed in cows fed non-
transgenic maize. The results support the hypothesis that the Cry1Ab protein was 
fragmented, yet still capable of immunoreacting with the ELISA antibodies (119). 
Similar results were observed in earthworm tissue samples. Emmerling et al. 
(122) collected samples of earthworm casts and gut content and analyzed the samples for 
the presence of Cry1Ab with ELISAs and Western blotting. ELISA results indicated a 
decreasing, yet still detectable concentration of protein as the protein moved through the 
earthworms’ digestive tract. However, no fully intact protein was observed in any of the 
samples. Three fragments with an approximate size of 17, 23, and 31 kDa were detected 
in the foregut and midgut samples. Western blotting did not indicate that fragments were 
present in samples of the hindgut or cast material, even though Cry1Ab was detected in 
these samples by ELISA. The authors did not specify if blank control samples were 
performed; thus, positive ELISA detections in the hindgut and cast samples may be the 
result of cross-reactivity with animal, microbial, plant, or soil components (122). 
These studies provide examples of why validation is necessary to ensure that only 
fully intact Cry proteins are being detected by ELISAs. Detection of non-bioactive Cry 
protein fragments by ELISAs may lead to an overestimation of the amount of protein in 
the environment. These overestimations could potentially have impacts on the risk 
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assessments for transgenic crops and insecticide formulations containing Cry proteins. 
Although validating ELISA results with bioassays is ideal, Western blotting and liquid 
chromatography – mass spectrometry also can be used to validate results generated by 
ELISAs.  
Bioassays 
 The best way to determine if biological activity of the Cry proteins remains is to 
perform bioassays on environmental samples with an insect species susceptible to the 
protein of interest. There are many different bioassay methods, depending on the sample 
matrix to be studied. Soil samples may be laid over the top of prepared insect diet or 
incorporated directly into the diet (115,123). Alternatively, Cry proteins may be extracted 
from soil samples and then the extract can be incorporated into the diet or overlaid on top 
of the diet (124). Plant tissue and detritus can be analyzed by direct feeding on the tissue, 
or by incorporating the tissue or detritus into the diet (37,125). Water samples may be 
analyzed by placing the insects directly into the water (92). After a pre-determined 
incubation period on the sample-infused diet, insect mortality and other parameters, such 
as insect weight or head capsule width, may be recorded to determine lethal and sub-
lethal effects. Bioassays are only semi-quantitative; exact protein concentrations are 
impossible to define, but based on known LC50 and EC50 values (the concentration 
needed to cause mortality or a specific effect in 50% of the sample population, 
respectively), a general idea of the concentrations present can be determined. Other 
drawbacks that limit the usefulness of bioassays for biological validation are that they are 
time-consuming, expensive, and labor-intensive to set up and analyze, as well as to 
maintain insect colonies for further studies. Also, results may be skewed if an increase in 
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sample material (soil, plant tissue) in the diet is needed to increase protein concentrations 
to levels sufficient to cause negative effects. This increase in sample material may cause 
a decrease in the essential nutrients needed for insect survival, which could result in 
higher than anticipated mortality or effect levels. 
 The three studies discussed below give a sampling of how bioassays have been 
used for biological validation. Head et al. (126) analyzed soil samples for the presence of 
Cry1Ac from cotton with ELISAs and bioassays. Bioassays were performed by mixing 
soil with water to form a slurry, which was then mixed with an agar-based diet. After the 
diet solidified, one first-instar Heliothis virescens larva was introduced into each well. 
Larval survival and insect weights were determined after seven days. The bioassays 
supported the ELISA results that indicated no protein was present in any of the soil 
samples (126). 
 Shan et al. (115) analyzed soil samples for the presence of Cry1F from maize 
with ELISAs and bioassays. Rhizosphere soil samples were collected and diluted by a 
factor of 10 (weight:volume) with agar. This suspension was then laid over the top of 
previously prepared insect diet and one neonate H. virescens was placed in each well. 
Mortality and insect weights were recorded after six days. Cry1F was not detected in any 
of the rhizosphere soil samples by bioassays, which corroborated the ELISA results 
(115). 
 Zwahlen et al. (125) analyzed maize detritus collected from litter bags over a 
period of several months for the presence of Cry1Ab with ELISAs and bioassays. In the 
first year of the study, maize detritus was incorporated directly into the insect diet and fed 
to neonate O. nubilalis; mortality and insect weights were recorded after six days. In the 
32 
 
second year, maize detritus was mixed with extraction buffer and then added to the insect 
diet; mortality and insect weights were recorded after five days. In both years, larval 
mortality decreased over time. This finding supported the ELISA results, which showed 
that the Cry1Ab concentration in maize detritus also decreased over time (125). 
Western blotting 
Western blotting is a technique used to identify specific proteins in a sample. 
First, gel electrophoresis is used to separate proteins and fragments in a sample by size. 
The proteins and fragments are transferred, or electroblotted, onto a nitrocellulose or 
polyvinylidene difluoride membrane. Antibodies specific to the protein of interest are 
incubated with the membrane and bind to the protein. The detecting antibody usually has 
an enzyme conjugated to it, similar to ELISA; in some cases, the enzyme is conjugated to 
a secondary antibody, which then binds to the detecting antibody. Finally, a substrate is 
added which allows for visualization of the protein bands on the membrane. Depending 
on the type of enzyme conjugated to the antibody and the type of substrate used, 
detection can be colorimetric, chemiluminescent, radioactive, or fluorescent (127). 
Unlike bioassays, western blotting is capable of detecting small quantities of protein in a 
sample. However, western blotting is still time-consuming, expensive, and not 
quantitative. These drawbacks are likely a few of the reasons western blotting is not used 
more often.  
In addition to the studies described above, two other studies also have used 
Western blotting to validate their results. Gruber et al. (128) traced the fate of Cry1Ab 
protein in transgenic maize, through animal feed, and into liquid manure. Cry1Ab was 
detected by ELISA in transgenic maize and animal feed prepared from transgenic maize; 
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Western blotting confirmed the presence of fully intact protein. In the liquid manure 
samples, ELISAs showed a decrease in Cry1Ab concentration overtime, which was 
confirmed by Western blotting; however, after 24 weeks of storage, ELISAs still showed 
that Cry1Ab was present, while Western blotting detected only a 34 kDa fragment (128). 
Paul et al. (129) analyzed gastrointestinal tract (GIT) samples from cows fed 
transgenic Cry1Ab maize or non-transgenic isoline maize. The ELISA results echoed the 
Einspanier et al. (121) and Lutz et al. (119) studies; Cry1Ab appeared to accumulate as it 
moved through the GIT. Western blotting determined that small quantities of fully intact 
Cry1Ab were present in all samples, but that the accumulation of protein observed in the 
ELISA results could be attributed to an increase in fragments approximately 17, 34, and 
42 kDa in size, and not due to a increase in fully intact Cry1Ab (129).  
LC/MS 
Liquid chromatography paired with mass spectrometry (LC/MS) is another 
analytical method that may be used to detected Cry proteins in environmental samples. In 
this method, proteins are digested into peptides via proteolytic enzymes. These peptides 
are separated by high efficiency nanocolumn liquid chromatography, which feeds the 
peptides directly into the mass spectrometer. The peptides are ionized by the mass 
spectrometer and all intact peptide ions are measured. The instrument then selects peptide 
ions based on pre-determined criteria such as charge state or mass-to-charge ratio (m/z) 
and subjects these selected peptides to collisionally induced dissociation (CID), which 
causes the peptide ions to fragment in a predictable manner. The CID fragmentation 
pattern can be used to determine the sequence of the peptide; this sequence can be 
compared to databases containing sequences of known proteins to identify the protein in 
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the sample and determine if it is fully intact or a fragment. This method allows for 
identification of a single protein or fragment in a complex mixture of proteins without the 
need for further purification (130).  
Currently, the study of Cry proteins with LC/MS has been limited to identification 
of new toxins and investigations into the mode of action of Cry proteins. Yang et al. 
(131) utilized 2-dimensional liquid chromatography – tandem mass spectrometry to 
analyze protein samples from Bacillus thuringiensis strain 4.0718. The authors identified 
more than 1,000 unique proteins; eleven of these proteins were determined to be 
insecticidal Cry proteins. Bayyareddy et al. (132) used LC/MS to identify 
aminopeptidases and alkaline phosphatases, which are known receptors for Cry4Ba, in 
the detergent-resistant membranes (also known as lipid rafts) of Aedes aegypti. These 
detergent-resistant membranes had previously been suggested as potential entry points for 
bacterial pathogens and their toxins. No studies using LC/MS to analyze environmental 
samples or validate ELISA results were found in this current literature review. This is not 
surprising as the high initial set-up costs, maintenance costs, specialized training required 
to operate the instrument, and long sample analysis time (>90 minutes in both 131-132) 
make LC/MS a less favorable option for detection of Cry proteins and validating ELISA 
results in environmental samples. 
Critical Review of Published Studies 
The final section of this article reviews several published studies and critiques 
their usage of ELISAs for detection of Cry proteins in the environment. This is not meant 
to be an exhaustive review of all published articles, but rather is intended to provide the 
reader with a general assessment of how the scientific community is utilizing ELISAs for 
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Cry protein detection and quantification and identify areas for improvement. Table 1 
summarizes the reviewed articles. 
Sensitivity 
 The sensitivity of ELISAs is one of the areas of validation that is most commonly 
reported in research articles. The limit of detection (LOD) is most often reported, while 
the lower limit of quantitation (LLOQ) is reported less often. A few studies reported 
decision limits instead of LLOQ; these decision limits were determined according to 
governmental criteria (103,128,133). Additionally, a few studies reported only the LOD 
for the commercial ELISA kit used in the study, and did not report the LOD or LLOQ for 
the different matrices investigated (134-135). Of the studies that reported LOD values, 
the results confirm that ELISAs are a sensitive methods of detection; the LOD in these 
studies ranged from 0.01 ng/g (0.01 ppb) to 4 µg/L(4 ppb) in soil and 2.1 ng/L (2.1 ppt) 
to 6 µg/L (6 ppb) in water (106,136-139).  
One-fourth of the studies reviewed failed to report any validation of sensitivity; 
thus, the sensitivity of the recovery methods and ELISA procedures used in these studies 
is unknown. In at least one study, the authors reported that no Cry1Ab protein was 
detected in soil that was in contact with decaying transgenic maize tissue (104). Since the 
authors did not report any sensitivity data, it is impossible to determine if, in fact, no 
protein was present, or if Cry1Ab protein was present in the soil, but the recovery 
methods and ELISA procedures used in the study were not sensitive enough to detect the 
protein.  
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Specificity 
 The use of commercial ELISA kits targeted for detection of only one or two 
proteins has helped resolve some of the specificity issues that occur in environmental fate 
studies, especially when multiple Cry proteins may be present. However, cross-reactivity 
of the antibodies with components in the sample matrix or interference of the sample 
matrix, preventing antibodies from binding to Cry proteins, still needs to be addressed, 
regardless of whether or not a commercial kit is used. For example, Shan et al. (115) used 
a commercial ELISA kit, and observed slight matrix effects in samples of soil extracts. 
To mitigate the matrix effects, a 2x dilution was used for all samples.  
 Several studies analyzed blank soil or water samples for the presence of Cry 
proteins in parallel with their analysis on environmental samples. In nearly all of those 
control samples, no positive detections occurred; thus, cross-reactivity with sample 
matrix components was excluded. However, these blank samples do not account for the 
ability of matrix components to interfere with the quantitation of a protein. Testing for 
interference (as well as cross-reactivity) should be performed by mixing a 2x standard 
curve with the blank sample matrix (water, soil extract, etc.), resulting in a 1x standard 
curve in a 2x dilution of the matrix. Using a 1x standard curve prepared in assay buffer as 
a reference, the differences between the theoretical and observed values for the points in 
the standard curve prepared in the matrix can be calculated. Differences of greater than 
20% may indicate interference or cross-reactivity, though this may vary (112). Another 
problem with running only blank matrix samples can be observed in Wang et al. (140). In 
that study, the authors detected protein in soil samples from plots planted with non-Bt 
rice. Since no further sensitivity validation steps were performed, it is difficult to 
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determine if the positive detection is the result of a basal level of protein in the soil, as the 
authors suggest, or if there was cross-reactivity to soil components (140).  
 As with sensitivity, one-fourth of the studies reviewed failed to report any 
validation of specificity. Therefore, the extent of the effect, if any, that cross-reactivity 
and interference of other proteins and matrix components may have on the results of 
these studies is difficult to ascertain.  
Accuracy 
 One-third of the studies reviewed failed to report any recovery or extraction 
efficiency values for accuracy. Thus, it becomes difficult to determine how efficient these 
extraction methods were at recovering Cry proteins from various environmental matrices. 
Further, of the studies that do include recovery values, many of the recovery values are 
significantly below the acceptable recovery range of 70-120%. Recovery values of 10-
50% in soil are common, although higher recoveries are attainable (105,128,139,141). 
Soil type has a significant impact on the recovery values of Cry proteins observed in soil 
samples. Soils high in clay and silt content typically yield poor recovery of Cry proteins 
(10-50%) while soils high in sand content yield better recoveries (75-98%)(103,115,141). 
Recovery of Cry proteins in water also is highly variable, ranging from 23% to 78% 
(92,139). One study avoided this issue by analyzing the water directly; however, since no 
protein was detected in the water samples, extracting the samples (i.e., concentrating) 
would have been advisable to increase the sensitivity of the method (75). 
Low recovery values are a known problem with extraction of Cry proteins from 
environmental matrices (78). One mechanism to manage this issue is to perform spike 
and recovery on multiple samples and determine the variation between the samples. A 
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coefficient of variation (%CV) of less than 20% provides support that a researcher is 
using an accurate extraction method, even though recovery of the protein may be less 
than 70% (112). Only one of the studies reviewed provided %CV values; Shan et al. 
(115) reported %CV values of 5.4-13.8% for soil recovery. An additional four studies 
reported recovery means and standard deviations (126,128,139,141). Thus, the %CV for 
these studies can be calculated by dividing the standard deviation by the mean, and 
multiplying by 100%. In these studies, the calculated %CV values range from 4.7 to 
21.2% depending on the sample matrix. Three additional studies reported means, 
standard error, and sample size (101,138,142). Standard deviation in these studies can be 
calculated through the equation 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑒𝑠𝑠𝑒𝑠 =  𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑑𝑑𝑑𝑠𝑠𝑑𝑑𝑠
�𝑠𝑠𝑠𝑠𝑠𝑑 𝑠𝑑𝑠𝑑 , or written another 
way, 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑒𝑑𝑑𝑠𝑠𝑑𝑒𝑠 = 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑒𝑠𝑠𝑒𝑠 × �𝑠𝑠𝑠𝑠𝑠𝑒 𝑠𝑑𝑠𝑒. In these three studies, 
the calculated %CV values ranged from 6.1 to 35.1%. Eight of the reviewed studies 
provided the standard error or percentage recovery, but did not provide enough additional 
information (i.e., sample size) to calculate %CV for the studies. As noted above, the 
remainder of the studies failed to even report percentage recovery. 
Precision 
 Precision is the area of validation reported the least in the literature reviewed here. 
Only six of twenty-six studies reported any information on validation of assay precision. 
Two studies used assay methods that previously had been validated for precision 
(137,139). Shan et al. (115) investigated precision of the assay across analysts and days 
(%CV = 9.4-14.6%), while Gruber et al. (128) validated the intra- and inter-assay 
precision (%CV = 5.9% and 14.6%, respectively). The final two studies reanalyzed plates 
that had a %CV less than 10% (75,101).  
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Three-fourths of the studies not reporting precision data did utilize commercial 
ELISA kits. Use of commercial kits is advantageous, as these kits undergo rigorous 
testing by the manufacturer during development to ensure uniformity with plates, 
between plates, across antibody lots, etc. Thus, some of the concerns regarding assay 
precision can be mitigated by the use of a commercial ELISA kit, while other areas still 
need to be validated (i.e., variation between analysts, etc.). Finally, five studies prepared 
ELISA plates in their laboratories using lab-generated or commercial sources of 
antibodies (92,103,125-126,133). All of these studies failed to report precision data. This 
is significant as the processes for preparing these plates in research labs is most likely not 
as refined as the processes used in commercial manufacturing facilities, which could 
result in inconsistencies across plates or even within a single plate. Additionally, there 
may be significant variability between lots of lab-generated antibodies. All of these 
factors can affect the variability of the assays, making comparisons between samples on 
separate plates difficult.  
Biological Validation 
 A vast majority of the studies failed to perform any form of biological validation. 
Thus, it is impossible to determine if the Cry proteins detected in environmental samples 
were fully intact and/or biologically active. A couple of papers recognized that the 
protein detected may not be fully intact and/or biologically active. Baumgarte and Tebbe 
(105) recognized that they could not “claim that the immunoreactive Cry1Ab protein 
detected in soils and plant residues was actually biologically active.” Nguyen and Jehle 
(143) also acknowledged that “it is not clear whether these ELISA detectable Cry1Ab 
residues still retain their bioactivity.” Gruber et al. (133) did not perform biological 
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validation, but protein was not detected in any of the soil samples, rendering biological 
validation unnecessary. 
 Seven papers performed bioassays with an insect species that was susceptible to 
the protein of interest in the study. In five of the studies, the bioassay results confirmed 
the ELISA results. In Zwahlen et al. (125) and Fejes et al. (92), the bioassay results 
showed decreasing mortality and sublethal effects as the protein levels, as determined by 
ELISA, also decreased. Bioassays performed by Head et al. (126) and Shan et al. (115) 
indicated that no Cry protein was present in any of the samples, which corresponded to 
the ELISA results. Wang et al. (142) performed bioassays on soil samples from the 
rhizosphere region of transgenic rice plants and observed no significant effects, 
confirming the ELISA results; however, the authors did not perform bioassays on 
samples taken from soil amended with transgenic rice tissue. 
 The remaining two studies produced the most interesting results. Bioassays 
performed by Marchetti et al. (144) suggested toxicity of the proteins decreased more 
rapidly than estimated by ELISA results. This is interesting because it indicates that the 
ELISAs may be detecting non-bioactive forms of the protein. Gruber et al. (128) 
biologically validated their results with Western blotting instead of bioassays. The results 
showed that Cry1Ab fragments of 17, 34, and 42 kilodaltons (kDa), as well as the full-
size 65 kDa parent molecule, were detected in transgenic plant tissue and animal feed 
from transgenic plants. Only the 34 kDa fragment and the full-size protein were detected 
in liquid manure. The most interesting result, however, is that after 24 weeks of storage, 
the full-size protein had been degraded and only the 34 kDa fragment remained, yet 
Cry1Ab could still be detected in the slurry by ELISA at a concentration of 
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approximately 1 µg/g. This is interesting because, as with the Marchetti et al. (144) 
study, it indicates that the ELISA may be detecting degraded, non-bioactive forms of the 
protein.  
Conclusions 
ELISAs have emerged as the predominant method for detecting Cry proteins in 
the environment. ELISA validation methods are necessary to ensure usable data are 
generated in environmental fate studies. These methods, and their associated acceptance 
criteria, have been validated through years of research, but they have yet to be widely 
adopted by environmental fate researchers. More than 90% of the studies reviewed failed 
to perform one or more of the five key areas of validation. Thus, substantial improvement 
in estimating the concentrations of Cry proteins in environmental samples can be made 
by simply increasing the practice of utilizing validation methods. Increasing the accuracy 
of environmental measurements will increase the usefulness of these data to regulators 
and will allow for a more efficient regulatory process. 
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Dissertation Organization 
This dissertation is organized into four chapters to investigate the fate of Cry 
proteins in the environment. The first chapter provides background information on Cry 
protein history and usage, and detection of the proteins with ELISAs. It also provides a 
review of studies utilizing ELISAs for detection of Cry proteins in environmental 
samples and critiques their usage of validation methods. The second chapter describes 
enzyme and non-enzyme based model systems that were screened for their ability to 
generate fragments of Cry1Ab. The third chapter analyzes the fragments generated in the 
second chapter with ELISAs and bioassays to determine if the fragments are still 
detectable and/or if the fragments retain any biological activity. Finally, chapter 4 
provides the overall conclusions that can be drawn from this research.  
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Figures 
 
Figure 1. Schematic of a typical direct sandwich ELISA. 
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Figure 2. Visual representation of accuracy and precision. The central ring, or bull's-eye, 
represents the true amount of target analyte in a sample and the individual dots represent 
sample replicates. A. All sample replicates are contained within the central circle; the 
results are both reproducible and accurate. B. Replicates are grouped tightly 
(reproducible), but provide an inaccurate result. C. Replicates are widely dispersed (not 
reproducible), but the average provides an accurate result. D. Replicates are neither 
accurate nor reproducible.  
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Tables 
 
Table 1. List of manufacturers of ELISA kits for detection of Cry proteins.  
 
 
  
Manufacturer Target Protein(s)
Agdia Cry1Ab/Cry1Ac
Cry1Ab/Cry3Bb1
Cry1Ac/Cry2Ab
Cry1F
Cry1F/Cry34Ab1
Cry2A
Cry2A/Cry3Bb1
Cry3A
mCry3A
Cry3Bb1
Cry34Ab1
Cry1Ab/Cry1Ac
Cry1Ab/Cry3Bb1
Cry1F
Cry1F/Cry34Ab1
Cry2A
Cry3A
Cry3Bb1
Cry34Ab1
Envirologix Cry1Ab/Cry1Ac
Cry1Ab/Cry3Bb1
Cry1Ac/Cry2Ab
Cry1C
Cry1F
Cry1F/Cry34Ab1
Cry2A
mCry3A
Cry3Bb1
Cry34Ab1
Cry9C
Fitzgerald Cry1Ab/Cry1Ac
(Acton, MA, USA)
Romer Labs Cry1Ab
Cry1Ac
Cry1F
Creative 
Diagnostics
(Shirley, NY, USA)
(Portland, ME, 
USA)
(Elkhart, IN, USA)
(Union, MO, USA)
 
 
46 
Table 2. Summary of the ELISA validation steps performed in studies on the environmental fate of Cry proteins. 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Head et al. 
(123) 
Cry1Ac Soil LOD = 3.68 ng/g; 
LLOQ not reported 
Analyzed soils 
from non-Bt fields 
in parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
interference not 
reported 
Mean recoveries ranged 
24-39% depending on 
soil type; 
%CV = 21.2%1 
Generated 
ELISA plates in-
house; 
data on variation 
between or 
within plates or 
across days and 
plate lots not 
reported 
Performed bioassays 
with a susceptible 
species; 
bioassays results 
indicated no protein 
was present in all 
samples, which 
confirmed the 
ELISA results 
        
Hopkins and 
Gregorich 
(142) 
Cry1Ab Soil LOD, LLOQ not 
reported 
Cross-reactivity 
and interference 
due to matrix 
components not 
reported 
No recovery methods or 
data reported efficiency 
of extraction procedure 
unknown 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Zwahlen et 
al. (122) 
Cry1Ab Maize 
detritus 
LOD, LLOQ not 
reported 
Analyzed maize 
detritus from non-
Bt plants in 
parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
interference not 
reported 
Extraction efficiency for 
maize detritus not 
reported 
Generated 
ELISA plates in-
house; 
data on variation 
between or 
within plates or 
across days and 
plate lots not 
reported 
Performed bioassays 
with a susceptible 
species; 
bioassay results 
indicated decreasing 
mortality and sub-
lethal effects over 
time, confirms 
ELISA results 
        
Ahmad et 
al. (131) 
Cry3Bb1 Soil Kit LOD = 1 
ng/mL; 
LOD, LLOQ for 
soil recovery 
method not 
reported 
Analyzed soils 
from non-Bt fields 
in parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
interference not 
reported 
Mean recoveries ranged 
17-66% depending on 
spiking solution and soil 
type; standard error 
reported, but insufficient 
information to calculate 
%CV 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed, 
unknown  if protein 
detected was fully 
intact and/or 
biologically active 
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Table 2. (continued) 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Baumgarte 
and Tebbe 
(102) 
Cry1Ab Soil, 
maize 
tissue 
LOD = 0.19 ng/g soil 
after adjusting for 
recovery percentage; 
LLOQ not reported 
Analyzed soils and 
maize tissue from 
non-Bt fields in 
parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
interference not 
reported 
Recovery values 
ranged 34-40% in 
soil; 
standard error 
reported, but 
insufficient 
information to 
calculate %CV; 
extraction efficiency 
for maize tissue not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active; 
authors recognized 
this data gap 
        
Wang et al. 
(140) 
Cry1Ab Rice 
tissue, soil 
LOD = 0.5 ng/g soil, 
not reported for rice 
tissue; 
LLOQ not reported 
Analyzed non-Bt 
rice tissue in parallel, 
no false positives, 
indicates cross-
reactivity not 
significant; 
cross-reactivity and 
interference in soil 
not reported 
Mean recoveries 
ranged 46-82% 
depending on soil 
type; 
%CV ranged from 
6.1-35.1%2 
depending on soil 
type; 
extraction efficiency 
for rice tissue not 
reported; 
 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Performed with 
susceptible species 
for rhizosphere soils, 
no significant effects 
observed, confirms 
ELISA results; 
not performed for 
soil amended with 
rice tissue, unknown 
if protein detected 
was fully intact 
and/or biologically 
active 
        
Marchetti et 
al. (141) 
Cry1Ab, 
Cry1Ac 
Soil LOD, LLOQ not 
reported 
Cross-reactivity and 
interference due to 
matrix components 
not reported 
Mean recoveries of 
67% in clay loam 
soil, 82% in sandy 
soil; 
%CV not reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Performed with a 
susceptible species; 
bioassay results 
indicated that the 
decrease in toxicity 
occurred more 
rapidly than shown 
by ELISA results 
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Tale 2. (continued) 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Nguyen and 
Jehle (139) 
Cry1Ab Maize 
tissue, 
detritus 
LOD = 0.14 ng; 
LLOQ not reported 
Analyzed non-transgenic, 
isoline mazie in parallel, 
no false positives, 
indicates cross-reactivity 
not significant; 
interference not reported 
Extraction efficiency 
from maize tissue not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active, 
authors recognized 
this data gap 
        
Gruber et al. 
(130) 
Cry1Ab Soil LOD = 0.4 ng/g 
soil; Decision 
Limit (2 ng/g soil) 
and Detection 
Capacity (3.1 ng/g 
soil) determined 
according to 
European 
Commission 
Decision 
2002/657/EC34 
Analyzed soils from non-
Bt fields in parallel, no 
false positives, indicates 
cross-reactivity not 
significant; 
interference not reported 
Mean recoveries 
ranged 45-91% 
depending on soil type 
%CV not reported 
Generated 
ELISA plates 
in-house; 
data on 
variation 
between or 
within plates 
or across days 
and plate lots 
not reported 
Not performed, but no 
protein detected in any 
soil samples 
potentially renders 
bioassays unnecessary 
        
Icoz and 
Stotzky 
(132) 
Cry3Bb1 Maize 
tissue, 
root 
extracts, 
soil 
Kit LOD = 
1ng/mL; 
LOD, LLOQ for 
soil recovery 
method not 
reported 
Cross-reactivity and 
interference due to matrix 
components not reported 
Recovery from soil and 
root extracts and 
extraction efficiency 
from maize tissue not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Prihoda and 
Coats (98) 
Cry3Bb1 Soil, 
maize 
tissue 
LOD = 0.7 ng/mL; 
LLOQ = 9 ng/g 
soil 
Analyzed non-transgenic, 
isoline maize in parallel, 
no false positives, 
indicates cross-reactivity 
not significant; 
interference not reported 
Mean recovery 
decreased from 41% (0 
hr) to 15% (96 hr); 
%CV ranged from 6.1-
35.1%2; extraction 
efficiency from maize 
tissue not reported 
Used 
commercial 
ELISA kit; 
reanalyzed 
plates with 
%CV >10%  
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
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Table 2. (continued) 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Prihoda and 
Coats (72) 
Cry3Bb1 Water, 
sediment, 
maize 
tissue 
LOD, LLOQ not 
reported 
Analyzed non-
transgenic, isoline 
maize in parallel, no 
false positives, 
indicates cross-
reactivity not 
significant; 
interference not 
reported 
Water analyzed 
directly; 
recovery from 
sediment and 
extraction efficiency 
from maize tissue 
not reported 
Used 
commercial 
ELISA kit; 
reanalyzed plates 
with %CV >10% 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Schrader et 
al.  (143) 
Cry1Ab Soil, 
maize 
detritus, 
earthworm 
tissue 
LOD = 0.017 ng/g 
soil, 1 ng/g maize 
detritus, 0.58 ng/g 
earthworm tissue; 
LLOQ not reported  
Cross-reactivity and 
interference not 
reported for any of 
the matrices 
investigated 
Recovery from soil 
and earthworm 
tissue and extraction 
efficiency from 
maize detritus not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Shan et al. 
(112) 
Cry1F Soil LOD, LLOQ 
determined 
empirically for each 
soil type 
Analyzed solutions 
of soil extracts for 
matrix effects; 
Used a 2x dilution to 
mitigate matrix 
effects 
Mean recoveries 
ranged 66.9-90.5% 
depending on soil 
type; 
%CV ranged from 
5.4-13.8% 
Used 
commercial 
ELISA kit; 
tested method 
with 2 analysts 
across 2 days; 
%CV = 9.4-
14.6% 
Performed with a 
susceptible species; 
bioassays indicated 
no protein present, 
confirmed ELISA 
results 
        
Daudu et al.  
(101) 
Cry1Ab Soil, 
maize 
tissue 
LOD, LLOQ not 
reported 
Cross-reactivity and 
interference due to 
matrix components 
not reported 
Recovery from soil 
and extraction 
efficiency from 
maize tissue not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
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Table 2. (continued) 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Badea et al. 
(133) 
Cry1Ab Soil, 
maize 
tissue 
LOD = 0.01 ng/g soil; 
LLOQ not reported 
Analyzed soil free of 
Cry protein in 
parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
interference not 
reported 
Mean recovery less 
than 40% in soil; 
%CV not reported; 
extraction efficiency 
from maize tissue 
not reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; unknown if 
protein detected was fully 
intact and/or biologically 
active 
        
Miethling-
Graff et al. 
(134) 
Cry3Bb1 Soil, 
maize 
detritus 
LOD = 0.01ng/g soil; 
LLOQ not reported 
Analyzed soils from 
non-Bt plots in 
parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
interference not 
reported 
Recovery from soil 
and extraction 
efficiency from 
maize detritus not 
reported 
Used 
commercial 
ELISA kit 
that had been 
previously 
validated 
(Nguyen et al. 
2008) 
Not performed; unknown if 
protein detected was fully 
intact and/or biologically 
active 
        
Tank et al. 
(103) 
Cry1Ab Maize 
detritus, 
water 
LOD = 0.56 ng/mL 
(maize detritus) and 6 
ng/L (water); 
LLOQ not reported 
 
Used buffer blanks 
to account of buffer 
matrix effects; 
Did not account for 
matrix effects from 
maize detritus and 
water samples 
Recovery from 
water and extraction 
efficiency from 
maize detritus not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; unknown if 
protein detected was fully 
intact and/or biologically 
active 
        
Gruber et al.  
(125) 
Cry1Ab Maize 
tissue, 
soil, 
animal 
feed, 
liquid 
manure 
LOD = 0.4 ng/g; 
Decision Limit and 
Detection Capacity 
determined according 
to European 
Commission Decision 
2002/657/EC34 
No cross-reactivity 
or interference 
observed in any of 
the blank matrix 
samples analyzed 
Mean recoveries 
ranged 68-98% 
depending on 
sample matrix; 
%CV ranged from 
4.5-16.7%1 
Intra-assay 
precision = 
5.9% CV; 
Inter-assay 
precision = 
14.6% CV 
Western blotting used to 
determine protein 
fragmentation; 
ELISA results indicated 
protein in slurry at 24 
weeks, but only fragments 
observed with Western blots 
 
 
51 
Table 2. (continued) 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Helassa et 
al. (135) 
Cry1Aa Soil LOD = 4 µg/L; 
LLOQ not reported 
No interference due to 
soil matrix 
Mean recoveries 
ranged 53-66% 
depending on soil 
type; 
%CV ranged from 
9.0-29.4%2 
depending on soil. 
Used commercial 
ELISA kit; 
additional 
precision data not 
reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Shu et al. 
(144) 
Cry1Ab Earthwor
m tissue, 
soil 
LOD, LLOQ not 
reported 
Cross-reactivity and 
interference to soil and 
earthworm tissue not 
reported 
Recovery from soil 
and earthworm 
tissue not reported 
Used commercial 
ELISA kit; 
additional 
precision data not 
reported 
Not performed 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Fejes et al. 
(89) 
Cry4 Water LOD = 2 ng/mL pure 
protein, 170-900 
ng/mL in samples 
concentrated via 
lyophilization; 
LLOQ not reported 
Matrix effects observed 
in undiluted Bti 
formulations used in 
standard curves; 
matrix effects of field-
collected water used in 
study not reported 
Mean recoveries 
23-30%; 
insufficient 
information to 
calculate %CV 
 
 
Used commercial 
antibodies, but 
prepared own 
microplates and 
antibody-enzyme 
conjugates; 
variability 
between plates, 
antibody-enzyme 
batches not 
reported 
Performed with a 
susceptible species; 
bioassays indicated 
increased larval 
survival as 
concentration of 
protein decreased 
(concentration of 
protein determined 
by ELISAs) 
        
Gruber et al. 
(100) 
Cry1Ab Soil LOD = 0.4 ng/g soil; 
Decision Limit (2 ng/g 
soil) determined 
according to European 
Commission Decision 
2002/657/EC34 
Analyzed soils from 
non-Bt fields in parallel, 
no false positives, 
indicates cross-reactivity 
not significant; 
interference not reported 
Mean recoveries 
ranged 49-89% 
depending on soil 
type; 
%CV not reported 
 
Generated ELISA 
plates in-house; 
data on variation 
between or within 
plates or across 
days and plate 
lots not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
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Table 2. (continued) 
Reference Protein Matrix Sensitivity Specificity Accuracy Precision Biological Validation 
Wang et al. 
(137) 
Cry1Ab/1Ac 
fusion 
protein 
Soil, root 
exudates, 
water 
LOD 0.1ng/g (soil) 
and 0.005 ng/mL 
(water); 
LLOQ not reported 
 
Analyzed water from 
non-Bt plots in 
parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
protein detected in 
soils from non-Bt 
plots 
Mean recoveries 
ranged 46-82% 
depending on soil 
type; 
%CV not reported; 
recovery from root 
exudates not 
reported 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Whiting et 
al.  (136) 
Cry1Ab 
Cry3Bb1 
Soil, 
sediment, 
water 
LOD = 0.86 ng/g 
soil, 2.1 ng/L water 
LLOQ not reported 
Previously validated 
(Mueting et al. 2014, 
Strain et al. 2014) 
Mean recoveries of 
77% in soil and 
sediment, 78% in 
water; 
%CV ranged from 
9.1-17.9%1 
Previously 
validated 
(Mueting et al. 
2014, Strain et 
al. 2014) 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
        
Xue et al. 
(138) 
Cry3Bb1 Soil, 
maize 
detritus 
LOD, LLOQ not 
reported 
Analyzed soils from 
non-Bt plots in 
parallel, no false 
positives, indicates 
cross-reactivity not 
significant; 
cross-reactivity and 
interference in maize 
detritus not reported 
Mean recoveries 
ranged 10-96% 
depending on soil 
type; 
%CV ranged from 
2.5-20.7%1; 
extraction efficiency 
for maize detritus 
not reported 
 
Used 
commercial 
ELISA kit; 
additional 
precision data 
not reported 
Not performed; 
unknown if protein 
detected was fully 
intact and/or 
biologically active 
1%CV calculated using mean and standard deviation provided by the authors. 
2%CV calculated using mean, standard error, and sample size provided by the authors. 
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CHAPTER 2. DEVELOPMENT OF A MODEL SYSTEM 
APPROACH FOR GENERATING FRAGMENTS OF THE 
CRY1AB PROTEIN 
A paper to be submitted to the Environmental Toxicology and Chemistry 
Vurtice C. Albright III, Richard L. Hellmich, Joel R. Coats 
Abstract 
The use of transgenic crops expressing one or more Cry proteins for insect 
management has grown dramatically since their introduction nearly two decades ago. 
However, many questions surrounding the environmental fate of these proteins still 
persist. One area of particular interest is the possible detection of Cry protein fragments 
by the antibodies used in ELISA kits. A model system approach is used to generate 
environmentally relevant fragments. Eight different types of model systems were 
screened for their ability to generate fragments of the Cry1Ab protein; five of these 
model systems reliably generated Cry1Ab fragments. These fragments were analyzed in a 
subsequent study to determine if the fragments are still detectable by ELISA and if they 
retain any bioactivity.  
Introduction 
Insecticidal crystal (Cry) proteins isolated from the bacterium Bacillus 
thuringiensis are widely used for insect pest management in agriculture. Since their 
introduction in 1996, transgenic maize expressing one or more of these Cry proteins now 
accounts for 81% of all maize planted in the United States [1]. Such widespread use has 
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led to questions regarding the environmental fate of these Cry proteins, including 
persistence, movement, and stability, in various environmental matrices.  
Many researchers are addressing these questions by attempting to detect and 
quantify the amount of Cry proteins in environmental samples. A variety of detection 
methods are used to monitor for Cry proteins in environmental samples, but the most 
commonly used method is enzyme-linked immunosorbent assays (ELISA) [2]. Microtiter 
plate ELISAs are preferred to methods such as liquid chromatography/mass spectrometry 
(LC/MS), as the ELISA kits typically include all required materials; a large number of 
samples can be processed in a short amount of time (4-8 hr) with little specialized 
training, making them very cost-effective for researchers in academia and industry [2]. 
Several manufacturers produce ELISA kits for detection of Cry proteins, 
primarily for seeds and leaf tissue. Before these ELISA kits are used for detection of Cry 
proteins in environmental samples, the entire analytical method (including extraction 
protocol) must be validated. A quality validation study addresses the following: 1) 
sensitivity – defining the quantitative range and determining the upper and lower limit of 
quantitation; 2) specificity – determining that only the protein of interest is detected and 
there is no cross-reactivity or interference with related proteins or components in the 
matrix; 3) accuracy – ensuring the amount of protein detected in the ELISA is close to the 
actual amount in a sample; 4) precision – ensuring that the results are repeatable across 
days, analysts, and laboratories. These steps are well-researched and common in the 
literature [3-5]. 
Despite these steps, biological validation, i.e., ensuring the proteins detected are 
bioactive, is usually lacking. This is a crucial oversight, as a majority of the ELISA kits 
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utilize polyclonal antibodies. Polyclonal antibodies are produced by injecting the antigen 
of interest into a vertebrate host organism and later purifying the antibodies out of the 
serum. The process results in a heterogeneous mixture of antibodies that bind to multiple 
epitopes on a protein, increasing the chances of detection, and leading to very sensitive 
assays. However, use of polyclonal antibodies also increases the likelihood of a false 
positive result through the detection of a partially degraded protein. Although some 
antibody-binding sites on a partially degraded protein may be lost, other antibodies in the 
heterogeneous mixture may still be capable of binding to the protein fragment. This could 
result in an ELISA test indicating a positive detection in a sample where no fully intact 
protein exists. False positive results may lead to overestimations of the concentrations of 
these proteins in the environment, which potentially could impact the risk assessment for 
these proteins.  
This phenomenon of Cry protein fragments producing false positive results is well 
known. Einspanier et al. [6] fed transgenic maize to cattle to trace select proteins through 
the bovine gastrointestinal tract (GIT) using a commercially available ELISA kit. They 
reported that Cry1Ab protein accumulated during the pass through the GIT; cross-
reactivity with other proteins was not the cause, as the effect was not observed in cattle 
fed isoline, non-transgenic maize [6]. In a subsequent study, the authors hypothesized 
that the protein was fragmented, yet still immunoactive, leading to its detection [7]. This 
hypothesis was tested by feeding transgenic maize containing Cry1Ab to cattle, collecting 
samples from the GIT at slaughter, and analyzing them with ELISAs and Western 
blotting. The ELISA results indicated that the Cry1Ab concentration increased during 
passage through the GIT. However, the Western blotting results showed that no Cry1Ab 
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was present in any samples; only bands of approximately 34 and 17 kDa were observed, 
whereas the source Cry1Ab was 60 kDa, calling into question the ELISA results [7]. 
Therefore, it is crucial to understand how fragmented proteins affect ELISAs and to 
determine if any bioactivity is retained by these fragments.  
In order to determine if Cry protein fragments are still detectable by ELISAs, a 
reliable and reproducible method of generating Cry protein fragments must first be 
developed. The objective of this study is to use a model system approach to degrade 
Cry1Ab protein into environmentally relevant fragments. A model system approach is 
useful in that it allows researchers to control all parameters in a system; one to a few 
parameters can then be altered to determine the effects changes would have on the system 
as a whole. In this study, use of a model system approach allows Cry1Ab to be degraded 
in a controlled manner and produce environmentally relevant fragments. Five enzyme-
based model systems using the enzymes trypsin, chymotrypsin, pepsin, proteinase K, and 
a simulated gut fluid are evaluated. Non-enzyme based model systems, including 
sunlight/UV photodegradation, an acidic buffer only, and long-term degradation in buffer 
were also tested for their ability to generate fragments of Cry1Ab. Gel electrophoresis 
with Coomassie or silver staining was used to confirm fragmentation of the protein. 
Bioassays were performed on model system components to ensure that these components 
would not have a significant effect on insect survival or weight gain.   
Methods and Materials 
Gel Electrophoresis 
Polyacrylamide gel electrophoresis with sodium dodecyl sulfate (SDS-PAGE) 
was used to screen model systems for production of Cry1Ab fragments. Gels were 
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prepared fresh daily according to a previously described procedure [8]. Recipes in Table 
1 were modified from Rosenberg [8] to fit a Bio-Rad Mini-Protean II gel apparatus (gel 
size 83 mm x 73 mm x 1 mm). Samples were prepared for electrophoresis by adding an 
appropriate amount of 4X sample buffer to obtain a 1X sample buffer concentration. 
Sample buffer was prepared by combining 4 g sucrose, 0.8 g sodium dodecyl sulfate 
(SDS), 2.5 mL 1M Tris-HCl (pH 6.8) and 250 µL 0.1% (w/v) bromophenol blue and 
diluting to 10 mL with nanopure water. Samples were heated to 100˚C for 3-4 min, 
chilled in ice for 10 min and centrifuged at 12,000 x g for 5 min. Running buffer (3.03 g 
Tris (hydroxymethyl)aminomethane (THAM), 14.42 g glycine, 1 g SDS, diluted to 1 L 
with nanopure water) was added to the upper and lower chambers of the apparatus. A 20-
µL sample was added to each well. Each gel also contained 5 µL of PageRulerTM 
Unstained Broad Range Protein Ladder (Fisher Scientific) with molecular bands ranging 
from 5 kilodaltons (kDa) to 250 kDa. Gels were run at a constant 180 volts until the dye 
front was within 1 centimeter of the bottom of the gel (approximate run times were 1 hr). 
Gels were then removed from the glass plates and stained with either Coomassie Brilliant 
Blue or silver stain. Gels were digitized using a Lexmark X83 All-in-One 
printer/copier/scanner and Lexmark Viewing Booth software (Lexmark International Inc., 
Lexington, KY). Images of the gels were edited and annotated using Adobe Photoshop 
CS5 (version 12.1 x64) (Adobe Systems Inc., San Jose, CA).  
Coomassie Staining 
The Coomassie staining procedure from Rosenberg [8] was used. Briefly, 
Coomassie stain was prepared by dissolving 1 g Coomassie Brilliant Blue R-250 (Fisher 
Scientific) in 100 mL acetic acid and 400 mL methanol and diluting to 1 L with nanopure 
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water. Destain solution was prepared by diluting 100 mL acetic acid and 400 mL 
methanol to 1 L with nanopure water. Gels were stained in Coomassie stain for 30 min 
and destained with destain solution for 2-3 hr or overnight with the destain solution being 
changed 1-2 times. All staining steps took place on an orbital shaker (ELMI Ltd., Riga, 
Latvia) at 100 rpm.  
Silver Staining 
The silver staining procedure from Rosenberg [8] also was used. Briefly, after gel 
electrophoresis, gels were stored in gel fix solution (50% (v/v) methanol, 12% (v/v) 
acetic acid, 38% (v/v) water) overnight. Gels were washed three times with 50% (v/v) 
ethanol for 20 min each. Gels were then submerged in sodium thiosulfate (0.2 g/L sodium 
thiosulfate) for exactly 1 min and then rinsed with nanopure water three times for 20 sec 
each. Gels were submerged in silver nitrate solution (2 g/L silver nitrate, 0.75 mL/L 37% 
(v/v) formaldehyde stock solution) for 20 min and rinsed with nanopure water 2 times for 
20 sec each. Bands were visualized by submerging gels in developing solution (60 g/L 
sodium carbonate, 0.5 mL/L 37% (v/v) formaldehyde stock solution, 4 mg/L sodium 
thiosulfate) for up to 10 min. The developing process was terminated by washing gels 
with nanopure water twice for 2 min each. Finally, gels were submerged in gel fix 
solution for 10 min and then in 50% (v/v) methanol for 20 min. All steps were performed 
at room temperature on an orbital shaker. 
Bioassays 
Insect diet was prepared by mixing one part Stonefly Heliothis diet (Ward’s 
Science, Rochester, New York) with three parts liquid, containing treatment or control 
solution. The diet was thoroughly mixed, and 0.3 mL of diet was placed into each well. 
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There were 16 wells per replicate and 3 replicates per treatment (N=48). One European 
corn borer (ECB) neonate, Ostrinia nubilalis, was placed in each well and incubated at 
27˚C (+ 2˚C) and 50-65% humidity. European corn borers were provided by the Corn 
Insects and Crop Genetics Research Unit of the USDA–ARS, Ames, IA. After seven 
days, larvae were assessed for survival and weight gain. Statistical significance (p < 0.05) 
was determined using an analysis of variance in SAS 9.3 software (SAS Institute, Cary, 
NC). 
Range-Finding Bioassays 
Range-finding bioassays were used to determine the LC90 and LC95 values 
specific to the protein and insect colony used in the study. The protein used in this study 
was trypsin-activated Cry1Ab protein (salt-free, 96% pure) dissolved in N-cyclohexyl-3-
aminopropanesulfonic acid (CAPS) buffer and was purchased from Case Western 
Reserve University (Cleveland, OH). The concentration of the stock solution was 900 
µg/mL.  
Two preliminary range-finding bioassays were performed to determine an 
appropriate range for the bioassays. The first preliminary bioassay used eight 
concentrations with a range of 1-500 ng/g diet, and the second preliminary assay 
narrowed the range to 5-125 ng/g diet. A water control and buffer control that consisted 
of equal parts 100 mM potassium phosphate, pH 7.6 (enzyme solution buffer) and 50 mM 
CAPS, pH 10.5 (protein solution buffer) were included in each bioassay. From the two 
preliminary bioassays, the concentrations of Cry1Ab used in the range-finding 
experiment were set at 15, 30, 45, 60, 75, 90, 105, and 120 ng/g diet. Five range-finding 
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bioassays were started on five different days. A probit analysis in SAS 9.3 was used to 
analyze the data and determine the LC90 and LC95 values.  
Buffer Determination 
A variety of buffers were screened with bioassays to determine if any of the 
buffer components affected insect survival or weight gain. Table 2 lists buffer 
composition and enzyme compatibility. A total of 7 different buffers were tested using 
the previously described bioassay procedure.  
Trypsin 
Trypsin was the first enzyme tested for the ability to degrade Cry protein. Trypsin 
is a serine protease found in the gastrointestinal tract of vertebrate and invertebrate 
animals. Vertebrates, such as cattle fed on transgenic maize, and invertebrates, such as 
detritivores feeding on maize detritus, may excrete Cry protein fragments into soil and 
water where they may be detected by ELISAs. Additionally, trypsin also acts as a 
surrogate for other serine proteases, which are ubiquitous in eukaryotes and prokaryotes. 
All enzymes were tested using an enzyme:toxin (mol:mol) ratio [9]. In order to terminate 
the model system at a specific time point, an appropriate enzyme inhibitor that has no 
significant effects on insect survival and weight gain is needed. Trypsin from bovine 
pancreas (cat. no. T9201), trypsin inhibitor from Glycine max (cat. no. 93620), and Nα-
benzoyl-L-arginine-p-nitroanilide hydrochloride (BAPA)(cat. no. B3133) were purchased 
from Sigma-Aldrich (St. Louis, MO) and were used in an activity assay to determine the 
amount of inhibitor needed to completely inhibit the activity of trypsin. The activity assay 
used was modified from Smith et al. [10]. Four types of sample tubes were prepared as 
described in Table 3: reagent blank, standard, sample blank, and sample. The substrate 
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solution was prepared by dissolving 10 mg BAPA into 50 mL of potassium phosphate 
buffer (KH2PO4) that was heated to 37˚C. The concentration of trypsin used in the model 
system and activity assay was a 5:1 mol:mol ratio trypsin:toxin dissolved in KH2PO4 
buffer.  A wide range of inhibitor concentrations (1-1000 µg/mL) dissolved in KH2PO4 
buffer was used to determine a narrow range (50-250 µg/mL) for use in the activity 
assay. Absorbance at 410 nm was recorded for each sample and sample blank, and 
corrected absorbance was determined by subtracting the appropriate blank from the 
corresponding sample. Then, change in absorbance was calculated by subtracting each of 
the corrected sample absorbance values from the corrected standard absorbance. Finally, 
percentage inhibition was calculated by dividing the change in absorbance from each 
sample by the corrected standard absorbance and multiplying by 100%.  
To ensure neither the trypsin nor the inhibitor have any detrimental effects on 
insect survival and growth, bioassays were performed with a water control, a buffer 
control, a 5:1 trypsin solution, a 200-µg/mL inhibitor solution, and the trypsin and 
inhibitor combined according to the previously described bioassay procedure. 
The trypsin model system consisted of three samples: Cry1Ab control, trypsin and 
inhibitor control, and a treatment (Table 4). At termination, 150 µL KH2PO4 (Cry1Ab 
control) or 150 µL 200 µg/mL trypsin inhibitor in KH2PO4 buffer (trypsin and inhibitor 
control, treatment) was added to each vial. Four time points were used, 10 min, 1 hr, 8 hr, 
24 hr, and each was performed in duplicate for a total of six vials per time point. All vials 
were held at 37˚C for the duration of the experiment. An additional two Cry1Ab control 
vials held at room temperature also were added for each time point, to determine if the 
elevated temperature produced any degradation of the protein. After termination, all 
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samples were flash frozen with liquid nitrogen and stored at -80˚C until analysis with gel 
electrophoresis.  
Chymotrypsin 
Alpha-chymotrypsin from bovine pancreas (cat. no. C4129) trypsin-chymotrypsin 
inhibitor from soybean (cat. no. T9777), and N-glutaryl-L-phenylalanine-p-nitroanilide 
(GPANA) (cat. no. G2505) were purchased from Sigma-Aldrich. Like trypsin, 
chymotrypsin is a serine protease that can act as a surrogate for other serine proteases. 
Chymotrypsin also is found in the gastrointestinal tract of vertebrate and invertebrate 
organisms. An activity assay modified from the previously described trypsin assay was 
performed to determine the amount of inhibitor needed to completely inactivate 
chymotrypsin. Four types of sample tubes were prepared as described in Table 5. 
Substrate solution was prepared by dissolving 27 mg GPANA into 2 mL methanol while 
gently heating and then diluting to 70 mL final volume with 68 mL KH2PO4. Two 
concentrations of chymotrypsin were used: a 50:1 and 5:1 mol:mol ratio by dissolving 
chymotrypsin into KH2PO4 buffer. Two concentrations were chosen to compensate for 
lowered chymotrypsin activity compared to trypsin activity (>40 units/mg and >7,500 
units/mg, respectively). Inhibitor concentrations of 500-1500 µg/mL and 50-250 µg/mL 
were used for the 50:1 and 5:1 ratios respectively. Absorbance at 410 nm was recorded 
for each sample and sample blank, and corrected absorbance was determined by 
subtracting the appropriate blank from the corresponding sample. Then, change in 
absorbance was calculated by subtracting each of the corrected sample absorbance from 
the corrected standard absorbance. Finally, percentage inhibition was calculated by 
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dividing the change in absorbance from each sample by the corrected standard 
absorbance and multiplying by 100%.  
To ensure neither the chymotrypsin nor the trypsin-chymotrypsin inhibitor have 
any detrimental effects on insect survival and growth, bioassays were performed with a 
water control, a buffer control, a 50:1 chymotrypsin solution, a 1300-µg/mL inhibitor 
solution, a 5:1 chymotrypsin solution, a 200-µg/mL inhibitor solution, and the two 
combinations of chymotrypsin and inhibitor according to the previously described 
bioassay procedure. 
The chymotrypsin model system consisted of a Cry1Ab control, and a 
chymotrypsin control and a treatment for each of two concentrations of chymotrypsin 
(50:1 and 5:1 solutions)(Table 6). No inhibitor was utilized in the chymotrypsin controls 
or treatments because the presence of the inhibitor would make identification of 
fragments difficult (see discussion). Instead, inhibition of the samples was achieved by 
flash freezing the samples in liquid nitrogen. Three time points were used, 1, 8, and 24 hr. 
At termination, 150 µL nanopure water was added to each vial. All vials were heated to 
37˚C for the duration of the experiment. After termination, all samples were flash frozen 
with liquid nitrogen and stored at -80˚C until analysis with gel electrophoresis. 
Pepsin 
Pepsin (cat. no. P6887) was purchased from Sigma-Aldrich. Pepsin is a 
proteolytic enzyme utilized in many digestibility studies and also serves as a surrogate for 
other aspartate proteases found in the environment. The substrate used in the activity 
assay, succinyl-albumin, was synthesized according to Furihata et al. [11]. An activity 
assay modified from Strugala et al. [12] was performed to determine the amount of 
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inhibitor needed to completely inactivate pepsin. Four types of sample tubes were 
prepared as described in Table 7. A 10 mg/mL-substrate solution was prepared by 
dissolving succinyl-albumin in 0.01M HCl. Pepsin was prepared by dissolving 1.86 mg 
into 10 mL KH2PO4 (pH 2.2) (186 µg/mL). A 10% (w/v) sodium bicarbonate solution 
was used to terminate the reaction, and a 10 mM 2,4,6,-trinitrobenzenesulfonic acid 
(TNBS) solution was used for color development. Initially, five concentrations of sodium 
hydroxide were used: 0.05, 0.125, 0.25, 0.5, and 1 M NaOH. Complete inhibition was 
observed for all concentrations, so a second assay was performed using lower 
concentrations, 2.5, 5, 12.5, 25, and 50 mM NaOH. Absorbance at 490 nm was recorded 
for each sample and sample blank, and corrected absorbance was determined by 
subtracting the appropriate blank from the corresponding sample. Then, change in 
absorbance was calculated by subtracting each of the corrected sample absorbance values 
from the corrected standard absorbance value. Finally, percentage inhibition was 
calculated by dividing the change in absorbance from each sample by the corrected 
standard absorbance and multiplying by 100%. 
To ensure neither the pepsin nor the inhibitor have any detrimental effects on 
insect survival and growth, bioassays were performed with a water control, a buffer 
control (KH2PO4, pH 2.2), a 5:1 mol:mol pepsin:toxin solution, a 60-mM NaOH inhibitor 
solution, and the pepsin and inhibitor combined according to the previously described 
bioassay procedure. 
The pepsin model system consisted of four buffer controls, a pepsin and inhibitor 
control, and a treatment (Table 8). Two concentrations of pepsin were prepared, a 10:1 
and a 5:1 mol:mol ratio pepsin:toxin, by dissolving the pepsin in 0.1 M KH2PO4, pH 1.3. 
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A more acidic pH than used in the activity assay was necessary to compensate for the 
basic pH of the CAPS buffer in which the Cry1Ab protein was dissolved. The final pH of 
the solutions after mixing was 1.64.  
In some preliminary experiments (not shown), Cry1Ab was degraded in the 
controls. To determine if this degradation was the result of the acidic buffer or the 
elevated temperature, four buffer controls were utilized. One control contained 75 µL 50 
mM CAPS, resulting in a basic pH (10.5). The other control consisted of 75 µL Cry1Ab 
solution and 75 µL KH2PO4 (pH 1.3), resulting in an acidic pH of 1.64, which mimicked 
the treatments. One of each type of control was held at room temperature, while another 
of each was held at 40˚C, for a total of four buffer controls. All controls were terminated 
with 150 µL nanopure water; the subsequent increase in pH resulted in termination of the 
reaction. Samples were held at 40˚C for 1 or 4 hr. There were two additional time points 
for the 10:1 concentration, 10 min and 30 min. All buffer controls were performed 
singularly, while the pepsin and inhibitor controls and the treatments were performed in 
duplicate. At termination, 150 µL of water or NaOH were added (Table 8). After 
termination, all samples were flash frozen with liquid nitrogen and stored at -80˚C until 
analysis with gel electrophoresis. 
Based on the results, a second model system was performed with pepsin. This 
model system consisted of a basic and acidic buffer control (previously described), three 
pepsin and inhibitor controls (10:1, 5:1, and 1:1 mol:mol pepsin:toxin ratios) and three 
treatments (10:1, 5:1, and 1:1 mol:mol pepsin:toxin ratios). All samples were held at 
40˚C for 30 min or 1 hr. Only 1 replicate was performed for each sample. Following gel 
electrophoresis, gels were stained with silver stain instead of Coomassie stain. Silver 
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stain was used as it is more sensitive than a Coomassie stain, and it may allow for 
visualization of fragments that are missed by the Coomassie stain.  
Acidic buffer 
Due to the high degree of fragmentation observed in the acidic buffer controls, an 
acidic buffer model system was investigated for its ability to degrade Cry1Ab. Although 
the preliminary results suggested that this model system was useful in generating 
numerous fragments of various sizes, these fragments are probably less environmentally 
relevant than fragments generated by other model systems because the acidic conditions 
under which the protein fragmented are not widely found in agricultural settings. To 
ensure that the acidic buffer would not have any detrimental effects on insect survival and 
growth, bioassays were performed with a water control and an acidic buffer (KH2PO4, pH 
1.3) treatment according to the previously described bioassay procedure. 
The first acidic buffer model system consisted of four samples and three time 
points; as this was a range-finding study to determine optimal incubation times, no 
replication was performed. One sample contained 75 µL Cry1Ab solution and 75 µL 50 
mM CAPS, resulting in a basic pH (10.5). The other sample consisted of 75 µL Cry1Ab 
solution and 75 µL KH2PO4 (pH 1.3), resulting in an acidic pH of 1.64. One of each type 
of sample was held at room temperature, while another of each was held at 40˚C, for a 
total of four samples per time point. All controls were terminated with 150 µL nanopure 
water at 24, 36, or 48 hr. After termination, all samples were flash frozen with liquid 
nitrogen and stored at -80˚C until analysis with gel electrophoresis. 
A second acidic buffer model system was evaluated, extending the incubation 
time to 4-7 days. The basic pH samples were dropped from the study, leaving only acidic 
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samples at room temperature and 40˚C, with the latter being performed in duplicate. 
Samples were terminated with 150 µL nanopure water at 4, 5, 6, and 7, days. After 
termination, all samples were flash frozen with liquid nitrogen and stored at -80˚C until 
analysis with gel electrophoresis. 
Proteinase K 
Proteinase K (cat. no. P6556) was purchased from Sigma-Aldrich. Proteinase K is 
the main proteolytic enzyme found in Engyodontium album (formerly Tritirachium 
album), a fungus that has been found in the cysts of soybean plants and found to be 
associated with reeds in wetland areas [13-15]. The buffer used for proteinase K was a 20 
mM Tris-(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) buffer, pH 7.5 [16]. 
No activity assay was performed for proteinase K. Inhibition of the samples was achieved 
by flash freezing the samples in liquid nitrogen. To ensure neither the buffer nor the 
proteinase K enzyme have any detrimental effects on insect survival and growth, 
bioassays were performed with a water control, a buffer control, and a 1:1 mol:mol ratio 
proteinase K:toxin solution in Tris-HCl buffer according to the previously described 
bioassay procedure. 
The proteinase K model system consisted of three samples: Cry1Ab control, 
proteinase K control, and a treatment (Table 9). Two time points were used, 1 hr and 24 
hr, and the proteinase K and treatment samples were performed in duplicate. A second 
model system was set up using shorter time points and less proteinase K. For the second 
model system, the same three sample types were used (Table 9). Only one Cry1Ab 
control and one proteinase K control (containing a 1:1 ratio of proteinase K) were used 
for each time point, while two concentrations of proteinase K (a 1:1 ratio and a 0.5:1 
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ratio) were used in duplicate in the treatments. Three time points were used in the 
experiment: 15 minutes, 30 minutes, and 1 hr. All vials were heated to 37˚C for the 
duration of the experiment. At termination for both model systems, 150 µL nanopure 
water was added to each vial. After termination, all samples were flash frozen with liquid 
nitrogen and stored at -80˚C until analysis with gel electrophoresis. 
UV/Sunlight 
An ultraviolet (UV) model system was set up to investigate if exposure to 
shortwave UV rays would degrade Cry1Ab protein. Two control samples were prepared 
by combining 75 µL Cry1Ab solution, 75 µL CAPS buffer, and 150 µL nanopure water 
into two wells of a 96-well plate. This plate was placed on a lab bench and remained 
uncovered. Four treatment samples were prepared using the same solutions as the 
controls; however, these samples were combined in a UV transparent plate (Corning Inc., 
Corning, NY) and placed in a UV light box (Ultra-Violet Products Inc., San Gabriel, 
CA). This plate was exposed to shortwave UV rays (254nm) and all other sources of light 
were blocked out. Both plates remained at room temperature for the duration of the 
investigation. Nanopure water was added as needed in response to evaporation. One 
control and two treatment samples were collected at 12 hr and at 24 hr. Samples were 
flash frozen in liquid nitrogen and stored at -80˚C until analysis with gel electrophoresis. 
A second model system was set up to use natural light to attempt to degrade 
Cry1Ab. Three control samples and three treatment samples were prepared by 
combining75 µL Cry1Ab solution and 225 µL CAPS buffer. The control samples were 
placed in separate wells in a non-UV transparent 96-well plate. The treatment samples 
were placed in a UV transparent 96-well plate. All wells were sealed with plastic wrap 
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and super glue to prevent evaporation. The control plate was wrapped in aluminum foil to 
completely block out any sunlight and both plates were laid out in direct sunlight on the 
roof of the National Laboratory for Agriculture and the Environment building in an area 
free from shadows. The experiment was started at 8:03 am (CDT) on July 28, 2014, and 
one control and one treatment sample were collected at 1, 4, and 8 hr by piercing the 
plastic wrap and pipetting out the solution. Solutions were transferred to 1.5-mL vials, 
flash frozen in liquid nitrogen and stored at -80˚C until analysis with gel electrophoresis. 
The temperature was 17.2˚C at the start of the experiment and was 22.8˚C at the end with 
a high of 23.2˚C. At the start of the experiment, there was no cloud cover, but conditions 
became mostly cloudy by hour 3 and remained that way for the duration of the 
experiment 
(http://www.wunderground.com/history/airport/KAMW/2014/7/28/DailyHistory.html?re
q_city=Ames&req_state=IA&req_statename=Iowa). 
A third model system was set up to use an artificial UV light source. This 
artificial light was generated by using a Rayonet® photoreactor (Southern New England 
Ultraviolet Company, Branford, CT). This photoreactor uses eight lamps to produce a 
high intensity light source. Two different model systems were screened; one using lamps 
producing light at 365 nm (±50 nm) and one using lamps producing light at 254 nm. For 
both model systems, 1 mL of Cry1Ab solution was placed in a Pyrex test tube (for use 
with the 365 nm lamps) or a quartz cuvette (for use with the 254 nm lamps). The sample 
containers were then placed separately into the machine on a rotating carousel. A 75 µL 
aliquot was removed and placed in separate 1.5 mL vials at each of the following time 
points: 5, 10, 15, and 30 minutes, and 1, 2, and 4 hr. After collection, 225 µL of nanopure 
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water was added to each vial. A 50-µL aliquot was prepared from each sample for gel 
electrophoresis, and all samples were flash frozen in liquid nitrogen and stored at -80˚C 
until analysis by gel electrophoresis and silver staining. 
Simulated Gut Fluid 
A simulated earthworm gut fluid model system was adapted from Ma et al. [17]. 
Two concentrations of enzymes were used: a 5:1 ratio (containing 5 mol amylase and 5 
mol cellulase to 1 mol Cry1Ab) and a 1:1 ratio (1 mol amylase and 1 mol cellulase to 1 
mol Cry1Ab). There were two time points, 1 hr and 24 hr, and 4 vials per time point 
(Table 10). All vials were kept at 40˚C for the duration of the study. At termination, 150 
µL nanopure water was added to each vial, and the samples were flash frozen in liquid 
nitrogen and stored at -80˚C until analysis with gel electrophoresis. 
Long-term degradation in buffer 
A model system was set up to explore degradation of Cry1Ab protein over 
extended periods of time. Unlike previous model systems, this system was performed in 
triplicate. Each sample in the model system contained 100 µL Cry1Ab solution and 100 
µL 50 mM CAPS. Four time points were used in the study and there were three replicates 
per time point: 4, 8, 12, and 16 weeks. All samples were stored in the dark at room 
temperature. At termination, 200 µL of nanopure water was added to each vial and a 50 
µL aliquot was removed and placed in a separate vial for gel electrophoresis. All vials 
were flash frozen with liquid nitrogen and stored at -80˚C until analysis by gel 
electrophoresis and silver staining. 
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Results 
Range-Finding Bioassays 
The results from the two preliminary bioassays were used to narrow the scope of 
concentrations for the range-finding bioassays (data not shown). The results of the range-
finding bioassays are in Figure 1. The original experiment was performed with three 
replicates on different days. The second replicate had significantly lowered survival in 
the controls (survival <80% for both the water and buffer control), so a fourth replicate 
was performed. This replicate also had significantly lowered survival in the controls 
(survival <35% for both controls), and thus a fifth replicate was performed. Therefore, 
the LC90 and LC95 values were calculated using only the first, third, and fifth replicates. 
The LC90 value was determined to be 82.4 ng protein per g insect diet, and the LC95 value 
was determined to be 103.7 ng protein per g insect diet. A concentration of 94.5 ng/g was 
chosen for use in the model system degradations. 
Buffer Determination 
Only one of the seven buffers, buffer 3, had no significant effects on insect 
survival or average weight gain (Figure 2). Of the remaining buffers, buffer 2 caused 
100% mortality of the ECB larvae, and four buffers significantly decreased average 
weight gain, while one significantly increased average weight gain. Buffer 3 was 
compatible with all three of the enzymes to be tested initially, and thus it was used in the 
following trypsin, chymotrypsin, and pepsin studies.  
Trypsin 
A preliminary activity assay using a wide range of inhibitor concentrations (1-
1000 µg/mL) was used to establish a narrower range of concentrations for the activity 
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assay (data not shown). The narrow range used in the activity assay was 50-250 µg/mL. 
Percentage inhibition was plotted, linear regression was performed, and the resulting 
equation was utilized to determine that a 147-µg/mL concentration of trypsin inhibitor 
was needed for complete inactivation of trypsin (Figure 3). For ease of solution 
preparation and to provide a margin for error, a 200-µg/mL inhibitor solution was used 
for all trypsin model systems. Bioassay results suggest that there were no significant 
differences in insect survival due to the presence of trypsin or the trypsin inhibitor 
(Figure 4). The presence of trypsin significantly decreased weight gain in larvae; 
however, this effect was not present in the trypsin-and-inhibitor treatment, indicating that 
the trypsin inhibitor from Glycine max used in the trypsin model system inhibited the 
activity of trypsin and prevented detrimental effects from occurring. Therefore, an 
assumption was made that any significant effects observed in bioassays with trypsin-
degraded Cry1Ab protein was not the result of the presence of trypsin or the trypsin 
inhibitor. 
No significant degradation of Cry1Ab was observed at any of the time points 
(Figure 5). Some minor degree of degradation was observed at 8 and 24 hr (Figure 5D) 
and in some of the controls, but this is more likely the result of freeze/thaw cycles or 
naturally occurring degradation over time than presence of trypsin. There was no 
difference between the room temperature Cry1Ab controls and the Cry1Ab controls held 
at 37˚C. 
Chymotrypsin 
Percentage inhibition was plotted separately for the 50:1 and 5:1 activity assays, 
linear regression was performed, and the resulting equations were utilized to determine 
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that 1210-µg/mL and 145-µg/mL concentrations of trypsin-chymotrypsin inhibitor, 
respectively, were needed for complete inactivation of chymotrypsin (Figure 6). For ease 
of solution preparation and to provide a margin for error, 1300-µg/mL and 200-µg/mL 
inhibitor solutions were used for 50:1 and 5:1 chymotrypsin model systems, respectively. 
Bioassay results indicated that 50:1 ratio and its corresponding inhibitor concentration 
did not significantly affect insect survival, but it did have significant effects on average 
weight gain of the larvae (Figure 7A). The 5:1 ratio and its corresponding inhibitor 
concentration did not significantly affect insect survival (Figure 7B). While the 5:1 
chymotrypsin and 200-µg/mL inhibitor samples individually did not affect average 
weight gain, when combined, the average weight of the larvae after 7 days was 
significantly increased. Due to the presence of multiple bands in the controls on the 
trypsin gels, a test gel was run with samples of only 5:1 chymotrypsin, only 200-µg/mL 
inhibitor, and the chymotrypsin and inhibitor together. The presence of numerous bands 
in all three wells made determination of Cry1Ab fragment bands from chymotrypsin and 
inhibitor bands difficult (Figure 8).  
The chymotrypsin model system was performed without an inhibitor, based on the 
success of the proteinase K model system, which did not utilize an inhibitor. A similar 
degradation pattern was observed for both amounts of chymotrypsin used at all three time 
points: decreased amounts of parent protein were present and two distinct fragment bands 
were observed (Figure 9). The amount of parent protein appeared to decrease between 1 
hr and 24 hr. The fragment bands also appeared to decrease over time, and no additional 
fragment bands were observed. The chymotrypsin bands also began to disappear at 24 hr, 
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suggesting that it also is being degraded and that longer incubation times would likely be 
of little use.  
Pepsin 
For the first pepsin activity assay (NaOH concentrations 0.05-1 M), 100% 
inhibition was observed for all concentrations (data not shown). The activity assay was 
then repeated using NaOH concentrations of 2.5-50 mM. Percentage inhibition was 
plotted, linear regression was performed, and the resulting equations were utilized to 
determine that an inhibitor concentration of 49.6 mM NaOH was needed for complete 
inactivation of chymotrypsin (Figure 10). To provide a margin for error, a 60-mM NaOH 
solution was used for termination of all pepsin model system incubations. 
Bioassay results indicate that the 5:1 pepsin solution and the 60-mM NaOH 
inhibitor have no effect on insect survival either individually, or when combined (Figure 
11). Average weight of the insects in the buffer control and pepsin only treatments was 
significantly lower than the water control, inhibitor only, and pepsin-and-inhibitor 
combined treatments. This is most likely due to the acidic pH values in the diet. Average 
weight of the insects in the inhibitor only and pepsin-and-inhibitor combined treatments 
was significantly lower than the water control, but significantly higher than the buffer 
only and pepsin only treatments. The acidity of the inhibitor only and the pepsin and 
inhibitor combined treatments, while more basic than the buffer control and pepsin only 
treatments, were still acidic enough to have negative effects on insect growth. 
A 10:1 pepsin concentration completely degraded all the Cry1Ab at 30 min, 1 hr, 
and 4 hr (Figure 12B-D). At 10 min, there was significant Cry1Ab degradation, with a 
little fully intact protein remaining (Figure 12A). A 5:1 concentration of pepsin also 
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degraded Cry1Ab substantially, leaving only a small amount of parent compound (Figure 
13). None of the time points and pepsin concentration combinations produced observable 
Cry1Ab fragments. However, repeatable degradation was observed in the buffer controls 
with an acidic pH. The degree of degradation observed appears to be correlated with 
incubation time; longer time points (Figure 12C-D) exhibited more degradation than 
shorter time points (Figure 12A-B). A second model system was performed using one 
additional, lower concentration (1:1) and a silver staining technique. As with the previous 
model system, Cry1Ab was substantially degraded at all concentrations of pepsin and 
small amounts of parent compound remained (Figure 14). While the silver staining 
allowed visualization of more bands on the gel, no fragments were observed that could 
not be accounted for by the controls. The acidic buffer controls again showed increasing 
fragmentation of Cry1Ab with increasing incubation time.  
Acidic buffer 
Bioassay results suggest that the acidic buffer has no significant detrimental 
effects on insect survival or average weight gain (Figure 15). This is in contrast to the 
result observed in the pepsin preliminary bioassay where the buffer control (i.e., same 
acidic buffer used in this bioassay) significantly decreased average weight gain. A 
possible explanation for this difference is that there is inherent variability in any 
biological system, and increasing the number of insects would resolve the issue.  
The first attempt at using only an acidic buffer to degrade Cry1Ab produced 
limited fragmentation (Figure 16). Almost no degradation was observed in any of the 
room temperature samples. Small amounts of degradation were observed in the 40˚C 
samples, with the acidic buffer samples exhibiting more degradation than the basic 
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samples. However, a substantial amount of parent Cry1Ab still remained. The model 
system was repeated and extended to four-seven days. These extended time points 
exhibited significant degradation of the protein with nearly all the parent protein 
completely degraded after seven days (Figure 17). Although there was substantial 
degradation at all four time points, the number of different fragments and the quantity of 
each fragment were low. The most prominent band for all samples is a band near 5 kDa.  
Proteinase K 
Neither the Tris-HCl buffer nor the proteinase K enzyme had any significant 
effects on insect survival or weight gain (Figure 18). The first proteinase K model system 
screened two time points to determine if any degradation of Cry1Ab occurred. Complete 
degradation of the Cry1Ab protein was observed at both one and 24 hr, yielding only a 
single band at around 5 kDa (Figure 19). A second model system was performed using 
shorter time points and less proteinase K in an attempt to capture more or larger 
fragments. However, nearly complete degradation of Cry1Ab was again observed (Figure 
20). This occurred even at the shortest time point and lowest proteinase K concentration. 
UV/Sunlight 
No significant degradation of the Cry1Ab protein occurred at either 12 hr or 24 hr 
(Figure 21) in the short-wave UV experiment. There were no differences between the 12-
hr and 24-hr time points and the controls, suggesting that short wave UV rays alone are 
not enough to substantially degrade the protein. For the sunlight experiment, there was 
not a significant difference between the dark controls and the sunlight treatments at any 
time period (Figure 22). Further, there appears to be similar amounts of degradation at the 
1-hr and 8-hr time points. In the photoreactor study, no significant degradation was 
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observed at any of the time points in the 365 nm treatment (Figure 23A). Under harsher 
conditions with the 254 nm lamps, some degradation was observed at the 5, 10, and 15-
minute time points (Figure 23B). However, another phenomenon was also observed: at 
all seven time points, a band larger than 100 kDa was observed. By 30 minutes, all of the 
fully intact protein had dissipated, replaced by substantial quantities of a considerably 
larger aggregate, and small quantities of a small fragment or fragments approximately 5 
kDa or smaller in size. 
Simulated Gut Fluid 
There was no significant degradation of Cry1Ab at either time point (Figure 24). 
Additionally, there was no difference in degradation between the two enzyme 
concentrations. Further, the enzymes themselves appeared to be mostly degraded after 24 
hr. This earthworm-based system only included enzymes for degrading lipids and 
starches, so it is not surprising that the Cry1Ab protein was still intact after incubation. 
Long-term degradation 
Degradation of the Cry1Ab protein occurred at all time points, and there appears 
to be an increase in quantities of the fragments over time (Figure 25). Substantial 
amounts of the parent protein still remain, even at 16 weeks. There is one anomaly; 
replicate 3 of the 12-week samples has undergone more degradation than the other two 
replicates, resulting in additional fragments smaller than 15 kDa (Figure 25B). Since a 
similar pattern was not observed in any other samples, this degradation is most likely the 
result of contamination. 
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Discussion 
Lethal concentration values generated in bioassays can vary among insect 
populations, the type of bioassay (i.e., overlay vs. incorporation), and, in the case of Cry 
toxin, the supplier of the toxin [18]. Therefore, it was important to determine the 
concentration of the Cry1Ab protein used in the study that would cause 90-95% mortality 
in the population of ECB to be used in the study. Normally, there is not much value in 
using LC90 or LC95 values due to the increase in variability away from the center of the 
curve (i.e., the LC50 value). However, in order to detect possible decreases in mortality as 
the Cry1Ab protein is degraded in this experiment, it is important to cause mortality in a 
large majority of the insects without using excessive amounts of Cry1Ab. Using the LC50 
value allows 50% of the insects in the experiment to survive, rendering them useless for 
the analysis. Likewise, using more protein than is needed could result in decreases in 
toxicity due to protein degradation being masked. By using a final concentration of 94.5 
ng of protein per g insect diet for the bioassays, which falls between the LC90 and LC95, 
the fully intact protein still causes significant mortality, while degraded proteins show 
decreasing mortality if they are no longer bioactive.  
Trypsin did not significantly degrade the Cry1Ab protein (Figure 5). Trypsin is 
one of the proteolytic enzymes present in an insect midgut that is responsible for cleaving 
the Cry1Ab protoxin to produce the active form. Since the protein utilized in this study 
was already activated, it could be expected that further degradation would not be 
observed. This result is supported by Diaz-Mendoza et al. [9]. In that paper, the authors 
subjected a Cry1Ab protoxin to degradation by three purified trypsins. In all three 
treatments, only a 69 kDa fragment was produced, even after 24 hr.  As a result of these 
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findings, it was determined that a trypsin-based model system would not be useful in 
generating Cry1Ab fragments.  
Pepsin and its inhibitor had no effect on insect survival, but did have some effects 
on weight gain. While it would be ideal for components of a potential model system to 
have no effect on survival and weight gain, it was decided to move forward with the 
pepsin model system to see if detectable fragments could be generated. Ultimately, it did 
not matter that weight gain of the insects was affected, as pepsin significantly degraded 
Cry1Ab, but yielded no fragments that were detectable by gel electrophoresis. This effect 
was consistently observed despite numerous attempts to alter pepsin concentration and 
reduce incubation time (Figure 14). A change in staining technique from a Coomassie 
stain to a more sensitive silver stain produced additional bands in the controls, but did not 
generate any Cry1Ab fragments that were detectable by gel electrophoresis. 
The current hypothesis is that pepsin (which cleaves between hydrophobic amino 
acids, such as tyrosine and phenylalanine) rapidly degrades Cry1Ab into amino acids or 
very small fragments that are not detectable by gel electrophoresis. This is most apparent 
at shorter time points (Figure 12A, 14A) where fully intact Cry1Ab protein remains, but 
no intermediate fragments are observed. As a result of these findings, it was determined 
that a pepsin-based model system would not be useful in generating Cry1Ab fragments. 
However, there were varying degrees of Cry1Ab degradation observed in the acidic 
buffer controls, suggesting that a model system based on an acidic buffer alone may be 
suitable for fragmenting Cry1Ab. An acidic buffer model system was tested over a range 
of incubation times to determine if prolonged exposure to an acidic environment would 
result in Cry1Ab degradation. Longer time points (4-7 days) were the best intervals at 
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generating fragments of Cry1Ab. The acidic buffer model system produced the highest 
number of different fragments, (4-8 bands on the gel [Figure 17]). Some parent Cry1Ab 
still remained after 4-7 days. This parent protein should still be detectable by ELISAs and 
have bioactivity; however, a decrease in absorbance (in the ELISAs) and bioactivity 
should be observed if the fragments are not detectable by ELISA. Further work is needed 
to determine the number of fragments present (particularly in the band near 5 kDa). This 
will be performed in a subsequent study (Chapter 3), which also will determine if the 
fragments are detectable by ELISAs and if any bioactivity is retained by the fragments.  
An activity assay was performed with proteinase K; however, the background 
absorbance of the inhibitor, proteinase K enzyme, and substrate utilized were too high to 
generate any significant results (data not shown, see Appendix A). As the samples were 
flash frozen with liquid nitrogen immediately after termination, the hypothesis was that 
an inhibitor would not be needed. Without the use of the inhibitor, all concentrations of 
proteinase K yielded nearly complete degradation of Cry1Ab at all tested time points. 
Changing the incubation time or amount of proteinase K did not affect degradation, as the 
product in all of the samples was the same: a single band in the 5 kDa range. It is possible 
that the visualized band is not a single 5 kDa fragment, but rather a combination of 
multiple fragments that are 5 kDa or smaller. The limitations of the gel mixture used in 
the current study made it impossible to resolve the fragments in more detail; a 15% gel is 
ideal for separating and resolving proteins between 10-60 kDa [8]. As the goal of this 
study was to identify model systems that were capable of degrading Cry1Ab into 
fragments, no further work was performed with the fragments in the study. Separating 
and determining the number of fragments present will occur in a subsequent study 
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(Chapter 3), where the fragments generated also will be subjected to bioassays and 
ELISAs to determine if any of the fragments are still detectable and/or if any bioactivity 
is retained.  
Initially, the chymotrypsin model system appeared not to be viable due to the 
presence of numerous bands from both chymotrypsin and the inhibitor. However, after 
the success of the proteinase K model system, in which no inhibitor was used, the 
chymotrypsin model system was revisited. Both levels of chymotrypsin significantly 
degraded Cry1Ab, producing two fragments that were visualized by gel electrophoresis 
(Figure 9). Longer time points produced decreasing amounts of parent Cry1Ab; however, 
no additional fragments were formed, and fragment and chymotrypsin abundance also 
decreased, suggesting further breakdown of both. There was no difference in degradation 
between the 50:1 and 5:1 mol:mol ratios of chymotrypsin:toxin. This is advantageous as 
it is best to avoid using the 50:1 ratio if possible due to the significant growth effects that 
were observed on insects fed diet containing that concentration of chymotrypsin (Figure 
7A). Further work to determine if the fragments are detectable by ELISAs and if they 
retain any bioactivity was performed in a subsequent study (Chapter 3). 
Degradation of proteins (including Cry proteins) subjected to UV light is known 
to occur, with cysteine, phenylalanine, tryptophan, and tyrosine being the primary sites of 
photodegradation [19-20]; however, no significant degradation was observed in this UV 
model system (Figure 21). This is not surprising as only a single UV wavelength was 
used and it was from a weak light source. In an attempt to generate environmentally 
relevant fragments, a model system was designed to use natural sunlight. While some 
degradation was observed in the samples, there was no difference between the controls 
93 
 
and treatments (Figure 22). A possible explanation for this is that the plastic wrap is not 
UV transparent and thus, it blocks UV rays from entering into the wells and degrading 
the protein. There was also no difference in degradation between the 1-hr and 8-hr time 
points. It is possible that most of the degradation observed occurred in the first hr of the 
experiment when direct sunlight was present. Further degradation may have been 
inhibited by cloud cover. This, however, is unlikely as UV rays can still penetrate cloud 
cover, and only heavy cloud cover can significantly reduce the amount of UV radiation 
reaching the earth’s surface [21].  
A final attempt to use UV light to degrade Cry1Ab utilized a photoreactor and 
two different wavelengths of light, 365 nm and 254 nm. The initial focus was on the 365 
nm wavelength because it produces light within the natural solar spectrum and provides 
the most relevant results [22]. No degradation was observed at this wavelength (Figure 
23A). This was unexpected as there are numerous reports of formulations of Bt 
insecticide being inactivated under natural sunlight [23-24]. The most likely explanation 
for this is that this study used pure Cry1Ab protein. Pure protein does not degrade readily 
in sunlight because the highest absorption band of pure protein is in the 280-285 nm 
range; the solar spectrum decreases to zero intensity in the 300-305 nm range [22]. Cry 
proteins in Bt insecticide formulations degrade readily in sunlight because the 
formulations often contain cofactors, prosthetic groups, or other adjuvants that can act as 
chromophores to capture photons and transfer energy to the Cry protein, resulting in its 
degradation [19, 22]. 
Since no degradation was observed at 365 nm, a harsher UV treatment, 254 nm, 
was used. Although this wavelength does not naturally occur, it may provide clues about 
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how Cry1Ab degrades under natural sunlight. Degradation of Cry1Ab occurs rapidly at 
254 nm, with fragments visible after only 5 minutes (Figure 23B). However, exposure to 
UV light at 254 nm also appears to have other unintended consequences. At all time 
points, a majority of the protein was converted into a molecule greater than 100 kDa in 
size, and by 30 minutes nearly all of the protein was in this form. The most likely 
explanation is that the UV light caused the fully intact protein and/or protein fragments to 
become cross-linked to each other, forming dimers and other types of aggregate 
molecules; such protein-protein crosslinking is known to occur at 254 nm [25]. It is 
unknown if the presence of these dimers/polymers will lead to a potential increase or 
decrease in toxicity or if the aggregates are even detectable by ELISA. Despite the 
presence of cross-linked protein, a UV photodegradation model system is capable of 
generating fragments of Cry1Ab protein. Further research in a subsequent study (Chapter 
3) at shorter time points will determine if the fragments and/or dimers are still detectable 
by ELISA and if they retain any bioactivity.  
Simulated gastric systems were investigated for their potential to degrade 
Cry1Ab. However, most gastric systems use pepsin as the prominent enzyme, which has 
already been explored separately in this paper [26-28]. One model system identified as 
not using pepsin was simulated earthworm gut model system described in Ma et al. [17]. 
In Ma et al. [17], the authors developed three simulated earthworm gut formulations: an 
enzyme formulation (amylase and cellulase), a microbe formulation (cultured from the 
gut of Eisenia andrei) and an enzyme and microbe combination. They tested the ability 
of these three formulations to affect the bioaccessibility of arsenic, copper, and zinc in 
digested field soils. Their results showed that the enzyme formulation and the enzyme 
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and microbe combination produced the best results with little to no difference between 
the two. For the sake of simplicity, only the enzyme formulation was chosen to be used in 
this study. No degradation of Cry1Ab was observed in this model system (Figure 24). 
Additionally, the enzymes themselves were almost completely degraded after 24 hr. This 
is not unexpected as the digestions in Ma et al. [17] only lasted 3.5 hr, which is the 
approximate residence time of the gut contents of E. andrei. Due to a lack of promising 
results and the rapid degradation of the enzymes used in this model system, no further 
work was performed with this simulated gastric system. 
Long-term degradation of Cry1Ab protein in CAPS buffer yielded low to 
moderate amounts of degradation, with substantial amounts of parent protein remaining, 
even after 16 weeks (Figure 25). This is in contrast to other studies where Cry1Ab has 
been reported to have half-lives of a few days [29-31]. However, these studies were 
performed in biologically active soil and water samples where microbes and other 
organisms are available to assist in the degradation of the protein. Although the model 
system components were not sterilized at the start of the experiment, there was no visual 
evidence that such organisms were present in the course of the study (i.e. the solution 
remained clear, and no algal or microbial films were observed on the surface of the 
solutions or the glassware). The 16-week samples were determined to exhibit substantial 
degradation. Further work to determine if the fragments are detectable by ELISAs and if 
they retain any bioactivity will be performed in a subsequent study (Chapter 3).  
Conclusions 
Multiple approaches were utilized in attempts to degrade Cry1Ab into 
environmentally relevant fragments. Five model systems were identified that could 
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reliably generate Cry1Ab fragments. These five systems, chymotrypsin model system, 
proteinase K model system, acidic buffer model system, photodegradation model system, 
and long-term degradation model system are used in further studies (Chapter 3) to 
determine if fragmented proteins generated in environmental matrices are still detectable 
by ELISAs and if they retain any bioactivity.  
Acknowledgements 
We thank Chad Boeckman and Kris Sturtz with DuPont Pioneer for providing 
training with the bioassay procedure and Keith Bidne with the U.S. Department of 
Agriculture – Agricultural Research Service Corn Insects and Crop Genetics Research 
Unit for kindly providing the European corner borer larvae used in the study. We thank 
William Jenks for access to the Rayonet photoreactor for the UV photodegradation 
studies. Mention of a proprietary product does not constitute an endorsement or a 
recommendation by Iowa State University or USDA for its use.  
97 
 
Figures 
 
 
 
Figure 1. Range-finding bioassays. Due to the lowered control survival in replicates 2 
and 4, only replicates 1, 3, and 5 were used to determine the LC90 and LC95 values of 82.4 
ng/g and 103.7 ng/g, respectively. 
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Figure 2. Buffer determination bioassays. Uppercase letters indicate significance within 
survival across buffers (p = 0.05). Lowercase letters indicate significance within average 
weight across buffers (p = 0.05). Buffer 1: 10 mM phosphate, pH 7.0-8.0. Buffer 2: 1 
mM Tris-HCl, 1 M urea, 0.01% (w/v) SDS, pH 8.5. Buffer 3: 0.1 M potassium 
phosphate, pH 7.6. Buffer 4: 98 mM sodium bicarbonate, 2 mM sodium carbonate, pH 
8.0. Buffer 5 0.1 M Tris-HCl, 10 mM calcium chloride, pH 7.8. Buffer 6: 50 mM HCl. 
Buffer 7: 50 mM KCl, 30 mM HCl, pH 1.5. 
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Figure 3. Trypsin activity assay results. Complete inhibition is achieved at 147 µg/mL 
trypsin inhibitor. 
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Figure 4. Bioassays with trypsin and its corresponding inhibitor, trypsin inhibitor from 
Glycine max. Uppercase letters indicate significance within survival across treatments (p 
= 0.05). Lowercase letters indicate significance within average weight across treatments 
(p = 0.05). 
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Figure 5.  Degradation of Cry1Ab with the trypsin model system. Incubation times: A – 10 minutes, B – 1 hr, C – 8 hr, D – 24 hr. 
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Figure 6. Chymotrypsin activity assay results. Complete inhibition is achieved at 1,210 µg/mL of trypsin-chymotrypsin inhibitor 
(50:1 chymotrypsin) and 145 µg/mL of trypsin-chymotrypsin inhibitor (5:1 chymotrypsin). 
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Figure 7. Bioassays with chymotrypsin and its corresponding inhibitor, trypsin-chymotrypsin inhibitor. A 50:1 chymotrypsin. B 5:1 
chymotrypsin. There were no significant differences in survival for either concentration of chymotrypsin. Lowercase letters indicate 
significance within average weight across treatments (p = 0.05). 
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Figure 8. Chymotrypsin test gel to determine if visualization of Cry protein fragment 
bands would be impaired by chymotrypsin and it’s inhibitor. Numerous bands are present 
in the sample with chymotrypsin and it’s inhibitor, which could make identification of 
fragments difficult.
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Figure 9. Degradation of Cry1Ab with the chymotrypsin model system. Incubation times: A – 1 hr, B – 8 hr, C – 24 hr. 
Degradation of the protein occurs at all three time points, with only two Cry1Ab fragment bands visualized. 
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Figure 10. Pepsin activity assay results. Complete inhibition is achieved at 0.0496 M 
NaOH. 
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Figure 11. Bioassays with pepsin and its corresponding inhibitor, sodium hydroxide.  
Lowercase letters indicate significance within average weight across treatments (p = 
0.05). 
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Figure 12. Degradation of Cry1Ab with the 10:1 pepsin model system. Incubation times: A – 10 minutes, B – 30 minutes, C – 1 hr, D 
– 4 hr. 
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Figure 13. Degradation of Cry1Ab with the 5:1 pepsin model system. Incubation times: 
A – 1 hr, B – 4 hr.  
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Figure 14. Degradation of Cry1Ab with the three pepsin model systems. Incubation 
times: A – 30 minutes, B – 1 hr.  
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Figure 15. Bioassays with acidic buffer. No significant differences were observed for 
survival or average weight between the water control and the acidic buffer at p = 0.05. 
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Figure 16. Degradation of Cry1Ab with the acidic buffer model system. Incubation 
times: A – 24 and 36 hr, B – 48hr. 
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Figure 17. Degradation of Cry1Ab with the acidic buffer model system. Incubation 
times: A – 4-5 days, B – 6-7 days.  
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Figure 18. Bioassays with proteinase K. No significant differences were observed for 
survival or average weight between the water control and the acidic buffer at p = 0.05. 
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Figure 19. Degradation of Cry1Ab with the proteinase K model system. Incubation 
times: A – 1 hr, B – 24 hr. 
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Figure 20. Degradation of Cry1Ab with the proteinase K model system. Incubation times: A – 15 minutes, B – 30 minutes, C – 1 hr. 
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Figure 21. Degradation of Cry1Ab with the short wave UV model system. 
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Figure 22. Degradation of Cry1Ab with the natural sunlight model system. 
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Figure 23. Degradation of Cry1Ab using a photoreactor. A – Degradation with 365 nm 
lamps, B – Degradation with 254 nm lamps. 
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Figure 24. Degradation of Cry1Ab with the simulated gut fluid model system. 
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Figure 25. Degradation of Cry1Ab in CAPS buffer over time. A – Degradation over 4 
and 8 weeks, B – Degradation over 12 and 16 weeks. 
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Tables 
Table 1. Recipes for separating and stacking gel used in gel electrophoresis. 
Separating Gel Stacking Gel 
2.474 mL 30% acrylamide 0.330 mL 30% acrylamide 
1.847 mL 1M Tris-HCl, pH 8.8 0.247 mL 1M Tris-HCl, pH 6.8 
0.610 mL nanopure water 1.391 mL nanopure water 
50 µL 10% (w/v) sodium dodecyl sulfate 20 µL 10% (w/v) sodium dodecyl sulfate 
4 µL N,N,N’,N’- 
tetramethylethylenediamine  
2 µL N,N,N’,N’- 
tetramethylethylenediamine  
17 µL 10% (w/v) ammonium persulfate 10 µL 10% (w/v) ammonium persulfate 
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Table 2. Buffer candidates tested to determine potential effects on European corn borer 
larvae.  
Buffer Composition 
Enzyme 
compatibility References 
1 10 mM phosphate pH 7.0-8.0 
Trypsin 
Chymotrypsin 
Araujo et al. [28] 
Yin et al. [29] 
2 
1 mM Tris-HCl 
1 M Urea 
0.01% (w/v) SDS 
pH 8.5 
Trypsin Hitchcock et al. [30] 
3 0.1 M Potassium phosphate pH 7.6 
Trypsin 
Chymotrypsin 
Pepsin (pH 2.0) 
Hamaker et al. 
[31] 
4 
98 mM Sodium bicarbonate 
2 mM Sodium carbonate 
pH 8.0 
Trypsin 
Chymotrypsin 
Singh and 
Creamer [32] 
5 
0.1 M Tris-HCl 
10 mM Calcium chloride 
pH 7.8 
Trypsin 
Chymotrypsin 
DelMar et al [33] 
Nielsen et al. [34] 
6 50 mM HCl Pepsin Nielsen et al. [34] 
7 
50 mM KCl 
30 mM HCl 
pH 1.5 
Pepsin Goni et al. [35] 
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Table 3. Samples and procedure used in the trypsin activity assay. 
Reagent Blank Standard  Sample Blank Samples 
1 mL KH2PO4 1 mL KH2PO4 1 mL inhibitor 1 mL inhibitor 
 
1 mL trypsin   1 mL trypsin 
Heat at 37ᵒC for 10 minutes 
2.5 mL BAPA 2.5 mL BAPA 2.5 mL BAPA 2.5 mL BAPA 
Heat at 37ᵒC for 10 minutes 
0.5 mL 30% (v/v) acetic acid 0.5 mL 30% (v/v) acetic acid 0.5 mL 30% (v/v) acetic acid 0.5 mL 30% (v/v) acetic acid 
1 mL trypsin   1 mL trypsin   
Filter with Whatman #3 
Measure at 410 nm 
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Table 4. Layout for trypsin model system. At the start of the experiment, the solutions in 
the initiation column were combined in a vial. All samples were held at 37°C for 10 min 
or 1, 8, or 24 hr. At the end of the experiment, the solution in the termination column was 
added. All samples were flash frozen in liquid nitrogen and stored at -80°C until 
analysis.  
Samples Initiation Termination 
Cry1Ab 
Control 
75 µL KH
2
PO
4
 
75 µL Cry1Ab solution 
150 µL KH
2
PO
4
 
Trypsin + 
Inhibitor 
control 
75 µL KH
2
PO
4
 
75 µL 5:1 trypsin solution in 
KH
2
PO
4
 
150 µL 200 
µg/mL inhibitor 
solution 
Treatment 
75 µL Cry1Ab solution 
75 µL 5:1 trypsin solution in 
KH
2
PO
4
 
150 µL 200 
µg/mL inhibitor 
solution 
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Table 5. Samples and procedure used in the chymotrypsin activity assay. 
Reagent Blank Standard  Sample Blank Samples 
0.5 mL KH2PO4 0.5 mL KH2PO4 0.5 mL inhibitor 0.5 mL inhibitor 
 
0.5 mL chymotrypsin   0.5 mL chymotrypsin 
Heat at 37ᵒC for 10 minutes 
2.5 mL GPANA 2.5 mL GPANA 2.5 mL GPANA 2.5 mL GPANA 
Heat at 37ᵒC for 10 minutes 
1 mL 30% (v/v) acetic acid 1 mL 30% (v/v) acetic acid 1 mL 30% (v/v) acetic acid 1 mL 30% (v/v) acetic acid 
0.5 mL chymotrypsin   0.5 mL chymotrypsin   
Filter with Whatman #3 
Measure at 410 nm 
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Table 6. Layout for chymotrypsin model system. At the start of the experiment, the 
solutions in the initiation column were combined in a vial. Two levels of chymotrypsin 
were used: a 50:1 mol:mol chymotrypsin:toxin ratio and a 5:1 mol:mol ratio. All samples 
were held at 37°C for 1, 8, or 24 hr. At the end of the experiment, the solution in the 
termination column was added. All samples were flash frozen in liquid nitrogen and 
stored at -80°C until analysis.  
Samples Initiation Termination 
Cry1Ab 
Control 
75 µL KH
2
PO
4
 
75 µL Cry1Ab solution 
150 µL 
water 
Chymotrypsin 
control 
75 µL KH
2
PO
4
 
75 µL chymotrypsin 
solution in KH
2
PO
4
 
150 µL 
water 
Treatment 
75 µL Cry1Ab solution 
75 µL chymotrypsin 
solution in KH
2
PO
4
 
150 µL 
water 
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Table 7. Samples and procedure used in the pepsin activity assay. 
Reagent Blank Standard  Sample Blank Samples 
0.5 mL pepsin 0.5 mL pepsin 0.5 mL NaOH 0.5 mL pepsin 
0.5 mL buffer 0.5 mL buffer   0.5 mL NaOH 
0.5 mL 10% (w/v) NaHCO3 
   Heat at 37ᵒC for 10 minutes 
0.5 mL succinyl-albumin 0.5 mL succinyl-albumin 0.5 mL succinyl-albumin 0.5 mL succinyl-albumin 
Heat at 37ᵒC for 30 minutes 
0.5 mL 10 mM TNBS 0.5 mL 10% (w/v) NaHCO3 0.5 mL 10% (w/v) NaHCO3 0.5 mL 10% (w/v) NaHCO3 
 
 0.5 mL 10 mM TNBS 0.5 mL 10 mM TNBS 0.5 mL 10 mM TNBS 
Heat at 50ᵒC for 10 minutes 
Measure at 490 nm 
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Table 8. Layout for pepsin model system. At the start of the experiment, the solutions in 
the initiation column were combined in a vial. Two levels of pepsin were used: a 50:1 
mol:mol pepsin:toxin ratio and a 5:1 mol:mol ratio. One basic and one acidic buffer 
control were held at room temperature, all other controls and samples were held at 40°C. 
Incubation times: 10:1 mol:mol ratio – 10 and 30 min, 1 and 4 hr; 5:1 mol:mol ratio – 1 
and 4 hr. At the end of the experiment, the solution in the termination column was added. 
All samples were flash frozen in liquid nitrogen and stored at -80°C until analysis. 
Samples Initiation Termination 
Cry1Ab Buffer Control  
(pH 10.5) Room Temp. 
75 µL CAPS 
75 µL Cry1Ab 
solution 
150 µL water 
Cry1Ab Buffer Control  
(pH 1.64) Room Temp. 
75 µL KH
2
PO
4
 
75 µL Cry1Ab 
solution 
150 µL water 
Cry1Ab Buffer Control  
(pH 10.5) - 40˚C  
75 µL CAPS 
75 µL Cry1Ab 
solution 
150 µL water 
Cry1Ab Buffer Control  
(pH 1.64) - 40˚C 
75 µL KH
2
PO
4
 
75 µL Cry1Ab 
solution 
150 µL water 
Pepsin & Inhibitor Control 75 µL Pepsin 75 µL CAPS 150 µL NaOH 
Treatment 
75 µL Pepsin 
75 µL Cry1Ab 
solution 
150 µL NaOH 
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Table 9. Layout for proteinase K model system. At the start of the experiment, the 
solutions in the initiation column were combined in a vial. Two levels of proteinase K 
were used in the treatment: a 1:1 mol:mol proteinase K:toxin ratio and a 0.5:1 mol:mol 
ratio. All samples were held at 37°C for 1 and 24 hr. At the end of the experiment, the 
solution in the termination column was added. All samples were flash frozen in liquid 
nitrogen and stored at -80°C until analysis. 
Samples Initiation Termination 
Cry1Ab 
Control 
75 µL Tris-HCl 
75 µL Cry1Ab solution 150 µL water 
Proteinase K 
Control 
75 µL CAPS 
75 µL proteinase K solution 
in Tris-HCl 
150 µL water 
Treatment 
75 µL Cry1Ab solution 
75 µL proteinase K solution 
in Tris-HCl  
150 µL water 
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Table 10. Layout for simulated gut fluid model system. At the start of the experiment, the 
solutions in the initiation column were combined in a vial. Two levels of enzymes were 
used in the treatment: a 5:1 mol:mol enzyme:toxin ratio and a 1:1 mol:mol ratio. All 
samples were held at 40°C for 1 and 24 hr. At the end of the experiment, the solution in 
the termination column was added. All samples were flash frozen in liquid nitrogen and 
stored at -80°C until analysis. 
Samples Initiation Termination 
Cry1Ab 
Control 
75 µL KH
2
PO
4
 
75 µL Cry1Ab solution 
150 µL water 
Enzyme 
Control 
75 µL CAPS 
75 µL 5:1 enzyme solution 150 µL water 
1:1 Treatment 75 µL Cry1Ab solution 75 µL 1:1 enzyme solution 150 µL water 
5:1 Treatment 75 µL Cry1Ab solution 75 µL 5:1 enzyme solution 150 µL water 
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CHAPTER 3. ELISA DETECTION AND BIOACTIVITY OF 
CRY1AB PROTEIN FRAGMENTS 
A paper to be submitted to Chemosphere 
Vurtice C. Albright III, Richard L. Hellmich, Joel R. Coats 
Abstract 
The continuing use of transgenic crops has led to an increased interest in the fate 
of Cry proteins in the environment. ELISAs have emerged as the preferred detection 
method for Cry proteins in environmental matrices. Concerns exist that ELISAs are 
capable of detecting fragments of Cry proteins, which may lead to an over-estimation of 
the concentration of these proteins in the environment. Five model systems were used to 
generate fragments of the Cry1Ab protein, which were then analyzed by ELISAs and 
bioassays. The fragments from four of the model systems were not detectable by ELISA 
and did not retain bioactivity. Fragments from the proteinase K model system were 
detectable by ELISA and retained bioactivity; the reason for this is not yet known. 
Despite this result, ELISAs appear to provide an accurate estimation of the amount of 
Cry proteins in the environment, as detectable fragments retained bioactivity, and non-
detectable fragments did not retain bioactivity.  
Introduction 
 Transgenic maize expressing one or more insecticidal crystalline (Cry) proteins 
for management of agricultural pests now accounts for 81% of all maize planted in the 
United States (NASS, 2015). The widespread use of these Cry proteins has raised 
questions regarding the fate of the proteins in various environmental matrices. Numerous 
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researchers have attempted to address the questions of persistence, movement, stability, 
etc., by detecting and quantifying the amount of Cry proteins in various environmental 
matrices. Several methods of detections are available to monitor for Cry proteins in 
environmental samples, including Western blotting and bioassays; however, enzyme-
linked immunosorbent assays (ELISA) have emerged as the preferred detection method 
(Brown 2011). ELISAs are a cost-effective method for researchers in academia and 
industry as the kits typically include all required materials and little specialized training is 
needed to analyze a large number of samples in a short time span (4-8 hours).  
 Most commercial ELISA kits are primarily designed and used for quality 
assurance/quality control procedures, i.e. the detection of Cry proteins in seed and plant 
tissues to distinguish genetically modified crops from non- genetically modified crops. 
Thus, before these ELISA kits can be adapted for use with environmental matrices, the 
analytical method, including extraction protocol, must be validated. The steps necessary 
for validation of ELISAs for use with environmental samples have been extensively 
studied and summarized elsewhere (Lipton et al. 2000, Grothaus et al. 2006, Schmidt and 
Alarcon 2011).  The main steps are briefly summarized here: 1) sensitivity – determining 
the quantitative range and limit of detection and defining the upper and lower limit of 
quantitation; 2) specificity – determining there is no cross-reactivity or interference with 
similar proteins or matrix components to ensure only the protein of interest is detected; 3) 
accuracy – confirming the amount of protein detected in the ELISA is close to the actual 
amount in an environmental sample; 4) precision – minimizing variability to verify 
ELISA results are repeatable across days, analysts, and laboratories.  
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 Biological validation of ELISAs to ensure the proteins detected in environmental 
samples retain bioactivity, is one area of validation that is understudied. A lack of 
biological validation is a major omission because most of the commercially available 
ELISA kits utilize polyclonal antibodies. Although the use of polyclonal antibodies leads 
to very sensitive assays because they bind to multiple epitopes on a protein and increase 
the chances of detection, their use also increases the likelihood of detecting a partially 
degraded protein, producing a false-positive result. Thus, even though some antibody-
binding sites on a partially degraded protein may be lost, other epitopes on the protein 
fragment may be intact and capable of binding with the antibodies. The binding of 
antibodies to protein fragments could result in an ELISA test indicating a positive 
detection in a sample where no fully intact protein exists. The risk assessments for these 
proteins and their associated products could be impacted if the false positive results lead 
to overestimations of the concentrations of these proteins in the environment. For 
example, if ELISA results indicate the protein concentrations in the environment exceed 
the concentrations needed to cause adverse effects, then additional restrictions may be 
placed on the use of these products. Alternatively, if risk assessors use ELISA results that 
over-estimate the concentrations of intact Cry proteins in exposure assessments, then the 
risk assessments will be conservatively protective.   
 There is a basis for the concern that Cry protein fragments could produce false 
positive results. Einspanier et al. (2004) tracked Cry1Ab with a commercially available 
ELISA kit as the protein passed through the gastrointestinal tract (GIT) of cattle fed 
transgenic maize. Their results indicated that the protein accumulated within the GIT; this 
effect was not observed in cattle fed isoline, non-transgenic maize, so the authors ruled 
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out cross-reactivity with other proteins as the cause of the reported protein accumulation 
(Einspanier et al. 2004). A follow-up study tested the hypothesis that the protein was 
fragmented, yet still immunoreactive, leading to detection of the fragments with ELISA 
(Lutz et al. 2005). The authors fed transgenic maize containing Cry1Ab to cattle and 
collected samples from the GIT at slaughter. The samples were then analyzed with 
ELISAs and Western blotting. The ELISA results indicated that the Cry1Ab protein 
accumulated in the GIT, as reported in the first study. However, Western blotting only 
detected bands at approximately 17 and 34 kilodaltons (kDa); no fully intact Cry1Ab was 
detected, which contradicts the ELISA results (Lutz et al. 2005). Based on these results, 
understanding how fragmented proteins affect ELISAs and determining if any bioactivity 
is retained by these fragments is hugely important.  
 Five model systems were used to generate Cry1Ab fragments:  chymotrypsin 
model system, proteinase K model system, acidic buffer model system, photodegradation 
model system, and long-term degradation in buffer model system. The solutions of 
fragments generated by these model systems will be analyzed with ELISAs to determine 
if the fragments are still detectable and analyzed by bioassays to determine if the 
fragments retain bioactivity. 
Methods and Materials 
Gel Electrophoresis 
Fragmentation of the Cry1Ab protein was confirmed for each model system by 
polyacrylamide gel electrophoresis with sodium dodecyl sulfate (SDS-PAGE). Tris-HCl 
gels (15% acrylamide) used for resolution of larger fragments and parent protein (10-70 
kDa) were purchased from Bio-Rad Laboratories Inc. (Hercules, CA, cat. No. 161-1157) 
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or were prepared fresh daily according to a previously described method (Rosenberg 
1996). The recipes from Rosenberg (1996) were modified to fit a Bio-Rad Mini-Protean 
II gel apparatus (gel size 83 mm x 73 mm x 1 mm)(Table 1). An appropriate amount of 
4X sample buffer was added to each sample to obtain a 1X sample buffer concentration. 
Sample buffer consisted 4 g sucrose, 0.8 g sodium dodecyl sulfate (SDS), 2.5 mL 1M 
Tris-HCl (pH 6.8) and 250 µL 0.1% (w/v) bromophenol blue dissolved to 10 mL with 
nanopure water. Samples were boiled at 100˚C for 3-4 min, chilled in ice for 10 min and 
centrifuged at 12,000 x g for 5 min. Running buffer (3.03 g Tris 
(hydroxymethyl)aminomethane (THAM), 14.42 g glycine, 1 g SDS, dilute to 1 L with 
nanopure water) was added to the upper and lower chambers of the apparatus. One well 
on each gels was loaded with 5 µL of PageRulerTM Unstained Broad Range Protein 
Ladder (Fisher Scientific) with molecular bands ranging from 5 kilodaltons (kDa) to 250 
kDa and 20 µL of sample was added to the remaining wells. A constant 180 volts was 
applied to the gels until the dye front was within 1 centimeter of the bottom of the gel 
(approximate run times were 1 hour). Gels were stained with either Coomassie Brilliant 
Blue or silver stain and digitized using a Lexmark X83 All-in-One printer/copier/scanner 
and Lexmark Viewing Booth software (Lexmark International Inc., Lexington, KY). 
Adobe Photoshop CS5 (version 12.1 x64)(Adobe Systems Inc., San Jose, CA) was used 
to edit and annotate each gel.  
Coomassie Staining 
The Coomassie staining procedure was adapted from Rosenberg (1996). Briefly, 1 
g Coomassie Brilliant Blue R-250 (Fisher Scientific) was dissolved in 100 mL acetic acid 
and 400 mL methanol and diluted to 1 L with nanopure water. Destain solution was 
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prepared by diluting 100 mL acetic acid and 400 mL methanol to 1 L with nanopure 
water. Staining occurred for 30 min and was followed by destaining for 2-3 hours or 
overnight with the destain solution being changed 1-2 times. All staining occurred on an 
orbital shaker (ELMI Ltd., Riga, Latvia) at 100 rpm.  
Silver Staining 
The silver staining procedure adapted from Rosenberg (1996) was used. Gels 
were stored at 4˚C in gel fix solution (50% (v/v) methanol, 12% (v/v) acetic acid, 38% 
(v/v) water) overnight following gel electrophoresis. Each gel was washed three times 
with 50% (v/v) ethanol for 20 min each. Each gel was submerged in sodium thiosulfate 
(0.2 g/L sodium thiosulfate) for exactly 1 min and immediately rinsed with nanopure 
water three times for 20 seconds each. Gels were submerged in silver nitrate solution (2 
g/L silver nitrate, 0.75 mL/L 37% (v/v) formaldehyde stock solution) for 20 min and 
immediately rinsed with nanopure water 2 times for 20 sec each. Developing solution (60 
g/L sodium carbonate, 0.5 mL/L 37% (v/v) formaldehyde stock solution, 4 mg/L sodium 
thiosulfate) was used to visualize protein bands by submerging the gels for up to 10 min. 
Gels were washed with nanopure water twice for 2 min each to terminate the developing 
process. Finally, gels were submerged in gel fix solution for 10 min and then in 50% 
(v/v) methanol for 20 min. All staining occurred at room temperature on an orbital 
shaker. 
Bioassays 
Diet for the bioassays was prepared by mixing three parts liquid containing 
treatment or control solution with one part Stonefly Heliothis diet (Ward’s Science). In 
addition to the controls outlined for each model system, an additional water control and 
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Cry1Ab control were prepared fresh at the start of each bioassay. All samples and 
controls were diluted so that if all protein was fully intact, the final concentration of 
protein in the diet would be 94.5 ng/g. This value falls between the LC90 and LC95 values 
for the protein and insect population used in the study (see Chapter 2). The use of a high 
initial concentration will allow for easier observation of any changes in mortality and 
sub-lethal effects.  Diet was mixed thoroughly and 0.3 mL of diet was placed into each 
well. There were 3 replicates per treatment and 16 insects per replicate (N=48). A single 
European corn borer (ECB) neonate, Ostrinia nubilalis, was placed in each well and the 
trays were incubated at 27˚C (+ 2˚C) and 60-70% humidity. The Corn Insects and Crop 
Genetics Research Unit of the USDA–ARS (Ames, IA) kindly provided all European 
corn borers. Larvae were assessed for survival and weight gain after seven days. 
Bioassays with less than 80% survival in the water controls were reassessed. Treatment 
replicates were combined and an analysis of variance in SAS 9.3 software (SAS Institute, 
Cary, NC) was used to determine statistical significance (p < 0.05). 
ELISAs 
 ELISA kits specific for Cry1Ab/1Ac (cat. No. PSP 06200) were purchased from 
Agdia Inc. (Elkhart, IN). Analysis of samples was performed according to the 
manufacturer’s instructions. Quantitative results were obtained through the use of a 
standard curve. A Cry1Ab reference standard, provided by Monsanto Company (St. 
Louis, MO), was used to prepare a fresh 1-20 ng/mL standard curve in the assay buffer, 
phosphate buffered saline with Tween 20 (PBST), daily. Experiments to validate the 
specificity and precision of the assay for each model system were carried out to ensure 
the performance of the assay. Validation of the sensitivity and accuracy of the assay were 
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not performed; model system samples were analyzed directly, eliminating the need for 
fortification and recovery or extraction efficiency studies, and all model system samples 
were diluted to fall in the middle of the quantitative range, thus eliminating the possibility 
of samples falling below the limit of detection and the lower limit of quantitation.  
 Specificity, cross-reactivity or interference of the model system components 
(buffers, enzymes, inhibitors) with the antibodies in the ELISA kit, was determined 
through buffer matrix testing. Multiple dilutions (1:5,000, 1:10,000, etc.) of only the 
model system components were prepared using the assay buffer. A 2x standard curve (2-
40 ng/mL) was prepared and mixed with equal volumes of the model system dilutions, 
resulting in a 1x standard curve in the model system buffer. The 1x standard curves in 
model system buffer were then analyzed with ELISAs in conjunction with a 1x standard 
curve in assay buffer. The relative percent difference (R%D) was calculated from each 
point on the standard curve with the following equation:  
𝑅%𝐷 =  (𝑠𝑑𝑠𝑑𝑠 𝑠𝑠𝑠𝑠𝑑𝑠 𝑏𝑏𝑏𝑏𝑑𝑠 𝑠𝑑𝑠𝑏𝑠𝑠−𝑠𝑠𝑠𝑠𝑠 𝑏𝑏𝑏𝑏𝑑𝑠 𝑠𝑑𝑠𝑏𝑠𝑠)
𝑠𝑠𝑠𝑠𝑠 𝑏𝑏𝑏𝑏𝑑𝑠 𝑠𝑑𝑠𝑏𝑠𝑠  𝑥 100%. The acceptance criterion 
for buffer matrix testing is R%D < │15%│ between the assay buffer and model system 
buffer (Schmidt and Alarcon 2011) If the R%D > │15%│ across two consecutive points 
in the standard curve, then there may be matrix effects due to the model system 
components.  
 Precision of the ELISA was validated through the use of positive and negative 
controls, standard curve precision, and dilution agreement. Positive controls (included 
with the kit) and negative PBST controls were included on every plate. Plates that had 
standard curve R2 < 0.90 were re-analyzed. Dilution agreement was used to ensure 
diluting the model system samples did not affect quantitation of the protein. Standardized 
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protein was diluted in the model system components (buffers, enzymes, inhibitors) and 
dilutions were selected to fall above, below, and within the quantitative range. Dilutions 
were analyzed with ELISAs and percent coefficient of variation (%CV) was calculated 
across all in-range dilutions with the following equation: %𝐶𝐶 =  𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑑𝑑𝑑𝑠𝑠𝑑𝑑𝑠
𝑠𝑑𝑠𝑠 𝑠𝑠𝑎𝑏𝑠𝑠𝑑𝑠 𝑠𝑑𝑠𝑏𝑠𝑠  𝑥 100%. The acceptance criterion for dilution agreement is 
a %CV < 20%. If the %CV > 20%, minimum or maximum dilutions were applied until 
the %CV was < 20%. 
Chymotrypsin 
 Trypsin-activated Cry1Ab protein (salt-free, 96% pure) dissolved in 50 mM N-
cyclohexyl-3-aminopropanesulfonic acid (CAPS), pH 10.5 was purchased from Case 
Western Reserve University (Cleveland, OH); the concentration of the protein in solution 
was 900 µg/mL. Alpha-chymotrypsin from bovine pancreas (cat. No. C4129) was 
purchased from Sigma-Aldrich (St. Louis, MO). The chymotrypsin model system 
consisted of a Cry1Ab control, a chymotrypsin control, and three sample replicates 
(Table 2). A 5:1 mol:mol ratio of enzyme to toxin was prepared by dissolving 
chymotrypsin in 100 mM potassium phosphate (KH2PO4) buffer, pH 7. All samples were 
incubated at 37˚C for 1 hour or 24 hours. At termination, 150 µL of nanopure water was 
added to each sample. Three 50 µL aliquots were removed for use in gel electrophoresis, 
ELISA, and bioassays. All vials were flash frozen in liquid nitrogen and stored at -80˚C 
until analysis.  
Long-term degradation in buffer 
 The long-term degradation in buffer model system consisted of three sample 
replicates. One hundred microliters of Cry1Ab solution and 100 µL of 50 mM CAPS was 
144 
 
placed in 1.5 mL vials and stored in the dark at room temperature for 16 weeks. To 
maintain consistency with the other model systems, 200 µL of nanopure water was added 
to each tube at termination. Three 50 µL aliquots were removed for use in gel 
electrophoresis, ELISA, and bioassays. All vials were flash frozen in liquid nitrogen and 
stored at -80˚C until analysis.  
Photodegradation 
 The photodegradation model system consisted of two treatments and three sample 
replicates per treatment. Each sample 115 µL of Cry1Ab solution placed in a quartz 
NMR tube. The samples were then placed in a Rayonet photoreactor (Southern New 
England Ultraviolet Company, Branford, CT) and irradiated with 254 nm light for either 
2.5 or 5 min. Following irradiation, 75 µL of sample was transferred into a separate vial 
and 225 µL of water was added. Three 50 µL aliquots were removed for use in gel 
electrophoresis, ELISA, and bioassays and all vials were flash frozen in liquid nitrogen 
and stored at -80˚C until analysis. 
Acidic buffer 
The acidic buffer treatment (pH 1.64) consisted of four time points, with three 
samples at each time point. All samples consisted of 75 µL Cry1Ab solution (in CAPS, 
pH 10.5) and 75 µL KH2PO4 (pH 1.3). At each time point, one sample was held at room 
temperature, while the remaining two samples were held at 40˚C. All samples were 
terminated with 150 µL nanopure water at 4, 5, 6, or 7 days. After termination, samples 
were flash frozen with liquid nitrogen and stored at -80˚C until analysis with gel 
electrophoresis.  
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Proteinase K 
Proteinase K from Tritirachium album was purchased from Sigma-Aldrich and a 
1:1 mol:mol ratio of enzyme to toxin was prepared by dissolving proteinase K in 20 mM 
Tris (hydroxymethyl)aminomethane hydrochloride (Tris-HCl) buffer, pH 7.5. The 
proteinase K model system consisted of a Cry1Ab control, a proteinase K control and 
three sample replicates (Table 3). All samples were incubated at 37˚C for 30 minutes. At 
termination, 150 µL of nanopure water was added to each sample and then three 50 µL 
aliquots were removed for use in gel electrophoresis, ELISAs, and bioassays. All vials 
were flash frozen in liquid nitrogen and stored at -80˚C until analysis. 
Following analysis of the proteinase K treatments, a mass digest of Cry1Ab was 
set up to generate sufficient quantities of fragments for additional analysis. For this mass 
digest, 4.5 mL of Cry1Ab was incubated with 4.5 mL of proteinase K at 37˚C for 30 
minutes. At termination, 9 mL of nanopure water was added aliquots of 50 µL, 300 µL, 
and 1 mL were prepared, and all aliquots were flash frozen in liquid nitrogen and stored 
at -80˚C. A Cry1Ab control (4.5 mL Cry1Ab and 4.5 mL 20 mM Tris-HCl; terminated 
with 9 mL water) and a proteinase K control (4.5 mL 50 mM CAPS and 4.5 mL 
proteinase K solution; terminated with 9 mL water) were also prepared and subjected to 
the same conditions. Gel electrophoresis was performed on an aliquot of the mass digest 
to confirm the degradation pattern remained the same.  
An aliquot of the mass digest was subjected to gel electrophoresis with a tris-
tricine gel; the use of a tris-tricine gel allowed for resolution of fragments with low 
molecular weights. Tris-tricine gels (16.5% acrylamide, cat. no. 456-3064), running 
buffer (cat. no. 161-0744), sample buffer (cat. no. 161-0739) and polypeptide SDS-PAGE 
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standards (cat. no. 161-0326) were purchased from Bio-Rad Laboratories Inc. and 
prepared according to the manufacturer’s directions. Equal volumes of sample and 
sample buffer were combined and heated at 95˚C for 5min, chilled in ice for 10 min, and 
centrifuged at 12,000 x g for 5 min. Twenty microliters of sample was loaded into the 
lanes and a constant 100 volts was applied to the gel until the dye front was within 1 cm 
of the bottom of the gel (approximate run time was 2 hours). The gel was stained with 
silver stain and digitized as previously described. 
A separatory column was used to isolate fragments for further analysis. 
Sephadex® G-50 separatory media was purchased from Sigma-Aldrich and placed in 
excess 50 mM sodium phosphate buffer (with 15 mM NaCl, pH 7.0) overnight to allow 
the beads to swell. Suspended particles were decanted and the media was degassed for 15 
minutes with occasional swirling. Glass wool was placed in the bottom of a 1 cm 
diameter column and 0.5 cm of sand was added to prevent column blockage. The column 
was filled 1/3 full with fresh buffer and the gel was poured in one continuous step until 
the desired height of 12.7 cm was reached (10 mL approximate column volume). The gel 
was allowed to settle for 10 min and then the outlet was opened to achieve even 
sedimentation; fresh buffer was continuously added to ensure the column did not run dry. 
Following sedimentation, the outlet was closed and excess buffer was removed with a 
Pasteur pipet. A 3 mL volume of sample was added via Pasteur pipet and the outlet was 
opened to allow the sample to enter the column bed, at which time the outlet was closed. 
Additional sample buffer was carefully added with a Pasteur pipet, the outlet was opened, 
and fraction collection was initiated. Fifteen 1 mL fractions were collected from the three 
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mass digest samples. A Nano-Drop® ND-1000 spectrophotometer was used to determine 
protein concentration in each fragment by recording absorbance at 280 nm.  
Following separation of the fragments, ELISAs were performed on selected 
fractions for all three samples. The total amount of protein in the fractions varied from 
fraction to fraction. To account for this variation, the protein concentration determined by 
Nano-Drop® spectrophotometry (Table 4) was used as a starting point, and all fractions 
were appropriately diluted so that the final concentration of total protein in each fraction 
was 11.25 ng/mL for the ELISA.  
Results 
Chymotrypsin 
The chymotrypsin model system produced minor degradation of Cry1Ab at 1 
hour (Figure 1A). Significantly more degradation of the protein was observed at 24 hours 
(Figure 1B); chymotrypsin was almost completely degraded at 24 hours, so longer 
incubations were not investigated. There was no difference in the number of fragments 
produced by the different incubations times; both yield two fragments, approximately 25 
and 34 kDa in size.  
Buffer matrix testing indicated there would be no effects from the buffer at a 
1:22,500 dilution of the samples (Table 5). Dilution agreement testing determined that 
diluting the samples in the range of 1:15,000 to 1:50,000 would not affect protein 
quantitation (%CV = 8.00) (Table 6). Therefore, all samples from the chymotrypsin 
model system were diluted by a factor of 1:22,500 prior to ELISA analysis. At 1 hour, 
ELISA results indicated that very little degradation of the protein occurred; 95-110% of 
the parent protein remained (Table 7). After 24 hours, ELISA results indicated the 
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Cry1Ab protein had been significantly degraded with only 21-68% of the parent protein 
remaining. Average survival for insects in the 1 hour treatments was 34.7% and 77.6% 
for the 24 hour treatments (Figure 2). The average weight of the insects was higher in the 
24 hour treatment (0.90 mg) compared to the 1 hour treatment (0.34 mg).   
Long-term degradation in buffer 
 The long-term degradation of Cry1Ab in only CAPS buffer produced multiple 
protein fragments (Figure 3). The majority of the fragments produced were three 
fragments approximately 27, 40, and 45 kDa; several fragments 25 kDa or smaller were 
also visualized. Buffer matrix testing determined that there would be no significant 
effects from the buffer in the dilution range of 1:10,000 – 1:50,000 (Table 8). Dilution 
agreement testing indicated that protein quantitation would not be affected if the samples 
were diluted in the range of 1:15,000 – 1:50,000 (%CV = 4.85)(Table 9). A dilution of 
factor of 1:22,500 was subsequently used to dilute all samples by prior to ELISA 
analysis. Since both the long-term degradation model system and the photodegradation 
model system consisted of only CAPS and water, the results from the buffer matrix and 
dilution agreement tests were also used to determine the dilutions used in the 
photodegradation model system.  
ELISA results indicated that significant degradation of the protein occurred; 
approximately 50% of the fully intact protein remained (Table 10). The average larval 
survival for the treatments (70.1%) was slightly lower than the water control survival; 
however, average larval weight was greatly reduced compared to the water control, 0.75 
mg and 6.60 mg respectively (Figure 4). 
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Photodegradation 
 Significant degradation of Cry1Ab occurred at both time points, but fully intact 
protein remained (Figure 5). A greater number of fragments and higher quantities of all 
fragments were present in the 5 min samples than the 2.5 min samples. Significant 
smearing was observed in the gel in all samples. The smearing was contained above the 
100 kDa, and thus, it did not interfere with fragment visualization. All samples were 
diluted by a factor of 1:22,500 prior to ELISA analysis, as determined previously (see 
long-term degradation in buffer results). Cry1Ab protein was detected at a low level by 
ELISA in only one of three 2.5 min samples and was not detected in any of the 5 min 
samples (Table 11), despite the presence of small amounts of Cry1Ab in all samples, as 
indicated by the gel (Figure 5).There were no significant differences between the 2.5 and 
5 min samples and the water control for larval survival; survival in all three was greater 
than 97% (Figure 6). Fragments of the photodegradation model system do not appear to 
have sub-lethal effects as no significant differences are present between the water control 
and the 2.5 min samples. Average weight in the 5 min treatments was significantly higher 
than the water control, suggesting a possible increase in growth, but this was not 
investigated further.  
Acidic buffer 
Minimal degradation was observed in the four room temperature controls. 
Significant degradation of the protein was observed in the 40˚C treatments at all four time 
points, with nearly all the parent protein completely degraded after 7 days (Figure 7). 
There were a larger number of different protein fragments in the treatments, but the 
quantities of each fragment were low; the prominent band for most samples is a band 
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near 5 kDa. Buffer matrix testing indicated that the buffer would not have significant 
effects on the ELISA results, if the samples were diluted in the 1:10,000 - 1:1,000,000 
range (Table 12). Protein quantitation would be unaffected if all samples were diluted in 
the 1:10,000 - 1:100,000 range; for consistency, a dilution factor of 1:22,500 was applied 
to all samples prior to analysis with ELISA (Table 13). No fully-intact Cry1Ab was 
detected in any of the room temperature controls or the 40˚C treatments by ELISA (Table 
14). Bioassays of the 4 and 5 day samples and the 6 and 7 day samples were performed 
on different days. Larval survival in all model system controls and treatments was high, 
>80%, and there were no significant differences when compared to the water control 
(Figure 8). Average weight of the insects in the 4 day room temperature control was low, 
suggesting possible sub-lethal effects, but this difference was not statistically significant. 
Average weight of the insects in the 6 and 7 day 40˚C treatment was significantly lower 
than the water control, suggesting possible sub-lethal effects. All other treatments and 
controls were either not significantly different from the water control, or were statistically 
higher than the water control.  
Proteinase K 
The proteinase K model system completely degraded the Cry1Ab protein (Figure 
9A). The resulting degradation pattern was dominated by a fragment or multiple 
fragments in the 5 kDa range. Smaller quantities of additional fragments in the 10-15 kDa 
range were also present. Buffer matrix testing indicated that buffer components would 
not significantly affect ELISA results (Table 15). Dilution agreement testing determined 
that diluting the samples in the 1:15,000 to 1:50,000 range would not affect protein 
quantitation (%CV = 11.11) (Table 16). Based on the buffer matrix and dilution 
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agreement results, all proteinase K model system samples were diluted by a factor of 
1:20,000 prior to ELISA analysis. ELISA results of the proteinase K treatments indicated 
that the Cry1Ab fragments were still highly detectable by the ELISA antibodies (Table 
17A).  
Significant biological effects were observed in all treatments. These bioassays 
were performed a second time and the combined data are presented (Figure 10A) (N=96). 
Survival in the treatments (52.4%) was comparable to the Cry1Ab controls (47-60%) and 
was significantly lower than the water and proteinase K controls (95% and 92% 
respectively). Average weight of the insects fed on diet containing the treatment solutions 
(0.33 mg) did not differ from the Cry1Ab controls (0.32 – 0.54 mg), but was significantly 
lower than the water and proteinase K controls (6.61 and 6.35 mg, respectively).  
Since the results of the gel electrophoresis (protein is highly degraded) and 
ELISAs and bioassays (protein still detectable and biological active) contradicted each 
other, the entire proteinase K model system was performed a second time. The results 
from the gel electrophoresis (Figure 9B), ELISAs (Table 17B), and bioassays (Figure 
10B) supported the previous findings.  
Proteinase K treatments from the first run were silver stained (Figure 9A) in an 
attempt to visualize fragments that might not have been captured by Coomassie staining. 
The silver staining procedure did detect additional bands in the treatments; however, all 
of these bands appeared to correspond to additional bands visualized in the proteinase K 
control (Figure 9C). 
Gel electrophoresis on the mass digest (Figure 11A) indicated a similar 
degradation pattern as previously observed (Figure 9). Gel electrophoresis with the tris-
152 
 
tricine gel adequately resolved the low molecular weight fragments (Figure 11B). 
Although many of the fragments in the treatment corresponded to bands in the proteinase 
K enzyme control, two bands in the treatment between 3.5 kDa and 6.5 kDa did not 
appear elsewhere; thus, the proteinase K digestion appears to produce at least two 
fragments that have low molecular weights.  
A G-50 separatory column was used to fractionate the treatment protein and the 
proteinase K control and Cry1Ab protein control. Fraction analysis by Nano-Drop® 
spectrophotometry yielded six fractions of interest in the treatment. High concentrations 
of protein were observed in fractions 4-7 and 12-13 in the treatment (Figure 12). The 
Cry1Ab control peaked across fractions 5-6, while no discernable peaks were observed in 
the proteinase K control. ELISAs were performed individually on fractions 4-7 and 12-13 
for the treatment and the two control samples. The ELISA results indicated that Cry1Ab 
was present in treatment fractions 4-7 and in Cry1Ab control fractions 5-7; no protein 
was detected in any of the proteinase K control fractions (Table 4).  
Discussion 
The gel electrophoresis, ELISA, and bioassay results in four of the five model 
systems tested corroborated each other. For the chymotrypsin model system, at 1 hour, 
very few fragments are observed in the gel and most of the parent protein remains intact 
(Figure 1A). ELISA results also indicate that similar amounts of parent protein are 
present in the treatments and the control. Bioassays suggest that more ECB larval 
survival occurs in the 1 hour treatments than the Cry1Ab control, though the cause of this 
is unknown. At 24 hours, the gel electrophoresis and ELISA results indicate that 
significant losses of the parent protein occurred. The bioassay results show significant 
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increases in larval survival; however, average larval weights are still suppressed. Thus, at 
24 hours, sufficient amounts of fully intact Cry1Ab remain to affect larval growth, but the 
quantities present are below the threshold needed for mortality to occur. Since the 
biological activity and ELISA detectability of the protein decreases as the protein 
becomes fragmented, the conclusion can be drawn that Cry1Ab fragments generated by 
the chymotrypsin model system are not detectable by ELISA and do not retain any 
bioactivity.  
 For the long-term degradation in buffer model system, multiple fragments of 
Cry1Ab were generated, but substantial quantities of the fully intact protein remained 
(Figure 3). The ELISA results indicate approximately half of the protein is no longer 
present (Table 10). Increased larval survival in the treatments suggests that substantial 
degradation of the protein occurred, but the low average weight of the insects in the 
treatments indicates that enough protein remains intact to cause sub-lethal effects (Figure 
4). Based on these results, the conclusion can be drawn that the fragments generated by 
the long-term degradation in buffer model system are not detectable by ELISAs and do 
not retain bioactivity. 
 In the photodegradation model system, numerous fragments were produced 
following 2.5 and 5 min exposure to UV light (Figure 5). Molecules larger than the 67 
kDa parent protein were also visible in all lanes. These larger molecules are most likely 
the result of two Cry1Ab molecules (or fragments) becoming cross-linked to each other 
and forming dimers or other complex molecules. Protein-protein cross-linking is known 
to occur at 254 nm (Martinson et al. 1976). Cry1Ab was detected in only one of six 
treatments by the ELISA, despite the presence of fully-intact protein still present in all 
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lanes (Table 11). Detrimental effects of the fragments were not observed in the bioassays 
(though the 5 min treatments seemed to promote insect growth)(Figure 6). This suggests 
that the structure of these fully-intact proteins may have been altered by the UV light to 
prevent antibody binding. Disulfide bonds can absorb light between 250-300 nm, which 
can lead to photo-dissociation of cystine into two thiyl radicals. These radicals can 
dimerize (explaining the larger molecules observed in the gel) or they may react with 
oxygen, resulting in an irreversible oxidation of the disulfide bond. This oxidation 
reaction can compromise the tertiary structure of the protein, and result in decreased 
antibody binding (from ELISAs) and decreased toxicity (Davies and Truscott 2001). 
From these results, the conclusion can be drawn that the fragments generated by the 
photodegradation model system do not retain bioactivity and are not detectable by 
ELISA.  
 The acidic buffer model system produced numerous fragments over the 4 to 7 day 
degradation, including nearly complete degradation of the protein at 7 days (Figure 7). 
However, the quantity of fragments produced never increased, and the amounts of 
individual fragments did not accumulate, suggesting continued degradation of the 
fragments. Fragments of the acidic buffer model system are not detectable by ELISA 
(Table 14). These fragments do not appear to retain bioactivity, as survival in all 
treatments did not differ from the water control (Figure 8). Survival in the room 
temperature controls also was not significantly different from the water control, though 
significant amounts of parent protein remained as observed in the gel (Figure 7). The 
acidic conditions in these controls and treatments possibly caused denaturing of the 
protein, resulting in a loss of bioactivity and detectability by ELISA. Denaturing of 
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proteins is known to occur at low pH (Goto et al. 1990). In some cases, denatured 
proteins may refold into a molten globule-like conformation (Goto et al.1990, Fink et 
al.1994), but the exact conformational state of the proteins and fragments in the controls 
and treatments was not investigated in the study and remains unknown. Decreased weight 
of the insects in the 6 and 7 day treatments indicate sublethal effect may be occurring 
(Figure 8B). The average weight in these treatments was significantly higher than the 
average weight in the Cry1Ab control; the average weight in other model systems where 
survival was not impacted but sub-lethal effects existed (such as the proteinase K model 
system) were not statistically different from the Cry1Ab control (Figure 10). This 
suggests that the effects observed in the 6 and 7 day treatments might not be attributable 
to Cry1Ab fragments, but rather to buffer components. The average weight in the 5 day 
treatment was statistically higher than the water control, further supporting the possibility 
that variation in the biological systems is responsible for the weight differences. 
Although additional bioassay replicates would provide more information on this issue, no 
further studies were performed to address this issue, due to a lack of promising results in 
the ELISAs and survival in the bioassays. Based on the results of the acidic buffer model 
system, the conclusion can be drawn that the fragments generated by this model system 
are not detectable by ELISA and do not appear to retain any biological activity. 
For these four model systems, the conclusion can be drawn that the fragments 
generated by the model systems are not detectable by ELISA, since the concentrations of 
Cry1Ab in the treatment solutions decreased. If the fragments were detectable by the 
ELISA, it would be expected that the concentrations of Cry1Ab, as determined by the 
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ELISA, would remain unchanged or even increase, if multiple fragments capable of 
binding with the antibodies were formed from the degradation of a single protein.  
 The proteinase K model system produced different results, because initial tests on 
the fragments generated by the proteinase K model system suggests the fragments are 
still detectable by ELISA and retain bioactivity (Figure 10, Table 17). The model system 
digestion was repeated, and the results of the first digestion were replicated (Figures 9B, 
10B, Table 17B). These positive ELISA and bioassay results were unexpected given the 
low molecular weight of these fragments (Figure 11B). A separatory column was used in 
an attempt to isolate separate fragments and test each fragment or a smaller collection of 
fragments with ELISAs. This separation resulted in six fractions of interest: fractions 4-7 
and 12-13 (Figure 12). The largest peak in the treatment was centered across fractions 4-
7, which aligned with the peak in the Cry1Ab control. This is surprising because the 
Sephadex® G-50 media used in the separatory column has a cutoff of approximately 30 
kDa; proteins larger than 30 kDa should elute in the first few fractions, while proteins 
smaller than 30 kDa should elute in later fractions. This is true for the Cry1Ab control, as 
the fully intact protein (67 kDa) elutes early in the column (fractions 5-6, Figure 12). This 
suggests that high molecular weight proteins (>30 kDa) are still present in the treatment; 
however, no proteins >30 kDa are observed in the gels (Figures 9, 11B). 
One possible explanation for why the fragments are still detectable by ELISA is 
that the proteinase K fragments may still be immunoreactive with the ELISA antibodies. 
Lutz et al. (2005) detected Cry1Ab with ELISA in gastrointestinal tract samples from 
cattle fed transgenic maize; however Western blotting indicated that only 17 and 34 kDa 
fragments were present. Emmerling et al. (2011) detected small amounts of Cry1Ab with 
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ELISA in hindgut and cast material samples from earthworms; Western blotting did not 
detect any fragments, leading the authors to speculate that the fragments detected by the 
ELISA were smaller than 17 kDa. The fragments in the current study meet these criteria 
as they are believed to be between 3.5 and 6.5 kDa in size. However, this does not 
explain why the fragments move through a separatory column in a manner similar to 
larger proteins or why the fragments still exhibit biological activity. Some fragments of 
Cry proteins are known to retain biological activity. Diaz-Mendoza et al. (2007) reported 
that 43 and 46 kDa fragments of Cry1Ab (69 kDa active form) generated by a trypsin 
purified from the Mediterranean corn borer, Sesamia nonagrioides, were still toxic to S. 
nonagrioides larvae. However, no other known studies have tested the bioactivity of Cry 
protein fragments with very low molecular weights; it seems unlikely that a highly 
degraded fragment (17 kDa or less) would retain enough structure to bind to and insert 
into an insect’s midgut cells, and ultimately, result in toxicity.  
Another possible explanation is that proteinase K degrades the protein, but the 
fragments then re-associate with each other, possibly through disulfide bridges. 
Proteinase K cleaves at the carboxylic group of aliphatic and aromatic amino acids with 
blocked α-amino groups; disulfide bridges may not be affected by this cleavage (Ebeling 
et al. 1974). Fragments may be visualized in gel electrophoresis because the denaturing 
conditions in SDS-PAGE break the disulfide bonds, causing the fragments to dissociate 
from each other. If the fragments do re-associate with each other, they would have a 
higher overall molecular weight, which would cause them to pass though the separatory 
column quickly and elute in earlier fractions, similar to fully-intact, large molecular 
weight proteins. This also may explain the positive ELISA and bioassay results; the 
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association of the fragments may allow the protein to retain enough of its native 
conformation to allow for antibody binding (resulting in positive ELISA detections) and 
binding to the insect midgut (resulting in toxicity).  
Two studies observed similar processes with Cry4A and Cry11A. Two Cry4A 
fragments of 20 and 45 kDa were formed by in vitro and in vivo processing (Yamagiwa et 
al. 1999). Individually, the two fragments exhibited no toxicity against Culex pipiens 
larvae; however, when the two fragments were mixed together, significant toxicity was 
observed. The authors proposed that the two fragments associated with each other to form 
an insecticidal complex since the fragments could not be separated by gel filtration; 
fragment association was confirmed with co-precipitation experiments (Yamagiwa et al. 
1999). Similar results were observed with Cry11A for which a 32- and a 36-kDa 
fragment had no toxicity individually, but exhibited significant toxicity when expressed 
together (Yamagiwa et al. 2004). The two fragments also eluted together in size-
exclusion chromatography, and co-precipitation experiments determined that they were 
associated with each other (Yamagiwa et al. 2004).  
A similar inability to resolve the fragments with gel filtration was observed in the 
current study, supporting the theory that the fragments were associated with each other.  
More research is needed to confirm this association of fragments. First, fragments should 
be separated further to allow for identification and sequencing of individual fragments. 
Once sequenced, fusion proteins containing fragments can be synthesized and used in co-
precipitation and toxicity experiments, similar to those described in Yamagiwa et al. 
(1999). In that study, fusion proteins of glutathione S-transferase (GST) linked to the 
fragments or fully-intact protein were used in a co-precipitation experiment to show that 
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the fragments associated with each other. The GST-fragment fusion proteins were also 
tested for toxicity individually and together; toxicity was observed when the fragments 
co-existed, and no toxicity was observed when the fragments were tested individually 
(Yamagiwa et al. 1999). 
Conclusions 
 Five model systems were used to generate fragments of Cry1Ab. In four of these 
model systems, the chymotrypsin model system, acidic buffer model system, 
photodegradation model system, and long-term degradation in buffer model system, the 
fragments generated were not detectable by ELISA and did not retain bioactivity. In the 
proteinase K model system, the fragments generated were detectable by ELISA and 
retained bioactivity. The reason for this is unknown; more research is needed to 
understand this phenomenon. Nevertheless, based on the results described here, 
researchers do not appear to be over-estimating the amount of Cry proteins in the 
environment, as fragments that are detectable by ELISA, also retain bioactivity, and those 
fragments not detectable by ELISA have no biological activity. However, only a few 
mechanisms of Cry protein degradation were investigated. Additionally, an ELISA from 
only one manufacturer was used. Other manufacturers may use different host organisms 
to produce antibodies for their ELISA kits, and these antibodies may bind to different 
epitopes on the fragmented protein, potentially generating different results.  Thus, more 
research is needed with other ELISA kits and additional model systems, especially 
microbe-based model systems, to obtain a better understanding of the fate of Cry proteins 
in the environment.  
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Figures 
 
 
Figure 1.  Degradation of Cry1Ab with the chymotrypsin model system. Incubation 
times: A – 1 hour, B – 24 hours. Cry1Ab control – Cry1Ab only; Chymo. control – 
chymotrypsin in buffer only; Rep 1-3 – treatments containing Cry1Ab and chymotrypsin. 
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Figure 2. A - Survival of insects fed on diet prepared from the chymotrypsin model system. B - Average weight of insects fed on diet 
prepared from the chymotrypsin model system. The determination of significance required the data to be log transformed due to a low 
number of individuals in some of the treatments. Cry1Ab = Cry1Ab only; Chymo = chymotrypsin in buffer only; Treatment = 
treatments containing Cry1Ab and chymotrypsin. Letters indicate significance across treatments (p = 0.05).
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Figure 3.  Degradation of Cry1Ab with the long-term degradation in buffer model system 
after a 16-week incubation. Cry1Ab = freshly prepared protein; Rep 1-3 = treatments 
containing Cry1Ab in 50 mM CAPS buffer. 
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Figure 4. Survival and average weight of surviving insects fed on diet prepared from the 
long-term degradation model system. Cry1Ab = Cry1Ab only; Treatment = treatments 
containing Cry1Ab degraded over 16 weeks at room temperature in 50 mM CAPS buffer, 
pH 10.5. Uppercase letters indicate significance within survival across treatments (p = 
0.05). Lowercase letters indicate significance within average weight across treatments (p 
= 0.05).   
165 
 
 
Figure 5. Degradation of Cry1Ab with the photodegradation model system. Samples 
were exposed to 254 nm light for 2.5 or 5 minutes. Cry1Ab = freshly prepared protein; 
Rep 1-3 = treatments containing Cry1Ab in 50 mM CAPS buffer.  
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Figure 6. Survival and average weight of surviving insects fed on diet prepared from the 
photodegradation model system. Cry1Ab = Cry1Ab only; 2.5 min = 2.5 min exposure to 
254 nm light; 5 min = 5 min exposure to 254 nm light. Uppercase letters indicate 
significance within survival across treatments (p = 0.05). Lowercase letters indicate 
significance within average weight across treatments (p = 0.05). 
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Figure 7. Degradation of Cry1Ab with the acidic buffer model system. Incubation times: 
A – 4-5 days, B – 6-7 days.  
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Figure 8. A – Survival and average weight of surviving insects fed on diet prepared from the 4-5 day acidic buffer model systems. B – 
Survival and average weight of surviving insects fed on diet prepared from the 6-7 day acidic buffer model systems. Cry1Ab = 
Cry1Ab only; 4 D RT = Cry1Ab incubated in acidic buffer (pH 1.64) at room temperature for 4 days. 4 D Treat = Cry1Ab incubated 
in acidic buffer (pH 1.64) at 40˚C for 4 days. 5 D RT = Cry1Ab incubated in acidic buffer (pH 1.64) at room temperature for 5 days. 5 
D Treat = Cry1Ab incubated in acidic buffer (pH 1.64) at 40˚C for 5 days. 6 D RT = Cry1Ab incubated in acidic buffer (pH 1.64) at 
room temperature for 6 days. 6 D Treat = Cry1Ab incubated in acidic buffer (pH 1.64) at 40˚C for 6 days. 7 D RT = Cry1Ab 
incubated in acidic buffer (pH 1.64) at room temperature for 7 days. 7 D Treat = Cry1Ab incubated in acidic buffer (pH 1.64) at 40˚C 
for 7 days. Uppercase letters indicate significance within survival across treatments (p = 0.05). Lowercase letters indicate significance 
within average weight across treatments (p = 0.05). 
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Figure 9. Degradation of Cry1Ab with the proteinase K model system. A – The proteinase K model system completely degraded 
Cry1Ab. B – The model system was repeated entirely, and the results were replicated. C – Silver staining performed on the treatments 
from the first model system run (A) did not detect additional fragment bands. 
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Figure 10. Survival and average weight of surviving insects fed on diet prepared from the proteinase K model system. A – The initial 
model system experiment. B – The model system experiment was repeated given the interesting survival and average weight results in 
the treatment. Cry1Ab = Cry1Ab only; Prtn. K = proteinase K in buffer only; MSCry1Ab = Cry1Ab subjected to the model system 
treatments (37˚C for 30 min); Treatment = treatments containing Cry1Ab and proteinase K. Uppercase letters indicate significance 
within survival across treatments (p = 0.05). Lowercase letters indicate significance within average weight across treatments (p = 
0.05). 
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Figure 11. Mass digest of Cry1Ab by the proteinase K model system. A – Fragmentation 
of the protein was not affected by a mass digest. B – Fragments generated by the mass 
digest were analyzed with a tris-tricine gel and silver stained. Two Cry1ab fragment 
bands of low molecular weight were identified (indicated by arrows). 
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Figure 12. Graph of results of Sephadex® G-50 separatory column for total protein concentration v. fraction number. Initial sample 
volume was 3 mL. A majority of the protein in the treatment appears in fractions 4-7, suggesting larger fragments and/or fully intact 
protein is present. Fractions 4-7 and 12-13 in all treatments were analyzed with ELISAs. Treatment = Cry1Ab degraded with 
proteinase K; Pr. K = Proteinase K enzyme only; Cry1Ab = Cry1Ab only.  
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Tables 
Table 1. Recipes for separating and stacking gel used in gel electrophoresis. 
 
Separating Gel Stacking Gel 
2.474 mL 30% acrylamide 0.330 mL 30% acrylamide 
1.847 mL 1M Tris-HCl, pH 8.8 0.247 mL 1M Tris-HCl, pH 6.8 
0.610 mL nanopure water 1.391 mL nanopure water 
50 µL 10% (w/v) sodium dodecyl 
sulfate 
20 µL 10% (w/v) sodium dodecyl 
sulfate 
4 µL N,N,N’,N’- 
tetramethylethylenediamine 
2 µL N,N,N’,N’- 
tetramethylethylenediamine 
17 µL 10% (w/v) ammonium 
persulfate 
10 µL 10% (w/v) ammonium 
persulfate 
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Table 2. Layout for chymotrypsin model system. At the start of the experiment, the 
solutions in the initiation column were combined in a vial. All samples were incubated at 
37˚C for 1 or 24 hr. At the end of the experiment, the solution in the termination column 
was added. All samples were flash frozen in liquid nitrogen and stored at -80°C until 
analysis. Cry1Ab = 900 ug/mL Cry1Ab in 50 mM CAPS, pH 10.5; KH2PO4 = 100 m M 
KH2PO4 pH 7; CAPS = 50 mM CAPS, pH 10.5. 
 
Samples Initiation Termination 
Cry1Ab Control 75 µL Cry1Ab solution 75 µL KH2PO4 
150 µL water 
Chymotrypsin 
control 
75 µL CAPS 
75 µL chymotrypsin solution in 
KH2PO4 
150 µL water 
Treatment (in 
triplicate) 
75 µL Cry1Ab solution 
75 µL chymotrypsin solution in 
KH2PO4 
150 µL water 
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Table 3. Layout for proteinase K model system. At the start of the experiment, the 
solutions in the initiation column were combined in a vial. All samples were incubated at 
37˚C for 30 min. At the end of the experiment, the solution in the termination column 
was added. All samples were flash frozen in liquid nitrogen and stored at -80°C until 
analysis. Cry1Ab = 900 ug/mL Cry1Ab in 50 mM CAPS, pH 10.5; Tris-HCl = 20 mM 
Tris-HCl, pH 7.5; CAPS = 50 mM CAPS, pH 10.5. 
 
Samples Initiation Termination 
Water Control 150 µL water 150 µL water 
Proteinase K 
Control 
75 µL CAPS 
75 µL proteinase K solution in Tris-
HCl 
150 µL water 
Cry1Ab Control 75 µL Tris-HCl 75 µL Cry1Ab solution 150 µL water 
Treatment 
75 µL Cry1Ab solution 
75 µL proteinase K solution in Tris-
HCl 
150 µL water 
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Table 4. ELISA results of the fractions from the G-50 separatory column experiment. 
Treatment = Cry1Ab degraded with proteinase K; Pr. K = Proteinase K enzyme only; 
Cry1Ab = Cry1Ab only. Significant amounts of protein are still detectable in the 
treatments that have been degraded by proteinase K.  
Fraction Absorbance
Concentration 
(ng/mL)
Adjusted 
Concentration 
(ng/mL)
Treatment
4 0.299 1.59 11284
5 0.330 2.00 24863
6 0.493 4.19 33654
7 0.232 0.68 4245
12 0.000 0.00 0
13 0.006 0.00 0
Pr. K
4 0.008 0.00 0
5 -0.004 0.00 0
6 -0.004 0.00 0
7 -0.005 0.00 0
12 -0.005 0.00 0
13 0.019 0.00 0
Cry1Ab
4 0.007 0.00 0
5 0.354 2.33 51792
6 0.840 8.87 118051
7 0.917 9.92 35265
12 0.050 0.00 0
13 0.028 0.00 0  
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Table 5. Relative percent difference (R%D) values for the standard curve prepared in 
chymotrypsin model system buffer and the standard curve prepared in assay buffer 
(PBST). Shaded cells fall outside the acceptance criterion of R%D < │15%│ between the 
assay buffer and model system buffer. If the R%D > │15%│ across two consecutive 
points in the standard curve, then there may be matrix effects due to the model system 
components. No buffer or matrix effects are expected to occur in a 1:15,000 or a 1:22,500 
dilution. 
 
 Dilution factor (1:x) 
Standard Curve 15,000 20,000 22,500 50,000 
20 ng/mL -8.28 -5.91 -23.75 -12.98 
16 ng/mL -1.00 11.32 -13.15 -14.32 
12 ng/mL -8.01 -9.37 -14.70 -25.83 
8 ng/mL 0.04 -25.60 1.04 -34.50 
4 ng/mL -8.10 -30.30 -20.16 -37.85 
1 ng/mL -1.71 -28.48 -12.85 -22.27 
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Table 6. Percent coefficient of variation (%CV) for the chymotrypsin model system 
buffer dilutions. Shaded cells in the upper portion of the table fall outside the quantitative 
range, or were purposely excluded to bring the %CV value in range. Shaded cells in the 
lower portion of the table fall outside the acceptance criterion of %CV < 20%. For those 
cells with %CV outside of the acceptance criterion, minimum or maximum dilutions 
were applied until the %CV was < 20%. Dilution the samples by a factor of 1:15,000 – 
1:50,000 is not expected to affect protein quantitation. 
 
  Concentration Mean 
Result 
(ng/mL) 
Adjusted 
Result 
(ng/mL) 
Removing 
out of range 
dilutions 
Applying 
maximum 
dilution of 
1:50000 
  
  
Rep 1 Rep 2 
  
1:5,000 15.15 14.69 14.92 74587 
Above 
ULOQ 
Above 
ULOQ 
1:10,000 8.67 9.43 9.05 90528 
Above 
ULOQ 
Above 
ULOQ 
1:15,000 4.49 7.92 6.20 93069 93069 93069 
1:20,000 3.47 5.01 4.24 84851 84851 84851 
1:22,500 3.67 5.49 4.58 103022 103022 103022 
1:50,000 0.36 3.49 1.93 96254 96254 96254 
1:100,000 -1.06 -1.08 -1.07 -106724 -106724 Excluded 
1:1,000,000 -3.01 -3.04 -3.02 -3022094 Below LLOQ Below LLOQ 
 
      Mean adjusted result -323313 54094 94299 
 
         Standard deviation 1092683 90137 7543 
  
%CV -337.96 166.63 8.00 
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Table 7. ELISA results from the chymotrypsin model system. Adjusted concentration 
was calculated by multiplying by the dilution factor, 1:22,500. % Cry1Ab remaining was 
calculated by dividing the concentration each of the replicates by the Cry1Ab control 
concentration. ELISA results indicate little degradation has occurred at 1 hour, and 
significant degradation has occurred at 24 hours.  
 
1 hour 
Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry1Ab control 0.466 4.22 95000  
Chymo control 0.034 -2.83 0  
Replicate 1 0.493 4.66 104804 110.3% 
Replicate 2 0.456 4.06 91324 96.13 
Replicate 3 0.456 4.05 91160 95.96 
     
24 hour 
Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry1Ab control 0.338 2.14 48105  
Chymo control 0.008 -3.27 0  
Replicate 1 0.258 0.83 18652 38.77 
Replicate 2 0.296 1.45 32663 67.90 
Replicate 3 0.235 0.45 10155 21.11 
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Table 8. Relative percent difference (R%D) values for the standard curve prepared in 
CAPS buffer and water and the standard curve prepared in assay buffer (PBST). This 
CAPS/water buffer system was utilized in both the long-term degradation in buffer model 
system and the photodegradation model system. Shaded cells fall outside the acceptance 
criterion of R%D < │15%│ between the assay buffer and model system buffer. If the 
R%D > │15%│ across two consecutive points in the standard curve, then there may be 
matrix effects due to the model system components. No buffer or matrix effects are 
expected to occur across a dilution range of 1:10,000 – 1:50.000. 
 
 Dilution factor (1:x) 
Standard Curve 10,000 50,000 10,0000 1,000,000 
20 ng/mL -9.06 -9.12 -14.19 -13.32 
16 ng/mL -9.28 -7.36 -14.95 -8.92 
12 ng/mL -3.94 -6.52 -17.53 -22.67 
8 ng/mL -15.54 -14.12 -17.84 -16.56 
4 ng/mL -3.96 -14.43 -16.44 -20.54 
1 ng/mL -12.30 -12.57 -16.58 -28.88 
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Table 9. Percent coefficient of variation (%CV) for CAPS buffer and water dilutions. 
This CAPS/water buffer system was utilized in both the long-term degradation in buffer 
model system and the photodegradation model system. Shaded cells in the upper portion 
of the table fall outside the quantitative range, or were purposely excluded to bring the 
%CV value in range. Shaded cells in the lower portion of the table fall outside the 
acceptance criterion of %CV < 20%. For those cells with %CV outside of the acceptance 
criterion, minimum or maximum dilutions were applied until the %CV was < 20%. 
Diluting the samples by a factor of 1:15,000 – 1:50,000 is not expected to affect protein 
quantitation. 
 
  
Concentration Mean 
Result 
(ng/mL) 
Adjusted 
Result 
(ng/mL) 
Removing 
out of range 
dilutions 
Applying 
maximum 
dilution of 
1:50000 
  
  
Rep 1 Rep 2 
  
1:5,000 22.88 23.19 23.03 115161 
Above 
ULOQ 
Above 
ULOQ 
1:10,000 18.55 17.76 18.15 181523 
Above 
ULOQ 
Above 
ULOQ 
1:15,000 12.87 12.90 12.89 193292 193292 193292 
1:20,000 9.55 10.36 9.96 199127 199127 199127 
1:22,500 8.29 8.76 8.53 191819 191819 191819 
1:50,000 3.77 4.75 4.26 213024 213024 213024 
1:100,000 0.74 0.92 0.83 83333 83333 Excluded 
1:1,000,000 -1.99 -0.50 -1.24 -1241274 Below LLOQ Below LLOQ 
 
       Mean adjusted result -7999 176119 199316 
 
          Standard deviation 500370 52540 9668 
   
%CV -6255.18 29.83 4.85 
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Table 10. ELISA results from the long-term degradation in buffer model system. 
Adjusted concentration was calculated by multiplying by the dilution factor, 1:22,500. % 
Cry1Ab remaining was calculated by dividing the concentration each of the replicates by 
the Cry1Ab control concentration. ELISA results indicate significant degradation has 
occurred after 16 weeks.  
 
Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry Control 0.553 5.75 129333  
Buffer Control 0.002 -2.12 0  
Replicate 1 0.354 2.90 65317 50.50 
Replicate 2 0.362 3.01 67743 52.38 
Replicate 3 0.349 2.83 63570 49.15 
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Table 11. ELISA results from the photodegradation model system. Adjusted 
concentration was calculated by multiplying by the dilution factor, 1:22,500. % Cry1Ab 
remaining was calculated by dividing the concentration each of the replicates by the 
Cry1Ab control concentration. ELISA results indicate significant degradation has 
occurred at both time points.  
 
 
Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry1Ab Control 0.636 6.04 136003  
Buffer Control -0.002 -1.78 0  
2.5 minutes     
Replicate 1 0.144 0.00 0 0.00 
Replicate 2 0.156 0.15 3457 2.54 
Replicate 3 0.033 -1.35 0 0.00 
5 minutes     
Replicate 1 0.062 -1.01 0 0.00 
Replicate 2 0.027 -1.43 0 0.00 
Replicate 3 0.134 -0.11 0 0.00 
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Table 12. Relative percent difference (R%D) values for the standard curve prepared in 
acidic buffer and the standard curve prepared in assay buffer (PBST). Shaded cells fall 
outside the acceptance criterion of R%D < │15%│ between the assay buffer and model 
system buffer. If the R%D > │15%│ across two consecutive points in the standard curve, 
then there may be matrix effects due to the model system components. No buffer or 
matrix effects are expected to occur across a dilution range of 1:10,000 – 1:1,000,000. 
 
 Dilution factor (1:x) 
Standard Curve 10,000 50,000 100,000 1,000,000 
20 ng/mL 4.18 3.36 -12.28 9.33 
16 ng/mL -10.83 -16.01 26.78 -4.79 
12 ng/mL 11.21 7.62 -3.64 -13.55 
8 ng/mL 7.72 4.33 3.48 -10.35 
4 ng/mL -18.78 -3.32 4.17 -1.14 
1 ng/mL -10.87 -25.15 -28.17 -15.11 
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Table 13. Percent coefficient of variation (%CV) for acidic buffer model system 
dilutions. Shaded cells in the upper portion of the table fall outside the quantitative range, 
or were purposely excluded to bring the %CV value in range. Shaded cells in the lower 
portion of the table fall outside the acceptance criterion of %CV < 20%. For those cells 
with %CV outside of the acceptance criterion, minimum or maximum dilutions were 
applied until the %CV was < 20%. Diluting the samples by a factor of 1:15,000 – 
1:100,000 is not expected to affect protein quantitation. 
 
  Concentration 
Mean Result 
(ng/mL) 
Adjusted 
Result (ng/mL) 
Removing out 
of range 
dilutions 
  
  
Rep 1 Rep 2 
  
1:5,000 19.55 19.57 19.56 97795 Above ULOQ 
1:10,000 15.40 14.83 15.12 151151 Above ULOQ 
1:15,000 11.84 12.22 12.03 180419 180419 
1:20,000 9.28 8.51 8.90 177922 177922 
1:22,500 7.65 7.84 7.74 174262 174262 
1:50,000 3.27 3.55 3.41 170581 170581 
1:100,000 1.02 1.12 1.07 107054 107054 
1:1,000,000 -1.42 -1.42 -1.42 -1421705 Below LLOQ 
  
     Mean adjusted result -45315 162048 
  
        Standard deviation 557079 30967 
   
            %CV -1229.34 19.11 
 
  
186 
Table 14. ELISA results from the acidic buffer model system. Adjusted concentration 
was calculated by multiplying by the dilution factor, 1:22,500. % Cry1Ab remaining was 
calculated by dividing the concentration each of the replicates by the Cry1Ab control 
concentration. ELISA results indicate significant degradation has occurred in all 
treatments and controls at all time points.  
 
 Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry1Ab control 0.713 5.42 121909  
Acidic buffer ctrl 0.007 -2.01 0  
Day 4     
Room Temp. 0.003 -2.05 0 0 
Replicate 1 0.002 -2.06 0 0 
Replicate 2 0.010 -1.98 0 0 
Day 5     
Room Temp. 0.011 -1.97 0 0 
Replicate 1 0.009 -1.99 0 0 
Replicate 2 0.004 -2.04 0 0 
Day 6     
Room Temp. 0.175 -0.24 0 0 
Replicate 1 0.011 -1.97 0 0 
Replicate 2 0.007 -2.00 0 0 
Day 7     
Room Temp. 0.006 -2.01 0 0 
Replicate 1 0.012 -1.95 0 0 
Replicate 2 0.013 -1.94 0 0 
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Table 15. Relative percent difference (R%D) values for the standard curve prepared in 
proteinase K model system buffer and the standard curve prepared in assay buffer 
(PBST). Shaded cells fall outside the acceptance criterion of R%D < │15%│ between the 
assay buffer and model system buffer. If the R%D > │15%│ across two consecutive 
points in the standard curve, then there may be matrix effects due to the model system 
components. No buffer or matrix effects are expected to occur across a dilution range of 
1:10,000 – 1:50,000. 
 
 Dilution factor (1:x) 
Standard 
Curve 10,000 15,000 20,000 22,500 50,000 
20 ng/mL -3.74 -14.18 -8.70 -11.17 -12.98 
16 ng/mL 7.17 -24.66 7.54 -6.33 6.33 
12 ng/mL 17.21 5.26 -1.21 -0.27 12.10 
8 ng/mL 2.57 11.07 -7.64 -4.38 -5.36 
4 ng/mL 5.70 14.08 13.70 19.56 -7.89 
1 ng/mL 8.49 -1.04 -0.41 -11.59 -14.29 
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Table 16. Percent coefficient of variation (%CV) for the proteinase K model system 
buffer dilutions. Shaded cells in the upper portion of the table fall outside the quantitative 
range, or were purposely excluded to bring the %CV value in range. Shaded cells in the 
lower portion of the table fall outside the acceptance criterion of %CV < 20%. For those 
cells with %CV outside of the acceptance criterion, minimum or maximum dilutions 
were applied until the %CV was < 20%. Diluting the samples by a factor of 1:15,000 – 
1:50,000 is not expected to affect protein quantitation. 
 
  Concentration Mean 
Result 
(ng/mL) 
Adjusted 
Result 
(ng/mL) 
Removing 
out of range 
dilutions 
Applying 
maximum 
dilution of 
1:50000 
  
  
Rep 1 Rep 2 
  
1:5,000 22.34 20.48 21.41 107057 
Above 
ULOQ 
Above 
ULOQ 
1:10,000 17.76 18.41 18.08 180819 
Above 
ULOQ 
Above 
ULOQ 
1:15,000 14.23 13.71 13.97 209521 209521 209521 
1:20,000 10.57 10.12 10.35 206928 206928 206928 
1:22,500 9.48 8.62 9.05 203599 203599 203599 
1:50,000 3.07 3.46 3.27 163418 163418 163418 
1:100,000 0.84 0.48 0.66 65782 65782 Excluded 
1:1,000,000 -1.84 -1.90 -1.87 -1868128 Below LLOQ Below LLOQ 
 
           Mean adjusted result -91375 169850 195866 
 
              Standard deviation 719768 61154 21768 
   
       %CV -787.70 36.00 11.11 
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Table 17. ELISA results from the proteinase K model system. Adjusted concentration 
was calculated by multiplying by the dilution factor, 1:20,000. % Cry1Ab remaining was 
calculated by dividing the concentration each of the replicates by the Cry1Ab control 
concentration. A – ELISA results from the first model system run indicate little 
degradation has occurred. B – ELISA results from the second model system run also 
indicate little degradation has occurred.  
 
A Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry1Ab control 0.726 5.15 102930  
Pr. K control 0.006 -2.73 0  
Replicate 1 0.719 5.07 101471 98.58 
Replicate 2 0.690 4.75 95077 92.37 
Replicate 3 0.546 3.17 63469 62.55 
     
B Absorbance 
Concentration 
(ng/mL) 
Adjusted 
Concentration 
(ng/mL) 
% Cry1Ab 
Remaining 
Cry1Ab control 0.713 5.62 112406  
Pr. K control -0.021 -2.93 0  
Replicate 1 0.695 5.41 108262 96.31 
Replicate 2 0.606 4.37 87464 77.81 
Replicate 3 0.632 4.67 93370 83.06 
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CHAPTER 4. GENERAL CONCLUSIONS 
The purpose of this research was to further the knowledge of the fate of Cry 
proteins in the environment. Specifically, this dissertation sought to address the question 
of whether fragments of Cry proteins are detectable by enzyme-linked immunosorbent 
assays (ELISAs), which are the preferred method of detection for Cry proteins in the 
environment. If Cry protein fragments are detectable by ELISAs, then biological 
validation of ELISA results may be necessary to characterize biological activity in 
environmental samples. There were two main objectives to accomplish this goal. For the 
first objective, numerous model systems were screened for their ability to generate 
fragments of the Cry1Ab protein in a controlled and predictable manner. For the second 
objective, these fragments were analyzed with bioassays and ELISAs to determine if 
these fragments retained bioactivity and if they were still detectable by ELISA.  
The screening of multiple model systems for their capability to generate 
fragments of Cry1Ab was investigated in Chapter 2. Eight different types of model 
systems were screened. The trypsin model system and the simulated gut fluid model 
system did not sufficiently degrade Cry1Ab, while the pepsin model system completely 
degraded the protein, but did not produce any protein fragments detectable by gel 
electrophoresis. The remaining five model systems yielded various types and quantities 
of Cry1Ab fragments. The fragments from these model systems, the chymotrypsin model 
system, proteinase K model system, acidic buffer model system, photodegradation model 
system, and the long-term degradation in buffer model system, were then used in the 
second objective (Chapter 3).  
193 
In Chapter 3, the model systems identified in Chapter 2 were used to generate 
fragments that were then analyzed with ELISAs and bioassays to determine if the 
fragments were still detectable and if they retained any bioactivity. The results indicated 
that fragments generated by four of the model systems were not detectable by ELISA and 
did not retain any bioactivity. These four model systems were the chymotrypsin model 
system, acidic buffer model system, photodegradation model system, and long-term 
degradation in buffer model system. Despite being highly degraded, the fragments 
generated by the proteinase K model system were still detectable by ELISA and still 
retained biological activity. Further investigations suggest that these fragments may be 
associating with each other, but more research is needed to understand this phenomenon. 
The primary concern at the beginning of this research was that fragments of Cry 
proteins may still be detectable by ELISAs, but not retain any biological activity. If true, 
this could lead to an over-estimation of the amount of biologically active protein in the 
environment, which in turn could affect the risk assessments for these proteins. The 
research described here primarily indicated that this was not observed in the model 
systems tested in this research project. Cry1Ab fragments that were detectable by ELISA, 
also retained bioactivity; those fragments that were not detectable, did not have 
bioactivity. Therefore, researchers using ELISA kits appear to be capturing an accurate 
picture of the amount of Cry protein in environmental matrices. However, more research 
is needed in this area to test additional ELISA kits and other model systems, including 
microbe-based model systems, in order to better understand the fate of Cry proteins in the 
environment.  
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APPENDIX A: CHAPTER 2 SUPPLEMENTAL 
INFORMATION 
 In addition to the buffers and inhibitors tested in Chapter 2, other buffers and 
inhibitors were tested that produced unsatisfactory results. 
Trypsin 
The trypsin model system was originally screened with a Tris-HCl buffer (0.1 M 
Tris-HCl, 0.15 M sodium chloride, 5 mM magnesium chloride, pH 7.5), and using an 
equal volume of 20% (w/v) tricholoroacetic acid as an inhibitor. An initial bioassay test 
showed that the trichloroacetic acid was acutely toxic to the insects, and its use in the 
model system was quickly abandoned (Figure 1). Trypsin inhibitor from Glycine max 
was purchased, and another screening bioassay was performed. The Tris-HCl buffer 
described above did not affect insect survival, but significantly reduced larval weights 
(Figure 2). This buffer also was abandoned, and the seven buffers described in Chapter 2 
were screened for use.  
Pepsin 
The pepsin model system was initially tested using sodium bicarbonate as an 
inhibitor. An activity assay, similar to the one described in Chapter 2, determined that 
complete inhibition of pepsin could be achieved at 10% (w/v) sodium bicarbonate (Figure 
3). However, the presence of sodium bicarbonate caused significant mortality in the 
bioassays, and its use as an inhibitor was discontinued (Figure 4). Sodium hydroxide was 
then chosen as the inhibitor and was used as described in Chapter 2. 
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Proteinase K 
An inhibitor was originally included in the proteinase K model system, but was 
removed due to high background absorbance in the activity assay. A known substrate for 
proteinase K, acetyl-L-tyrosine ethyl ester, was not available at the time, so the feasibility 
of using N-benzoyl-L-tyrosine ethyl ester (BTEE) was investigated. This was deemed an 
acceptable substitute as proteinase K cleaves adjacent to the carboxylic group in aromatic 
amino acids (Ebeling et al. 1974). A 5-mM concentration of BTEE was prepared by 
dissolving the substrate in 50% (v/v) methanol. One milliliter of this solution was 
combined with 4 mL of four different proteinase K solutions (5, 25, 100, and 500 µg/mL 
proteinase K). The background absorbance of proteinase K and BTEE only was 0.041 
and 2.251, respectively. The absorbance in the proteinase K solutions was 2.377-2.815. 
Since the background absorbance of proteinase K plus the background absorbance of 
BTEE (2.292) was less than then the absorbance observed in the samples, the increased 
absorbance in the samples must have come from proteinase K cleaving BTEE; this 
information supported using BTEE as a substrate for proteinase K. An activity assay was 
then set up using 5 mM phenylmethane sulfonyl fluoride (PMSF) as the inhibitor. The 
background absorbance values for proteinase K, BTEE, and PMSF were 0.199, 2.227, 
and 1.429, respectively. When combined, these gave a total background of 3.855, which 
exceeds the maximum absorbance recordable, and leaves no margin for an increase in 
absorbance due to cleavage of the BTEE substrate. Instead of working with the activity 
assay further, the decision was made to try degrading Cry1Ab first to determine if further 
studies with proteinase K would be worthwhile. During this experiment (Figure 19, 
Chapter 2), it was determined that flash freezing the samples in liquid nitrogen was 
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sufficient for termination of the reaction. This termination mechanism also was employed 
in the chymotrypsin model system without any issues.  
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Figures 
 
Figure 1. Bioassay results from the initial trypsin model system test using a Tris-HCl 
buffer and trichloroacetic acid as the inhibitor. Uppercase letters indicate significance 
within survival across buffers (p = 0.05). Lowercase letters indicate significance within 
average weight across buffers (p = 0.05). 
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Figure 2. Bioassay results from the second trypsin model system test using a Tris-HCl 
buffer and trypsin inhibitor from Glycine max. Uppercase letters indicate significance 
within survival across buffers (p = 0.05). Lowercase letters indicate significance within 
average weight across buffers (p = 0.05). 
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Figure 3. Pepsin activity assay results with sodium bicarbonate as an inhibitor. Complete 
inhibition is achieved at 10% (w/v) sodium bicarbonate. 
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Figure 4. Bioassay results from the initial pepsin model system test using 10% (w/v) 
sodium bicarbonate as the inhibitor. Uppercase letters indicate significance within 
survival across buffers (p = 0.05). Lowercase letters indicate significance within average 
weight across buffers (p = 0.05).   
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APPENDIX B: CHAPTER 3 SUPPLEMENTAL 
INFORMATION 
G-50 Separatory Column Experiment 
Bioassays also were performed on the fractions generated by the G-50 separatory 
column experiment in Chapter 3. Significant challenges were encountered while trying to 
obtain the bioassay data from this experiment. The water control survival in several 
bioassay experiments fell below the acceptable threshold (survival <80%). The need to 
repeat these experiments numerous times led to multiple freeze-thaw cycles, which 
compromised the integrity of the protein. This compromise was discovered when ELISAs 
were repeated. The first ELISA run did not contain a fully intact Cry1Ab standard to 
compare to the results. When a second ELISA was performed on the same fractions, 
significant losses in detectable protein were observed in the treatment and Cry1Ab 
control samples (Table 1B). The multiple freeze/thaw cycles the protein solutions were 
exposed to while trying to complete the bioassay results is probably responsible for the 
loss of detectable protein. Due to this discrepancy in ELISA data, the bioassay results 
must be classified as inconclusive. These bioassay results are reported here for reference, 
and any assumptions made from these results should be considered inconclusive (Figures 
1-3).  
Native PAGE 
A native PAGE experiment was performed on an aliquot of the proteinase K mass 
digest. Native PAGE gels do not contain SDS or mercaptoethanol and heating is not 
used; thus denaturing of the protein should not occur (i.e., disulfide bonds should remain 
intact) and the protein should retain its native conformation. If the fragments are not 
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associated together, then, multiple bands should be visible; however, if the fragments are 
associating to each other, only one band should be visible. Sample buffer, running buffer 
and gels free of denaturing agents were prepared. Sample buffer consisted of 62.5 mM 
Tris-HCl, pH 6.8, 25% (w/v) glycerol, and 1% (w/v) bromophenol blue. The running 
buffer was a 40 mM CAPS buffer, pH 11. An 8% separating gel and the stacking gel 
were prepared as described in Table 2. Samples were mixed at a 1:1 ratio of sample to 
sample buffer and allowed to sit for 10 minutes. Samples were centrifuged at 12 x g for 5 
minutes and 20 uL of each sample was loaded in each lane. A constant 150 volts was 
applied to the gel for 30-40 min. The gel is in Figure 4. Only one band appears in the 
treatment. This band migrated approximately the same distance as the fully-intact 
Cry1Ab, suggesting the fragments are still associated. It was only after performing this 
experiment that we learned that native PAGE gel results are dependent on pH and 
isoelectric point, which can vary significantly depending on gel conditions. Therefore, the 
reliability of this experiment is questionable and was not included in Chapter 3.  
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Figures 
 
Figure 1. Bioassay results from fractions 4-5 of the treatment, Cry1Ab, and proteinase K 
solutions. Tr = Treatment, Cry1Ab degraded with proteinase K; PrK = Proteinase K 
enzyme only; Cry = Cry1Ab only. No useful information can be gained from these 
bioassays, as the solutions were compromised. 
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Figure 2. Bioassay results from fractions 6-7 of the treatment, Cry1Ab, and proteinase K 
solutions. Tr = Treatment, Cry1Ab degraded with proteinase K; PrK = Proteinase K 
enzyme only; Cry = Cry1Ab only. No useful information can be gained from these 
bioassays, as the solutions were compromised. 
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Figure 3. Bioassay results from fractions 12-13 of the treatment, Cry1Ab, and proteinase 
K solutions. Tr = Treatment, Cry1Ab degraded with proteinase K; PrK = Proteinase K 
enzyme only; Cry = Cry1Ab only. No useful information can be gained from these 
bioassays, as the solutions were compromised. 
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Figure 4. Results from a native PAGE gel performed on an aliquot of the proteinase K 
mass digest. Denaturing conditions are not present in native PAGE gels; and proteins 
present should retain their native conformation. Only one band appears in the digested 
treatment, suggesting that the protein fragments are associating with each other.   
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Tables 
 
Table 1. ELISA results of the fractions from the G-50 separatory column experiment. 
Treatment = Cry1Ab degraded with proteinase K; Pr. K = Proteinase K enzyme only; 
Cry1Ab = Cry1Ab only; Pure Cry1Ab = protein not fractionated with separatory column. 
A – First ELISA run. Significant amount of protein are still detectable in the treatments 
that have been degraded by proteinase K. B – Second ELISA run. Significantly less 
protein is present in all samples, indicated the samples were compromised. 
  
Fraction Absorbance Concentration Absorbance Concentration
Treatment
4 0.299 1.59 0.088 0.00
5 0.330 2.00 0.352 2.52
6 0.493 4.19 0.111 0.01
7 0.232 0.68 0.029 0.00
12 0.000 0.00 0.014 0.00
13 0.006 0.00 0.012 0.00
Pr. K
4 0.008 0.00 0.002 0.00
5 -0.004 0.00 0.010 0.00
6 -0.004 0.00 0.011 0.00
7 -0.005 0.00 0.225 1.20
12 -0.005 0.00 0.009 0.00
13 0.019 0.00 0.010 0.00
Cry1Ab
4 0.007 0.00 0.011 0.00
5 0.354 2.33 0.099 0.00
6 0.840 8.87 0.198 0.92
7 0.917 9.92 0.074 0.00
12 0.050 0.00 0.009 0.00
13 0.028 0.00 0.005 0.00
Pure Cry1Ab N/A N/A 0.585 4.95
A B
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Table 2. Recipes for separating and stacking gel used in native PAGE gel 
electrophoresis. 
Separating Gel Stacking Gel 
1.3 mL 30% acrylamide 0.335 mL 30% acrylamide 
3.65 mL 0.375 Tris-HCl, pH 9.4 2.138 mL 0.375 Tris-HCl, pH 8.8 
5 µL N,N,N’,N’- 
tetramethylethylenediamine  
2.5 µL N,N,N’,N’- 
tetramethylethylenediamine  
50 µL 10% (w/v) ammonium 
persulfate 
25 µL 10% (w/v) ammonium 
persulfate 
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